Science & health
Every item from Trenri daily that fell into Science & health, latest first.
November 2026 ยท 1
Novartis discloses 9 tumor reports in children given Zolgensma
Since FDA approval in 2019, there have been 9 tumor reports, and the company said 2 of them have evidence suggesting a possible link to the treatment. Regulators are reviewing the cases.
October 2026 ยท 139
First Dwarf Planet Candidate 2026 ED138 Identified in Rubin Observatory Data
Matthew Holman found candidate 2026 ED138 in Rubin Observatory data. It lies about 46 au from the Sun with an estimated diameter of 600-1,500 km, and it has not yet been confirmed. It was detected 30 times between March and July this year.
Study Suggests Betelgeuse's Atmosphere Is Disturbed by Companion Star Siwarha
A radio observation study using VLA and ALMA found that the cycle in which Betelgeuse's atmosphere changes into an egg shape matches a period of about 5.9 years. It was presented as the strongest evidence that the companion star Siwarha exists, but it is not confirmed.
Lithium Fluoride Crystal Sensors Used to Measure Radiation on Artemis I
A Polish research team published results from radiation sensors on a mannequin flown aboard Artemis I in Radiation Measurements. The lithium fluoride crystals matched plastic detectors in the intermediate energy range, but overestimated dose by about 30% in the higher range.
Study Finds Comet Impacts Rarely Delivered Life Ingredients to Earth
A Scientific Reports study concluded that hydrogen cyanide in comets is destroyed on impact and diluted in crater lakes, so very few comets delivered meaningful amounts to Earth. It said the share of comets that survived impact on Mars is about five times higher.
KDCA Names CRE Top Priority for Hospital Control of Multidrug-Resistant Bacteria
The KDCA and a research team from Seoul National University Bundang Hospital surveyed 49,651 inpatients at 21 hospitals and rated CRE as the top priority for infection control. The 30-day mortality rate for infected patients was 16.9% for CRE, and the median medical cost was 46 million won.
Health Ministry to Invest 2.7 Trillion Won a Year in Regional and Essential Medicine from January
Starting January next year, 2.7 trillion won in National Health Insurance funds will be invested annually in regional and essential medicine, while annual spending will be reduced by 2.6 trillion won through lower fees for specimen tests and CT/MRI. The ministry plans to revise the related notice in November.
Lumina Large Simulation Recreates First 2 Billion Years of the Universe
Researchers at the Harvard-Smithsonian Center for Astrophysics unveiled Lumina, using over 15,000 GPUs on Frontier across a volume about 1.5 billion light-years on a side. The paper appeared in MNRAS.
709 BC Chinese Eclipse Record Used in Earth Rotation Research
Nagoya University's Hisashi Hayakawa and team said Qufu's coordinates in the Spring and Autumn Annals' total eclipse record were off by about 8 km. They re-estimated rotation using the corrected location. The paper appeared in ApJL.
Samsung Bioepis Presents Phase 1 Results for Keytruda Biosimilar SB27 at ESMO
In a Phase 1 trial of 163 non-small cell lung cancer patients, pharmacokinetic equivalence to original Keytruda was confirmed on the primary endpoint AUC, with similar efficacy and safety, it said.
HLB Elevar Presents Rivoceranib Phase 2 Follow-up at ESMO
The rivoceranib thymic epithelial tumor Phase 2 showed ORR 35%, DCR 85% and mPFS 11.8 months at median follow-up of 13.6 months. Bile duct cancer drug Rivfitu received FDA approval on the 23rd of last month.
Astronomers Report Gamma-Ray Burst Active for 27 Days
The energy source of GRB 220706A, observed on July 6, 2022, was reported to have been active for about 27 days. That is about 20 days longer than the previous record. The study is a peer-review-pending preprint posted on arXiv.
NASA Announces CM 2.0, Overhaul of Science Mission Selection
Nicky Fox of NASA's Science Mission Directorate announced CM 2.0 on October 21. The selection period for medium-class missions such as Discovery and New Frontiers will shrink from about 35 months to about 19.5 months.
FDA Approves Talazoparib Plus Enzalutamide for Prostate Cancer
In TALAPRO-3, which involved 599 patients, median radiographic progression-free survival was not reached in the combination arm versus 45.8 months in the placebo arm (HR 0.48). It was reviewed under priority review.
FDA Approves Genentech's Enspryng for Thyroid Eye Disease
It is indicated for adults with thyroid eye disease (TED), and during maintenance, the patient or caregiver administers it every four weeks. Phase 3 SatraGO-1 did not meet its primary endpoint at 24 weeks, while SatraGO-2 showed significant improvement.
Supreme Court Reverses and Remands Hospital Director Case: Medical Benefit Fraud Over Surgeries by Unlicensed Staff
The Supreme Court's First Division overturned the appellate ruling that acquitted the case, which treated claims for surgeries involving unlicensed participants as fraud, and sent it back to the Seoul Central District Court. The claims totaled 23 cases, about 95.39 million won.
NASA announces end of 22-year mission for Swift gamma-ray observatory
NASA announced on October 23 the end of Swift's science mission. Launched in 2004, with its last observation on October 20. It observed more than 2,000 gamma-ray bursts and more than 1,400 supernovae.
Roche divarasib cuts death risk 44% in Phase 3 lung cancer trial
In the Phase 3 trial (338 patients) in KRAS G12C-mutant non-small cell lung cancer, median overall survival was about 18 months vs. 12 months, and progression-free survival was 9.8 months vs. 5.7 months. Presented at ESMO and published in NEJM.
Takeda gastric cancer ADC meets Phase 3, plans Japan filing next year
The claudin 18.2-targeted ADC, tested in a trial of 464 patients with gastric cancer at third line or later, showed overall survival of 10.2 months vs. 6.9 months and progression-free survival of 7.1 months vs. 3.1 months. Takeda plans to submit a Japan NDA next year.
NASA unveils plan for Artemis 3 low Earth orbit docking test
At a Kennedy Space Center briefing on October 23, NASA described Artemis 3 as a low Earth orbit docking test. No launch date has been set, and NASA is targeting summer 2027.
Bennu sample isotopes resemble Ryugu and CI meteorites
ETH Zurich researchers measured the iron, titanium and chromium isotopes of 0.5 g of Bennu samples. Their isotopic fingerprints are close to those of Ryugu and CI meteorites, suggesting formation near the water-ice line (Science Advances).
Magnetic mesh in the Sun's chromosphere captured by stratospheric telescope
A team led by Japan's National Astronomical Observatory used the Sunrise III telescope to observe thread-like magnetic structures in the chromosphere of a quiet solar region. Simulations reproduced this pattern.
Mars quake confirmed to originate below Valles Marineris
Imperial College researchers said Mars quake S0976a, recorded by InSight on August 25, 2021, originated from a fault 20โ40 km below Valles Marineris (Nature Communications).
Five of 151 white dwarfs are not white
Researchers at the University of Warwick modeled 151 white dwarfs within 20 parsecs and identified 2 yellow and 3 pink ones. Carbon in the atmosphere makes them appear pink or purple.
Kenya records second Ebola death, 9 confirmed cases
A 65-year-old woman died of Ebola in Kenya, bringing the death toll to 2. There are 9 confirmed cases, and 135 contacts have been traced, with 118 placed in quarantine, according to reports.
Immatics presents clinical results for PRAME-targeted therapies at ESMO
In the phase 1b evaluation of IMA402 (40 patients), the confirmed objective response rate was 25% (10/40) and the disease control rate was 63%. In the phase 1 evaluation of IMA203CD8 (90 evaluable patients), the objective response rate was 51% (46/90) and the disease control rate was 82%.
Celcuity presents updated PIK3CA mutation cohort results from VIKTORIA-1
The median progression-free survival without liver metastases was 21.5 months for the gedatolisib triplet regimen and 9.1 months for the alpelisib combination. The objective response rate for the triplet regimen was 59%.
NASA compares current El Nino using 35-year satellite altimetry record
NASA compared the current El Nino with 1997-98 and 2015-16 using 35 years of satellite altimetry. In October 2026, sea levels in the central and eastern equatorial Pacific were above normal. NOAA's Oct. 8 outlook put the chance of a strong to very strong El Nino at 83%.
Magma reservoir beneath Japan's Kikai caldera found to be recharging
Kobe University researchers found a large magma reservoir beneath the Kikai caldera, site of a major eruption about 7,300 years ago. They also found evidence it is being refilled. The researchers said this does not mean a large eruption is imminent.
MFDS moves to allow sale after approval of drugs made before approval
The MFDS unveiled a biotech deregulation plan at the Oct. 23 regulatory rationalization committee. Batches made before approval can be sold after approval if conditions such as GMP compliance are met. Currently they must be discarded.
Africa CDC: Ebola deaths exceed 4,600
Semafor reported that Bundibugyo-strain Ebola deaths exceed 4,600. It is the second deadliest outbreak since 2014-16. Nigeria confirmed its first case and Kenya has nine.
US measles cases at 4,588 this year, up 178 from last week
As of CDC's Oct. 22 count, US measles cases this year stand at 4,588, reported from 47 jurisdictions. There were 479 hospitalizations (10%) and 3 deaths.
NASA APOD features WD J1330+6435, the first green star
NASA's October 22 APOD presented an illustration of WD J1330+6435 made by Mark Garlick with the University of Warwick. Some white dwarfs may be yellow, green, teal, pink or purple, it says.
FDA grants accelerated approval to Ultomiris for IgA nephropathy proteinuria
Ultomiris (ravulizumab) received accelerated approval for proteinuria reduction in adults with primary IgA nephropathy. In the 34-week interim analysis of the Phase 3 I CAN trial, the proteinuria ratio fell 46.6% versus 5.6% for placebo.
Jemperli gets accelerated approval for MSI-H/dMMR locally advanced rectal cancer
GSK's Jemperli (dostarlimab) received accelerated approval for adults with stage II-III MSI-H or dMMR locally advanced rectal cancer. In the AZUR-1 trial, 47% of 116 evaluable patients maintained a clinical complete response for 12 months.
Orladeyo 150mg oral pellets approved for HAE prevention in ages 12 and up
The FDA approved berotralstat (Orladeyo) 150mg oral pellets as a second formulation for preventing hereditary angioedema attacks in patients 12 and older. BioCryst said the approval rests on no new efficacy data.
NASA study: Thwaites Glacier contribution up to 2x current projections in some models
In a model study by NASA's Jet Propulsion Laboratory, the end-of-century sea-level rise contribution of West Antarctica's Thwaites Glacier was up to twice current projections in some simulations. The study was published in Nature Communications on October 12.
14 patients and staff at Changwon hospital dialysis unit confirmed with hepatitis C
13 dialysis patients and 1 staff member at a hemodialysis unit at A Hospital in Changwon were infected with hepatitis C. Of 75 people subject to full testing, 14 were confirmed, and most of those infected show no symptoms. Gyeongsangnam-do and KDCA are conducting an epidemiological investigation.
Week 40 flu detection rate rises to 28.0%, COVID hospitalizations at 283
Under KDCA sentinel surveillance, influenza-like illness cases per 1,000 outpatients in week 40 of 2026 fell to 23.6, while the detection rate rose to 28.0%. Hospitalized COVID-19 patients at hospital level rose to 283.
NASA simulated Mars crew marks one year inside habitat
The four crew members of the second CHAPEA mission reached one year inside the 3D-printed habitat at Johnson Space Center in Houston. They entered on October 19, 2025, and have grown crops and carried out simulated spacewalks.
ISS prepares for spacewalk to roll out solar array
Anil Menon and Joshua Kutryk carried out spacesuit checks. Menon cleaned a cooling loop, and Kutryk filled a water tank. On-orbit biological sample analysis tests were also conducted.
NASA improves launch shock and vibration analysis method
The Launch Services team at the Kennedy Space Center created a standard finite element analysis procedure based on commercial software. It replaces estimates based on rules of thumb, and the team said it saved several months.
FDA grants accelerated approval to Jemperli for dMMR rectal cancer
The FDA granted accelerated approval to dostarlimab (Jemperli) for patients with locally advanced rectal cancer that is dMMR or MSI-H. The phase 2 AZUR-1 trial enrolled 154 patients, and about three-quarters had not received surgery, chemotherapy or radiation.
26 of 35 regional public hospitals halt or scale back some services
According to data from the Association of Regional Public Hospitals released by Rep. Park Ji-won's office, 26 of 35 regional public hospitals had some departments halted or reduced in the first half of this year. Of those 26, 22 are outside the capital area.
Bill requiring specialist staffing at regional emergency centers draws debate
The amendment to the Emergency Medical Service Act proposed by Rep. So Byeong-hun would require regional emergency medical centers to staff at least one specialist each in internal medicine, surgery, neurology and neurosurgery on weekday daytime. The Korean Medical Association and the Korea Hospital Association oppose it, while the Ministry of Health and Welfare favors keeping the current system.
NHIS names Prof. Lee Jun-hee as director for benefits
The National Health Insurance Service selected Professor Lee Jun-hee of the Soonchunhyang University College of Medicine as its new standing director for benefits through public recruitment, effective the 19th. He said he would work to stop financial leakage.
Citizen Scientists Sought to Find Hidden Black Holes in the Milky Way
The Black Hole Hunters project by British astronomers is seeking volunteers to help analyze NASA TESS data. About 70 black holes have been found in the Milky Way, and the project has close to 23,000 participants.
Artemis II Crew Receive Stephen Hawking Medal
Wiseman, Glover, and Hansen received the Hawking Medal on the 17th at the opening ceremony of Starmus VIII in Tenerife. The medal honors all four crew members, and Christina Koch did not attend.
Effects of Simulated Microgravity on Cell Nuclei and Genome
An NYU research team exposed cell cultures to 24 hours of simulated microgravity, which enlarged the nuclei without DNA damage. Fluid flow stretched the cells and caused DNA damage. The paper was published in Science Advances.
Stroke From Neck and Head Artery Dissection, Recurrence Concentrated in the First Week
A team led by Professor Bae Hee-jun at Bundang Seoul National University Hospital analyzed 711 patients with arterial dissection. The cumulative recurrence rate was 8.7% on the first day, 17.4% within one week, and 19.9% within one year. The paper was published in Neurology.
India Announces 70% Price Cut on 137 Anticancer Drugs
India's Department of Chemicals and Fertilizers said it will cut the prices of 137 anticancer drugs by 70% and limit distribution margins to 30% of the maximum retail price. The changes take effect on November 9 and cover more than 20 cancer treatments.
Dankook University Hospital Holds Symposium on Emergency Care System in South Chungcheong
Dankook University Hospital, a regional responsible medical institution in South Chungcheong, held a joint symposium on building an emergency care system on October 18. South Chungcheong Province and five responsible medical institutions co-hosted it, and video information sharing and transfer coordination were discussed.
Warning Against Indiscriminate Testing Such as Whole-Body MRI
A 59-year-old woman in Florida had a pancreatic lesion found on a whole-body MRI, but a follow-up MRI confirmed a benign cyst. Reports say major medical societies do not recommend whole-body scans for people outside high-risk groups.
SpaceX Dragon Delivers Final New Solar Array to ISS
Dragon docked with the ISS on October 15. Its cargo of more than 6,300 pounds included the last rollout solar array, equipment for making artificial retinas, and gear for brain organoid experiments.
NASA Selects Project to Explore Caves Beneath Marius Hills Pit on the Moon
NASA selected the GIMLI project, led by PSI, to check whether lava tubes extend beneath the pit. Ground-penetrating radar and other instruments on the lander and rover will be used.
New Golden Tree Coral Species from Costa Rica Waters Establishes a New Family
Researchers at the University of Costa Rica described an octocoral found at depths of 360 to 529 meters in ZooKeys. Genetic analysis made it the first member of the newly established family Laurinkiidae.
Kenya Adds 4 New Ebola Cases, Cumulative Total Reaches 7
Kenya's Ministry of Health said three health workers who treated the first fatal patient and one close relative tested positive for Bundibugyo virus disease. Of 130 contacts, 128 have been traced and placed in quarantine.
CDC Tallies 9,235 Ebola Cases and 4,444 Deaths in DR Congo
As of October 15, the CDC recorded 9,235 confirmed Bundibugyo virus disease cases and 4,444 deaths, describing it as the second-largest outbreak on record. There are no related confirmed cases in the United States.
India Caps Distribution Margins at 30% for 137 Anticancer Drugs
India's Drug Price Control Authority published a gazette notice on October 17 limiting distribution margins for 137 non-scheduled anticancer drugs to 30% of the MRP. The revised prices will apply from November 9.
Novo Nordisk Korea Applies for Health Insurance Coverage of Wegovy
Novo Nordisk Korea has applied to the Health Insurance Review and Assessment Service for insurance coverage of its obesity drug Wegovy, according to a report citing Yonhap News.
Hubble Captures Spiral Galaxy NGC 1827 in Columba
NASA released a Hubble image of NGC 1827, about 37 million light-years from Earth. Hubble has so far observed 111 of the 260 satellite galaxies around 22 galaxies similar to the Milky Way.
Earth's Mantle Began Oxidizing 3.4 Billion Years Ago, Nature Geoscience Reports
A research team led by Hugo Moreira at the University of Portsmouth reported that the mantle beneath subduction zones has been more oxidized than its surroundings since 3.4 billion years ago. They analyzed 337 measurements from 39 apatite inclusions in 14 rock samples.
Jim Green and Others Argue Solar System Boundary Should Be Redefined to About 3.8 Light-Years
Former NASA chief scientist Jim Green and Ed Belbruno argue that, based on the galaxy's gravitational field, the solar system's boundary is about 3.8 light-years, or 241,000 AU. The paper was published in the August 2026 issue of ROOM.
El Gordo Collision Simulation Fits Self-Interacting Dark Matter Model
In N-body simulations of El Gordo, a supercluster about 7 billion light-years away, the two-state self-interacting dark matter model matched observations better than the non-interacting model. The model does not fit if the mass and collision velocity estimates are low.
Radio Phoenix Treble Clef Identified Beyond the Galactic Zone of Avoidance
Andrea Botteon's team confirmed for the first time that Treble Clef is a radio phoenix belonging to a merging galaxy cluster. The team used data from Chandra, eROSITA, LOFAR and the UK Infrared Telescope.
MFDS Approves Quinlock Tablets for Rare Gastrointestinal Stromal Tumor Treatment
On the 16th, the Ministry of Food and Drug Safety approved Quinlock 50 mg tablets containing ripretinib as an imported rare medicine. The target is adult patients with advanced gastrointestinal stromal tumors who have received three or more kinase inhibitors, including imatinib.
Ministry of Health to Closely Monitor Mounjaro Insurance Listing Process
In written answers for the National Assembly audit, the Ministry's Pharmaceutical Insurance Division said the drugmaker recently applied and the insurance listing process for Mounjaro (tirzepatide) is under way. The Ministry said it will closely monitor the process to ensure it proceeds smoothly.
Ministry of Health Agrees Abortion Pills Should Be Covered by Health Insurance
In written answers for the National Assembly audit, the Ministry said it agrees there is a need for health insurance coverage of abortion medications, but acknowledged limits to listing them on its own authority. It said it will actively review any application from a drugmaker and will disclose non-covered prices before insurance coverage.
Welfare Committee Audit: Next Year's Health Insurance State Subsidy at 13.8 Trillion Won
In the audit of the NHIS and HIRA, it was noted that the state subsidy budget for health insurance next year totals 13.8 trillion won, and that the ratio including the Health Promotion Fund is 14.4%, below the statutory 20%. The subscriber data leak reported in July was also discussed.
AriBio Shares Experience of Independently Completing Global Phase 3 for AR1001
AriBio presented its operational experience from the Phase 3 trial (POLARIS-AD) of AR1001, its oral Alzheimer's candidate, at KIC 2026 on the 15th. The trial enrolled 1,535 participants at 240 sites in 13 countries, and 1,348 participants, or 87.8%, completed dosing.
NASA releases performance analysis of Artemis II heat shield
In a post-flight analysis, NASA said the heat shield performed as expected. Areas with cracks or char loss fell from 103 on Artemis I to 9, and Orion splashed down within 0.59 miles of its target point.
SpaceX Dragon docks at ISS with more than 6,300 pounds of cargo
SpaceX Dragon docked with the Harmony module's space-facing port on October 15. It was the 35th commercial resupply mission, carrying more than 6,300 pounds of food, equipment and research materials, including equipment for making artificial retinas.
NASA publishes satellite observations of the 2026 El Niรฑo
NASA said it is using satellites to observe an El Niรฑo that began with a Kelvin wave detected near Micronesia in January. NOAA put the probability that this will be the strongest El Niรฑo since 1950 at 83%.
Two more roll-out solar array sets reach ISS, bringing total to eight
NASA said a second set of roll-out solar arrays (IROSA) was aboard the 35th commercial resupply mission. Six were installed in 2021 to 2023, and with eight in total, station power will rise by more than 160 kW.
KMA and pediatric emergency society denounce Ajou University Hospital search
The Korean Medical Association and the Korean Society of Pediatric Emergency Medicine denounced police's search of the Ajou University Hospital pediatric emergency center at a press conference on the 15th at the National Assembly. They demanded that investigation guidelines be established and an apology be issued.
Ajou center head: forensic investigators entered on the day the child died
Lee Ji-sook, head of the Ajou University Hospital pediatric emergency center, said at a National Assembly briefing on the 15th that investigation guidelines reflecting emergency situations are needed. Police said there was no interference with medical treatment.
Emergency medicine society's autumn conference discusses amending the Emergency Medical Service Act
At a session of the Korean Society of Emergency Medicine's autumn conference on the 15th, the society explained that the revised Emergency Medical Service Act aims to split individual doctors' responsibility into a regional transfer system. A Ministry of Health and Welfare official said the ministry would monitor the situation.
Urology society warns of residency hospitals losing accreditation and mobile training
Park Hyun-jun, training director of the Korean Urological Association, warned at a press briefing on the 15th that some hospitals are losing their status as residency hospitals because faculty are leaving. At one non-capital-area hospital, one resident became subject to mobile training.
Chandra Pins Down Galaxy Cluster Collision Behind Treble Clef Radio Structure
X-ray observations by NASA's Chandra and Germany's eROSITA confirmed that the radio structure belongs to a galaxy cluster. The analysis indicates that a galaxy cluster collision occurred several hundred million years ago, after a black hole outburst.
NASA Develops SPEARS Solid-Electrolyte Battery for Lunar South Pole Cold
A prototype cell using ceramic and polymer solid electrolytes instead of liquid operated at minus 60 to 80 degrees in Langley testing, and withstood exposure from 100 degrees down to minus 170 degrees.
Jellyfish Display in US East Coast Sky During CRS-35 Dragon Launch
At dawn on October 13, a Falcon 9 launched CRS-35 from Cape Canaveral. Space.com reported that rocket exhaust froze into crystals, and sunlight hitting them created a jellyfish shape.
Welfare Audit Questions Criteria for Comprehensive Disability Support Assessment
At the welfare committee audit of the National Pension Service on the 14th, Rep. Seo Mi-hwa called a reference witness and questioned the criteria and methods of the comprehensive service-needs assessment that determines the amount of disability activity support benefits.
SpaceX Dragon Launches 35th ISS Resupply Mission
NASA and SpaceX launched CRS-35 on a Falcon 9 on the 13th at 6:33 a.m. Eastern Time. Dragon carried more than 6,300 pounds of supplies and a final pair of rollout solar arrays, and is scheduled to dock with the Harmony module at 11 a.m. on the 15th.
National Assembly Health Committee Audits 14 Agencies Including MFDS
The National Assembly Health and Welfare Committee audited 14 agencies, including the Ministry of Food and Drug Safety (MFDS), on October 13. Questions covered allegations of lobbying over approval of Genexine's COVID-19 treatment clinical trial, Mifegymiso approval, and misuse of obesity drugs.
Treatment-Purpose Use Approvals Average 92 Days from Approval to First Dose
According to an analysis by lawmaker Heo Jong-sik's office, MFDS treatment-purpose use approvals take an average of about 13 days from application to approval, but an average of about 92 days from approval to first dose, with the longest taking about 826 days.
MFDS Audit Issues: Essential Drug Supply and Illegal GLP-1 Sales
Pharmacy Journal reported that from January through September this year, MFDS detected 949 cases of illegal online sales and advertising of GLP-1 obesity drugs, and that it urgently introduced 105 essential drug items by the end of September.
Hubble Data Reanalysis Finds Niobium in White Dwarf HS 0209+0832
A University of Warwick research team reanalyzed 1999 Hubble observations using an updated chemical database and identified niobium. Niobium has not previously been reported in analyzed white dwarfs, and the article says the star may host a second-generation planet.
LBT Team Measures Primordial Helium at 24.58% from Gas Observations of 54 Galaxies
The Large Binocular Telescope project observed interstellar gas regions in metal-poor galaxies and obtained a primordial helium value of 24.58% of early-universe matter. The article says this agrees well with the Planck cosmic microwave background estimate of 24.67%.
New Shepard Capsule Experiment Shows Water Surface Rounder at Lunar Gravity
In an experiment on the NS-29 capsule in February 2025, a centrifugal acceleration close to lunar gravity was created for about two minutes, and water and glycerol solutions were observed. The water meniscus was rounder than at Earth gravity, and the measured surface tension was lower than textbook values.
KDCA Runs Healthcare-Associated Infection Prevention Week, October 12 to 16
The Korea Disease Control and Prevention Agency is running a healthcare-associated infection prevention week from October 12 to 16. It has designated the third week of October every year since 2023.
NHIS Links Nursing and Care Hospital Information to Naver and Kakao Maps
The National Health Insurance Service said on the 12th that it will provide information on hospitals offering integrated nursing and care services through Naver Map and Kakao Map. According to the article, 837 hospitals nationwide can be used this year.
Antarctic IceCube Neutrino Detection Research Wins 2026 Nobel Prize in Physics
The 2026 Nobel Prize in Physics was awarded for detecting high-energy cosmic neutrinos using the IceCube Observatory buried 2.7 km beneath Antarctic ice. NASA featured it as the Astronomy Picture of the Day on October 11.
Mars Transits Beehive Cluster M44 โ Visible to Naked Eye and Binoculars on Oct 11
From October 9 to 16, Mars is passing through the Beehive Cluster (M44), a group of about 400 stars. On October 11, the planet crosses the cluster's core and is visible to the naked eye and with binoculars.
Sun Emits M-Class Flare from Unexpected Active Region, Aurora Alert Issued
An M-class solar flare erupted from an unexpected active region on the Sun's surface. EarthSky reported the region will soon rotate out of view, and a geomagnetic disturbance warning was issued.
Bangladesh Measles Outbreak Passes 1,140 Deaths โ World's Worst Measles Crisis
Cumulative deaths from Bangladesh's measles outbreak have exceeded 1,140. WHO and UNICEF mounted an emergency response while a nationwide vaccination campaign has been intensified.
Kent, UK Meningitis Cluster at 34 Cases โ New Cases Declining After 8,000+ Vaccines Administered
The meningitis cluster in Kent, UK reached 34 confirmed cases. After more than 8,000 preventive vaccines were administered, the rate of new cases showed its first signs of decline.
Artemis II Moon Expedition's 12,000 Photos Now in Scientific Analysis for Future Base Sites
NASA Artemis II astronauts publicly released 12,000 photos taken during their lunar flight with scientific annotations. Researchers are analyzing lunar surface geology and lava tube locations to identify potential sites for a crewed lunar base with radiation shielding.
ESA-JAXA BepiColombo Enters Final Approach to Mercury Orbit After 8-Year Journey
The ESA-JAXA joint Mercury probe BepiColombo completed approximately 8 years of flight since its 2018 launch and entered the final stage of Mercury orbit capture. ESA released spacecraft status and initial Mercury observation data ahead of the planned orbit insertion in November.
PAHO Issues Very High Alert for Measles Spread in Americas Ahead of Religious Mass Gatherings
The Pan American Health Organization (PAHO) assessed the risk of measles spread in the Americas as very high ahead of large religious gatherings. Ongoing outbreaks across multiple countries combined with mass population movements and declining vaccination rates are driving the risk higher.
World Mental Health Day Calls for Stronger Mental Health Support in Humanitarian Crises
International health organizations marked World Mental Health Day on Oct 10 by calling for stronger mental health support amid conflict and disaster. One in eight people globally experience mental health issues, yet access to services remains inadequate for vulnerable populations.
India Metabolic Health Summit Highlights Deepening Crisis from Surging Diabetes and Obesity
Experts at India's Metabolic Health Summit warned of a deepening crisis as diabetes and obesity burdens surge. They emphasized the urgency of preventive approaches through lifestyle changes and early diagnosis, along with strengthening healthcare system capacity.
SpaceX Crew-12 splashes down with 4 astronauts after 237-day ISS mission
SpaceX Crew Dragon splashed down off the California coast on October 8, 2026, returning four astronauts after a 237-day ISS mission.
2026 Draconid meteor shower peaks October 8-9 with ideal dark-sky viewing conditions
The annual Draconid meteor shower, radiating from the constellation Draco, reached its 2026 peak on October 8-9. With no bright moon, conditions were optimal to observe dozens of meteors per hour.
Roche receives FDA approval for atezolizumab as adjuvant therapy in stage III dMMR colon cancer
Roche's immunotherapy atezolizumab (Tecentriq) received FDA approval as adjuvant therapy for patients with surgically resected stage III mismatch repair deficient (dMMR) colon cancer. Clinical trials demonstrated superior tumor recurrence suppression compared to chemotherapy alone.
HHS and NIH announce $200M national cancer vaccine clinical initiative
The U.S. Department of Health and Human Services and NIH announced a $200 million cancer vaccine clinical initiative to accelerate development of mRNA-based therapeutic cancer vaccines. Shares of related biotechs including Moderna and BioNTech surged.
Ebola (Bundibugyo strain) continues spreading in DRC and Uganda; WHO maintains emergency response
An outbreak of Ebola Bundibugyo strain in the Democratic Republic of Congo and Uganda continues to spread with the WHO maintaining an emergency response. The CDC has also joined international efforts as confirmed cases and deaths continue to rise.
Nobel Physics: Francis Halzen, IceCube Neutrino Observatory
Francis Halzen of the University of Wisconsin received the 2026 Nobel Prize in Physics for leading the IceCube Neutrino Observatory. IceCube's 5,160 optical sensors in 1 kmยณ of Antarctic ice detect high-energy cosmic neutrinos, enabling multi-messenger astronomy.
Nobel Medicine: Optogenetics Inventors Win for Brain Control Breakthrough
Deisseroth, Hegemann and Nagel were awarded the 2026 Nobel Prize in Medicine for inventing optogenetics, a technique that switches individual neurons on and off with light. The technology is the foundation of clinical trials targeting Parkinson's disease, depression and blindness.
Optogenetics Nobel Win Accelerates Parkinson's & Depression Therapy
The 2026 Nobel Medicine prize for optogenetics is expected to accelerate clinical development of light-based therapies for Parkinson's disease, treatment-resistant depression and vision disorders. Biotech and medical device stocks rose sharply following the announcement.
Brigham and Women's Nurses Strike Threat Risks Patient Care Gaps
Brigham and Women's Hospital nurses' threat of an indefinite strike from October 14 is creating anxiety over patient care gaps at the flagship Boston academic hospital. The hospital is seeking backup nursing staff but acknowledges difficulty filling specialty roles.
Explosion Reported at Russian Siberian Plague Research Facility
An explosion occurred at a plague-pathogen research facility in Siberia, Russia. Authorities stated there was no biosafety threat, but the cause of the blast is under investigation.
DRC Ebola Cumulative Death Toll Surpasses 3,000
Cumulative Ebola-related deaths in the Democratic Republic of the Congo exceeded 3,000. The WHO issued an urgent appeal for additional support to contain the ongoing outbreak.
2026 Nobel Prize in Chemistry: Kagan & Soai Honoured for Chiral Catalysis
Henri Kagan and Kenso Soai won the 2026 Nobel Prize in Chemistry for jointly developing asymmetric chiral catalysis methods. Their work enabling selective synthesis of mirror-image molecules is widely applied in the pharmaceutical industry.
NASA Astronomy Picture of the Day Features Supernova Remnant Pa 30
NASA's October 7 Astronomy Picture of the Day (APOD) showcased Pa 30, a supernova remnant from an explosion roughly 1,000 years ago. The image clearly captured the nebula's sulphur-emission filament structure.
2026 Nobel Physiology Prize Goes to Three Optogenetics Pioneers Who Unlocked Brain Control with Light
Karl Deisseroth (Stanford), Peter Hegemann and Georg Nagel (Germany) won the 2026 Nobel Prize in Physiology or Medicine for pioneering optogenetics, a technique that uses light to precisely switch neurons on and off, providing a revolutionary tool for decoding brain function.
Amsterdam Long-COVID Conference Centers on Biological Pathways and Mechanistic Trials
The first International Long-COVID and Post-Acute Infection Syndromes Conference (ISLC-PAIS) was held in Amsterdam in early October, with presentations focused on immune dysfunction, biological disease pathways and mechanistic clinical trials, according to The Sick Times reporting on October 6.
Prof. Halzen, Designer of IceCube in Antarctica, Wins 2026 Nobel Physics Prize Alone
Francis Halzen, 82, of the University of Wisconsin, won the 2026 Nobel Physics Prize โ alone. He designed and built the IceCube Neutrino Observatory beneath the Antarctic ice, achieving the world's first detection of high-energy cosmic neutrinos. It is the first solo physics Nobel in 34 years.
2026 Nobel Prize in Medicine Awarded to 3 Optogenetics Researchers
Karl Deisseroth (U.S.), Peter Hegemann and Georg Nagel (Germany) received the 2026 Nobel Prize in Physiology or Medicine for developing optogenetics, a technology that precisely controls brain neurons using light. The Swedish Nobel Committee announced on October 5.
Mixed Results from Multiple mRNA Cancer Vaccine Trials Spark Experts' Efficacy Debate
Divergent results from various mRNA-based cancer vaccine clinical trials have sparked a debate among experts about the reliability of therapeutic efficacy. Some trials showed positive outcomes while others fell short of expectations.
SpaceX Scrubs Launch of 21 SDA Data Transport Satellites Due to Technical Issue; Retries Tuesday
SpaceX aborted the Falcon 9 launch carrying 21 Space Development Agency (SDA) data transport satellites on October 4 due to a technical issue. A re-launch from Vandenberg Space Force Base is being prepared for October 6.
NASA Shares M104 Sombrero Galaxy Giant Tidal Streams as Astronomy Picture of the Day
NASA released an image of the giant tidal streams around the M104 Sombrero Galaxy as its Astronomy Picture of the Day (APOD) on October 5. The structure is noted as evidence of the galaxy's history of collisions and mergers with smaller galaxies.
Samsung BioLogics & Lotte Biologics Expand CDMO Pipeline at BioJapan
Samsung BioLogics and Lotte Biologics both participated in BioJapan, seeking to expand their CDMO order books. Both companies plan to broaden their Japan and Asia market pipelines by strengthening global customer touchpoints.
GC Biopharma Enters Phase 2 for COVID-19 Vaccine Using Proprietary mRNA-LNP Platform
GC Biopharma entered Phase 2 clinical trials for a COVID-19 vaccine built on its proprietary mRNA-LNP platform technology. The platform improves protein translation efficiency by over 50% and will be expanded to oncology and other fields.
Mediana Secures 6,500-Bed Contracts With AI-Integrated Patient Monitoring
Medical device maker Mediana secured cumulative contracts for 6,500 hospital beds with its wired/wireless integrated patient monitoring solution. The company is accelerating integration with deep-learning medical AI 'DeepCAS' to advance smart hospital operations.
ISS Command Transferred to Crew-13, Expedition 74 Officially Begins
At 10:20 a.m. ET on October 4, the Crew-12 commander officially transferred ISS command to Crew-13, beginning Expedition 74. Crew-12 is expected to return as early as October 7.
Saturn at Opposition Oct 4 โ Best Viewing Opportunity of 2026
Saturn reached opposition on October 4, making it closest to Earth and the brightest and largest it will appear all year. It is visible to the naked eye, and a small telescope will show its rings clearly.
World Space Week Opens, Theme 'Rocket Revolution' With 5,000+ Global Events
World Space Week (October 4-10) kicked off with the 2026 theme 'Rocket Revolution,' featuring more than 5,000 events worldwide spotlighting the democratization of space access across nations.
KT releases hospital AI standard model targeting top-tier hospitals
KT unveiled a medical AI standard model automating reception, medical records and cancer diagnostics, with plans to expand it to top-tier general hospitals.
COVID mRNA vaccines shown to boost immune response in brain tumour patients
Research confirmed that COVID-19 mRNA vaccines enhance immune responses in brain tumour patients. Synergy with tumour immune checkpoint inhibitors is drawing attention as a potential cancer treatment approach.
Crew-13 docks ISS 8 hours after launch, fastest U.S. crewed spaceflight
NASA and SpaceX's Crew-13 docked with the International Space Station just 8 hours after launch, setting the fastest crewed docking record in U.S. history.
First daytime polar aurora captured from space during active mission
A space mission captured daytime aurora borealis over Earth's polar regions for the first time, offering new insights into the mechanisms of high-latitude aurora formation.
NASA APOD releases complete visualisation of 313 Sharpless catalog nebulae
NASA's Astronomy Picture of the Day featured a complete visualisation of all 313 nebulae in the Sharpless catalog, covering the full expanse of the catalogue in a single image.
Saturn reaches optimal viewing conditions Oct 2โ9, closest approach and best ring angle
Saturn approaches opposition between October 2 and 9, offering the best viewing conditions of the year with optimal ring angle and closest approach to Earth.
FDA approves Wegovy cardiovascular indication for non-diabetic obese patients
The FDA approved an additional indication for Novo Nordisk's semaglutide (Wegovy) on October 1, covering reduction of cardiovascular death and heart attack risk in obese patients without diabetes, marking the first cardiovascular prevention indication for an obesity drug.
โฆ RELATED STORYLINEKorea's MOHW issues health insurance coverage rules for AI diagnostics
The Ministry of Health and Welfare issued health insurance coverage standards for AI-based medical imaging diagnostic aids on October 1. AI-assisted reading of gastroscopy and chest CT scans will be reimbursed at 30,000-80,000 won per case.
Severance Hospital announces Korea's first brain tumor CAR-T Phase 1 results
Severance Hospital published results of Korea's first Phase 1 CAR-T cell therapy trial for glioblastoma (GBM) on October 1. Partial tumor remission was confirmed in 4 of 12 enrolled patients.
SpaceX launches 3 Falcon 9 rockets in 13 hours, shortest tripleheader ever
SpaceX launched three Falcon 9 rockets from Florida and California in just 13 hours on October 1, achieving the shortest tripleheader in history. Missions included Starlink satellite deployment and a military cargo payload.
Crew-13 Dragon docks ISS 9 hours after launch, sets crewed record
SpaceX's Crew-13 Dragon capsule docked with the ISS just 9 hours after launch on October 1, setting the fastest crewed docking record. Four NASA astronauts began their 6-month mission.
NASA confirms Europa Clipper successfully enters Jupiter orbit
NASA confirmed on October 1 that the Europa Clipper spacecraft successfully completed its Jupiter Orbit Insertion (JOI) maneuver. A first close flyby of Europa is scheduled within two weeks.
KAIST publishes revalidation study of novel material K-55 in PRL
A KAIST research team published revalidation results for the electrical resistance properties of novel material K-55 in Physical Review Letters on October 1. The team stated room-temperature superconductivity cannot be ruled out, but further verification is needed.
September 2026 ยท 139
Hanmi Pharmaceutical's Tuspetinib Achieves 86.2% Complete Remission in Elderly AML
In the TUSCANY Phase 1/2 trial, 25 of 29 elderly AML patients ineligible for intensive chemotherapy achieved complete remission with tuspetinib combined with venetoclax and azacitidine, matching or exceeding more intensive regimens.
Childhood Obesity in Korea Nears 30%; Parliament Calls for Insurance Coverage
The overweight/obesity rate among school-age children rose from 13.6% in 2017 to 18.5% in 2025, approaching 30% for all students. Experts at a parliamentary forum called for a 26-week treatment pathway and health insurance coverage for counseling and education.
Daewoong Pharmaceutical Opens Cell and Immunotherapy Clinical Facility in Songdo
A clinical-grade sterile manufacturing and quality control facility for cell, stem cell, and immunotherapy drugs opened at Yonsei University's international campus in Songdo on September 28, 2026, with over 30 attendees including Ministry of Health and Incheon FEZ Authority representatives.
Hypertrophic Cardiomyopathy: Only 3,657 of Estimated 100,000 Patients Diagnosed in Korea
Despite an estimated global prevalence of 1 in 500, only 3.6% of Korea's estimated patients have an official diagnosis. Mavacamten (Camzyos) showed 74% LVOT gradient improvement in trials and 90% symptom improvement in real-world data.
SpaceX Starship 14 Achieves Historic First Orbital Entry and Sea Landing
SpaceX's Starship launched from Starbase, Texas on September 28 and entered orbit for the first time in history before successfully splashing down at sea. The mission also carried the first Starlink V3 satellites, validating Starship's complete orbital operational capability.
Ganymede Transits Jupiter on September 29 โ Shadow Also Visible
Jupiter's largest moon Ganymede was observed transiting Jupiter's disk on September 29. Even small telescopes could track Ganymede and its shadow moving across the Jovian disk.
NASA APOD Spotlights Shrimp Nebula Sh2-188
NASA selected the Shrimp Nebula (Sh2-188) as the Astronomy Picture of the Day for September 29. This planetary nebula, formed by gas released from a dying white dwarf, is known for its distinctive shrimp-like structure.
FDA Grants Final Approval for Once-Weekly Insulin
The FDA has granted final approval to a once-weekly injectable insulin for diabetes patients. The new dosing regimen is expected to significantly improve convenience compared with daily injections, benefiting millions of patients.
Mayo Clinic AI Pancreatic Cancer Early Detection Model Achieves AUROC 0.853
Mayo Clinic's AI-based pancreatic cancer early detection model achieved an AUROC of 0.853, substantially outperforming current clinical standards and demonstrating strong potential to improve early diagnosis rates.
Survey Finds 16.8% Pediatric GLP-1 Prescription Shortage Rate
A survey of U.S. pediatricians found that GLP-1 obesity drugs face a 16.8% shortage rate for pediatric prescriptions. Adult demand growth is squeezing supply and reducing medication access for children with obesity.
โฆ RELATED STORYLINESpaceX Starship 14 Achieves First Full Orbital Flight
SpaceX's Starship 14 completed its first fully orbital flight on September 28. The vehicle completed a full orbit, and both the Super Heavy booster and the Starship upper stage were recovered successfully at their designated landing sites.
26 Starlink V3 Satellites Successfully Deployed to Orbit
The Starship 14 mission successfully placed 26 next-generation Starlink V3 satellites into orbit. The V3 constellation offers significantly higher data throughput than earlier generations, promising improved global broadband coverage.
โฆ RELATED STORYLINEISS Ready for New Crew, Current Team Conducting Health Research
The International Space Station has completed preparations for an incoming crew. The current crew members are conducting human health research in microgravity conditions as part of long-duration spaceflight studies.
CIDRAP releases broccoli sprout salmonella cluster findings
CIDRAP published results of an epidemiological investigation into a US salmonella cluster linked to broccoli sprouts. A total of 89 patients across 11 states were confirmed, with supply chain tracing pointing to a single distributor as the common source.
CDC issues early alert for E. coli O26 outbreak
The CDC issued an early alert for an E. coli O26 outbreak with 34 confirmed cases across 6 states. Officials noted that underreporting likely means the true case count is higher; the source has not yet been identified.
WHO recommends 2026-27 Northern Hemisphere flu vaccine composition
The WHO released its recommended flu vaccine antigen composition for the 2026-27 Northern Hemisphere season. The recommendation incorporates updated analysis of H1N1, H3N2, and influenza B strain variants, and manufacturers have begun production.
FDA launches simultaneous safety probes on 17 drugs
The FDA initiated concurrent safety investigations on 17 prescription drugs following a spike in adverse event reports. Most involve GLP-1 obesity drugs and new anticoagulants, reflecting heightened post-market monitoring amid rapid market growth.
โฆ RELATED STORYLINESpaceX Crew-13 splashes down at Kennedy Space Center
Four Crew-13 astronauts returned from the International Space Station, splashing down successfully off Kennedy Space Center in a SpaceX Dragon capsule. After 181 days in orbit, the crew completed post-landing medical checks before reuniting with family.
SpaceX launches fourth Starshield military satellite batch
SpaceX successfully launched the fourth batch of Starshield military communications satellites for the US Department of Defense on a Falcon 9 rocket. The launch brings the total number of Starshield satellites in LEO past 80.
Starship Flight 14 ground checks complete; awaiting FAA approval
SpaceX announced that ground systems checks for Starship's 14th test flight are complete. The vehicle is awaiting final FAA approval; a key goal of the flight is a renewed Super Heavy booster propulsive landing attempt.
Congo Ebola Death Toll Exceeds 3,700
According to UN reports, the Ebola outbreak in the Democratic Republic of Congo has resulted in over 3,700 cumulative deaths. MSF continues ground response operations while WHO calls for sustained international support.
Karolinska Institute Links Reduced Brain Blood Flow to Long COVID Fatigue
Researchers at Sweden's Karolinska Institute confirmed through imaging studies that reduced brain blood flow in Long COVID patients directly correlates with post-COVID fatigue symptoms. Cerebral blood flow abnormalities are gaining attention as the biological mechanism behind Long COVID fatigue.
CDC Updates 2026-27 Fall Vaccination Guidance for Flu, COVID, and RSV
Health authorities including the CDC updated the 2026-27 season vaccination guidance for influenza, COVID-19, and RSV. Experts recommend simultaneous fall vaccination, with priority urged for high-risk groups including elderly and immunocompromised individuals.
Fiji Declares National HIV Emergency with 1 in 60 People Infected
The Fiji government declared a national HIV emergency due to rapid spread of the virus. Approximately 1 in 60 people was reported as infected, with a methamphetamine crisis identified as a major contributing factor. UNAIDS and WHO have stepped in with international support.
SpaceX Crew-13 Lands at Kennedy Space Center After Completing ISS Mission
NASA and SpaceX Crew-13 astronauts landed at Kennedy Space Center on September 26, completing their long-duration International Space Station mission. The landing was confirmed through NASA's official blog.
Next ISS Crew Arrives in Florida for Pre-Launch Preparations
Astronauts assigned to the next International Space Station mission arrived at Kennedy Space Center on September 26. According to Spaceflight Now, they arrived in Florida to complete final pre-launch procedures.
SpaceX Falcon 9 Launches Classified Space Force Payload from West Coast
A SpaceX Falcon 9 rocket launched a classified U.S. Space Force payload from the West Coast launch site. Orbital Radar reported this as the mission scheduled for September 26.
SpaceX Starship 14 Fully Stacked for First Orbital Flight Attempt
SpaceX completed the full stack of Starship and the Super Heavy booster for the first orbital flight attempt. According to AIAA reporting, Starship Flight 14 is in final preparations targeting a possible launch as early as September 28.
Each Extra 100g of Ultra-Processed Food Raises Cardiovascular Risk by 14%
A Duke-NUS medical school team's meta-analysis of 8.8 million people across 51 cohorts found each additional 100g/day of ultra-processed food raises cardiovascular disease risk 14%, cancer 4%, depression/anxiety 27%, and digestive disease 31%.
Former Professional Soccer Players Have 16% Lower Mortality Than Peers
A study tracking 7,620 British Football League players from 1963โ2022 found former players had a standardized mortality ratio of 0.84, 16% lower than same-age peers. Researchers described soccer as combining endurance, high-intensity interval, and strength training.
Korea's EGFR Lung Cancer First-Line Drug Rybrevant Not Covered by Insurance
The amivantamab (Rybrevant) plus lazertinib combination therapy is gaining attention as a first-line treatment for EGFR-mutated non-small cell lung cancer, but experts noted that Korea's national health insurance does not cover it, limiting patient access.
NASA Selects Far-Infrared Telescope PRIMA as First in New Mission Class
NASA selected the PRIMA far-infrared space telescope as the first example of a new Probe-class mission. Valued at $1.2 billion with a target launch date of 2033, it has entered Phase B (design) development.
NASA Roman Space Telescope Confirms Ground Station Contact, Activates Coronagraph
The NASA Roman Space Telescope team officially confirmed ground station data reception. It has deployed solar panels and communications systems and begun initial commissioning with the coronagraph instrument and 300-megapixel camera operational.
Northrop Grumman Cygnus XL Successfully Completes ISS Reboost
Northrop Grumman's Cygnus XL successfully completed an ISS orbital reboost on September 25. NASA and SpaceX said they are in the final preparation phase for the Crew-13 launch.
Korea Flu Cases Quadruple Year-on-Year, Children Hardest Hit
According to the KDCA, flu suspect patients have quadrupled compared to the same period last year, rising for 8 consecutive weeks. The outbreak is concentrated among elementary school children and is more than a month earlier than normal.
Govt Moves Up Flu Vaccination Schedule Amid Early Epidemic
As the flu detection rate surged to 25.4% and an epidemic alert was issued, the government and local authorities decided to advance the national vaccination schedule. Elderly and young children in high-risk groups are prioritized for vaccination.
SpaceX Starship Flight 14 Wet Dress Rehearsal Complete
SpaceX completed the wet fueling rehearsal for Starship Flight 14 on September 24. This flight is Starship's first-ever orbital launch attempt, carrying 26 Starlink V3 satellites.
โฆ RELATED STORYLINENASA Roman Telescope Captures First Starlight with 300-Megapixel Camera
The NASA Roman Space Telescope, launched in late August, activated its 300-megapixel camera and captured starlight from space for the first time. With a field of view 100 times wider than Hubble, it will be used to study dark matter and the expansion of the universe.
Government and Medical Community Resume Healthcare Reform Talks
The government and the medical community have resumed healthcare reform negotiations to discuss improved residency training conditions and adjustments to medical school enrollment.
South Korea's 2027 Health & Welfare Budget Set at Record High
The government has drafted the 2027 health and welfare budget at a record-high level, focusing on long-term care services for an aging population and expanding mental health support.
JWST Detects Water Molecules in Exoplanet K2-18b Atmosphere
The James Webb Space Telescope (JWST) has detected water molecules and carbon-based chemical compounds in the atmosphere of exoplanet K2-18b. Researchers say there is a possibility of liquid water on its surface.
2026 flu epidemic alert issued in September, pediatric outpatient rate near 79.6 per 1,000
The Korea Disease Control and Prevention Agency issued an influenza epidemic alert on Sept 11. The outpatient rate for Sept 7-13 was 31.0 per 1,000, a 4.6-fold increase year-on-year. Children aged 7-12 showed the highest rate at 79.6 per 1,000 outpatient visits.
Free flu vaccination expanded to age 14 for 2026-27 season, rolling out from Sept 21
The target age for the 2026-27 national influenza vaccination was expanded from 13 to 14 years old. Due to the early outbreak, the vaccination schedule was moved forward with sequential rollout from Sept 21. Those aged 65 and older can receive shots from Oct 6.
Autumnal equinox arrives as sun crosses celestial equator, marking start of astronomical fall
The 2026 autumnal equinox occurred on Sept 22 at 8:05pm EDT as the sun crossed the celestial equator from north to south, officially marking the start of astronomical fall in the Northern Hemisphere. The Southern Hemisphere simultaneously began its astronomical spring.
Sunspot group AR4534 growing on sun-facing side; C-class solar flare recurs
Three solar phenomena were observed on Sept 22. The growing sunspot group AR4534 reappeared on the Earth-facing side of the sun, a C-class solar flare recurred, and a coronal hole reached an Earth-effective position.
Earliest flu outbreak on record; national flu vaccination for children and pregnant women begins Sept 21
Korea's KDCA launched national influenza vaccination for children and pregnant women on Sept 21 in response to the early outbreak. The eligible age was expanded from 13 to 14 years old; flu cases have surged 4.6 times compared to last year.
Flu-COVID-19 twindemic concerns ahead of Chuseok; elementary students show highest case rates
Flu suspected cases surged 4.6 times year-on-year ahead of the Chuseok holiday, coinciding with ongoing COVID-19 circulation. Children aged 7-12 showed the highest rate at 79.6 per 1,000 outpatient visits; health authorities emphasized vaccination and hygiene.
NASA Roman Space Telescope confirms successful activation of 300-megapixel infrared camera (WFI)
NASA's Roman Space Telescope, launched Aug 30, confirmed successful activation of its 300-megapixel Wide Field Instrument (WFI) on Sept 21. The planet-hunting coronagraph also verified normal operation, entering the calibration and testing phase.
Albania officially joins Artemis Accords as 73rd signatory, expanding European participation
Albania officially signed the Artemis Accords at NASA headquarters on Sept 21, becoming the 73rd member. The accords, launched in 2020, are an international agreement on principles for the peaceful use of space exploration including the Moon and Mars.
President Lee Backs Abortion Pill Rollout...Q1 Rollout at Medical Institutions Planned
President Lee Jae-myung expressed support on September 17 for the government's plan to introduce abortion pills (mifepristone) in stages. The government plans to allow prescriptions within nine weeks of pregnancy at medical institutions starting in the first quarter of next year.
40% of Koreans Received Prescription Opioids in 2024...Teen Prescriptions Up 1.9x in 5 Years
According to the National Assembly Research Service, 20.01 million Koreans (40% of the population) received prescription controlled substances in 2024, with total prescriptions reaching approximately 1.9 billion. Prescriptions for children and teenagers under 19 grew 1.9 times in five years, and ADHD medication prescriptions rose 139% in the same period.
SK Biopharmaceuticals' Cenobamate Wins Japan MHLW Approval...Northeast Asia Trio Complete
SK Biopharmaceuticals' partner Ono Pharmaceutical received Japanese Ministry of Health, Labour and Welfare approval for cenobamate (Xcopri) for epilepsy treatment. Following approvals in South Korea and China, the Northeast Asian trio of approvals is now complete, and SK Biopharmaceuticals holds milestone payment rights.
Youngest-Ever Exoplanet Elias 2-24b Officially Confirmed by Keck Observatory
Jupiter-sized exoplanet Elias 2-24b was confirmed to be less than 1 million years old using Keck Observatory data. Located 453 light-years from Earth, it is still growing within a gas and dust disk, shattering the previous youngest record and raising questions about planet formation theory.
NASA New Horizons Data Reveals First Evidence of Liquid Nitrogen Flow on Pluto's Surface
The Southwest Research Institute (SwRI) analyzed New Horizons data and announced the first evidence that subsurface liquid nitrogen has risen to Pluto's surface through fractures in the northern edge of Sputnik Planitia. Computer models show melted nitrogen at the base of glaciers ascending through microscopic channels.
Ministry of Health and Welfare Officially Announces Plan to Introduce Abortion Medication Domestically
The Ministry of Health and Welfare officially announced on September 16 a plan to introduce abortion medication domestically. Improved medical accessibility is expected when introduced as an alternative to existing surgical methods. Specific implementation timeline and prescription requirements remain under discussion.
Flu Alert Issued Early...25.3 per 1,000 Outpatient Visits, 3.8 Times Year-Over-Year
The Korea Disease Control and Prevention Agency issued a flu alert for the 2026-2027 season more than a month earlier than usual. Suspected influenza cases per 1,000 outpatient visits reached 25.3, 3.8 times higher than the 6.6 per 1,000 from the same period last year, and national vaccination for children and pregnant women begins on September 21.
NASA Crew-12 Holds Press Briefing on ISS Return Schedule for 16th...Splashdown Off California Coast Planned
Four astronauts from NASA SpaceX Crew-12 held a press briefing at 2:45 p.m. EDT on September 16 from the International Space Station to announce their return schedule and mission achievements. Splashdown is planned for the Pacific Ocean off the California coast.
SpaceX Crew-13 Dragon Oxidizer Leak Persists into Third Week...Progress 96 Docks with ISS
SpaceX Crew-13 Dragon capsule's oxidizer leak problem continues into its third week as of September 16. On the same day, Russia's Progress 96 cargo spacecraft successfully docked with the ISS carrying approximately 3 tons of food, fuel, and supplies.
Flu-COVID Twindemic Alert Raised; Vaccination Schedule to Be Advanced
Concerns over a simultaneous flu and COVID-19 epidemic have intensified. Health authorities said they are discussing moving up the national flu vaccination schedule for high-risk groups to address the dual surge.
Sillajen Files IND for Pain-Relief Injectable WS2405 Phase 1 Trial
Sillajen filed for IND approval with the MFDS on September 15 for a Phase 1 clinical trial of its dexibuprofen injectable WS2405. The trial is planned with 24 healthy adults at Seoul Bumin Hospital.
Shinpoong Pharma Files to Amend Phase 3 Protocol for Stroke Drug SP-8203
Shinpoong Pharmaceutical filed for approval to amend its Phase 3 clinical trial protocol for acute ischemic stroke drug SP-8203 (otaplimastat) with the MFDS on September 15. The multi-center study targets 852 patients receiving thrombolytic therapy.
ESA FLEX Satellite Successfully Launched to Map Global Photosynthesis
Avio successfully launched ESA's Earth Explorer FLEX satellite on September 15. The satellite will map photosynthetic activity and carbon cycling across the entire planet.
NASA Crew-12 Holds ISS Press Conference to Announce Return Timeline
On September 16, NASA astronauts Jessica Meir and Zach Hairston, ESA's Sophie Adenot, and Roscosmos's Andrei Fedyaev held a press conference aboard the ISS to announce their upcoming return schedule.
Coreline Soft AI lung nodule CAD first Korean product to receive Japan PMDA approval
Coreline Soft's chest CT-based lung nodule detection aid AVIEW Lung Nodule CAD received approval from Japan's PMDA. It is the first Korean CT-based lung nodule CAD to enter the Japanese market, adding to existing U.S. FDA and European CE clearances.
KDCA issues 2026-27 influenza epidemic alert as hospitalizations double in one week
The Korea Disease Control and Prevention Agency issued the official 2026-27 seasonal influenza epidemic alert. The influenza-like illness rate at clinics stood at 25.3 per 1,000 outpatients, nearly double the epidemic threshold, while hospitalizations in week 36 surged to 300 cases, double the prior week.
9 Korean K-AI medical device firms showcase at Medical Fair Asia 2026 in Singapore
The Korea Medical Device Cooperatives operated a 144-square-meter K-AI Medical pavilion at Medical Fair Asia 2026 in Singapore. Nine Korean AI medical device companies including Airs Medical and Promedius exhibited products in imaging analysis and monitoring.
LZ dark matter experiment detects unexplained 2.6-sigma signal; possible WIMP candidate
The LZ experiment collaboration detected a 2.6-sigma particle interaction signal in its 10-tonne liquid xenon detector that cannot be explained by known background sources. The signal could be a trace of WIMPs, a dark matter candidate, but falls short of the 5-sigma threshold required to claim a discovery.
Large solar filament erupts on Sun's southwest region; CME headed toward Earth vicinity
A large filament eruption accompanied by a C1.4-class flare was observed in the Sun's southwest region in the early hours of September 14 (KST). The resulting coronal mass ejection (CME) is predicted to deliver a glancing blow to Earth around September 17.
Cygnus XL completes ISS orbit reboost to normal altitude on September 14
The Cygnus XL cargo spacecraft, docked to the International Space Station, completed a reboost burn on September 14 to restore the ISS to its normal orbital altitude. The ISS requires periodic reboosts to counteract gradual orbital decay.
Flu-like symptoms surge 4x, disease control agency issues influenza alert for 2026-27 season
The Korea Disease Control and Prevention Agency confirmed flu-like illness occurrence surged 4x year-over-year and issued an official influenza alert for the 2026-2027 season. It strongly recommended vaccination for vulnerable populations.
Samsung BioLogics announces 350.8 billion won CMO contract with European pharmaceutical company
Samsung BioLogics announced through disclosure that it has signed a 350.8 billion won biopharmaceutical contract manufacturing organization (CMO) contract with an anonymous European pharmaceutical company.
Lasertinib wins inaugural Prix Galien Korea Best Drug Award
Lasertinib, an EGFR-targeting lung cancer therapeutic, won the inaugural Prix Galien Korea Award for Best Drug. The achievement recognized the competitiveness of the Korean innovative drug jointly developed by Oscotec and Yuhan-Kimberly.
GC Pharma receives MFDS approval for COVID-19 mRNA vaccine candidate Phase 2 IND
GC Pharma obtained approval from the Ministry of Food and Drug Safety for a Phase 2 clinical trial of its COVID-19 mRNA vaccine candidate.
First confirmation of 10-sided atmospheric pattern at Saturn's south pole, symmetrical to north pole hexagon
Hubble observation-based research presented at EPSC2026 first officially confirmed a 10-sided jet stream wave at Saturn's south pole at 63ยฐ latitude. The findings suggest a symmetrical structure with the north pole's hexagonal pattern.
International Space Summit 2026 opens in Daejeon with ~4,000 space industry leaders and researchers
The International Space Summit 2026 was held in Daejeon, bringing together approximately 4,000 space industry leaders and researchers. Korea's status as a space industry hub was highlighted.
UN-Korea space weather workshop concludes in Seoul after September 7-11 sessions
The International Space Weather Initiative (ISWI) workshop, jointly hosted by UNOOSA and the Korea Aerospace Administration, concluded on September 11 after sessions in Seoul September 7-11. Results on strengthening Sun-Earth research capabilities were shared.
WHO: DRC Ebola Sets Record with 6,757 Cases, 3,267 Deaths, 48.3% Fatality Rate
WHO Disease Outbreak Notice 617 (September 10) confirmed 6,757 DRC Ebola cases and 3,267 deaths โ a 48.3% case fatality rate โ making this the largest Ebola outbreak ever recorded in the DRC. The outbreak has spread across 61 health zones in six provinces, with new cases in South Ubangi province.
International Physics Team: Quantum Collapse Models May Impose Fundamental Limit on Clock Precision
An international research team analyzed quantum collapse models and showed that time itself may carry a subtle fundamental uncertainty. While the effect is far beyond current atomic clock precision, the researchers said it could serve as a clue for unifying quantum mechanics and gravity.
Mercury Shrank Up to 23km in Diameter โ 30% More Than Previous Estimates, German Team Finds
A German Aerospace Center team re-analyzed Mercury's surface and uncovered shrinkage evidence buried under asteroid debris. The results show Mercury's diameter decreased by up to 23 km โ approximately 30% more than prior estimates.
STAREE trial: statins cut major cardiovascular events 30% in adults over 70 with no prior CVD
In a trial of approximately 10,000 adults over 70 with no cardiovascular or diabetes history, atorvastatin 40mg reduced major cardiovascular events by 30% compared with placebo. Results were simultaneously published in the NEJM.
US' largest cyclosporiasis outbreak near official end โ 11,458 infected, 2 dead across 20 states
Contaminated Taylor Farms romaine lettuce from Mexico infected 11,458 people and hospitalized 495 across 20 US states, with 2 deaths, in the country's largest known cyclosporiasis outbreak. Federal authorities were poised to declare the outbreak over on September 10.
SpaceX Falcon 9 successfully launches classified USSF-153 โ booster completes 27th flight
A Falcon 9 lifted off from Vandenberg SLC-4E at 15:43 UTC on September 10, delivering a classified payload to low Earth orbit. Booster B1081 completed its 27th flight and successfully landed on a Pacific drone ship.
Interstellar comet 3I/Atlas: deuterium ratio 30x higher than solar comets, formed 12 billion years ago in extreme cold
Measurements from the James Webb Space Telescope and ALMA show the deuterium-to-hydrogen ratio in 3I/Atlas water is about 30 times higher than in solar system comets. The research team concluded it formed approximately 12 billion years ago below -243 degrees Celsius.
Bangladesh Measles Death Toll Passes 1,002; CDC Declares World's Largest Outbreak
WHO and UNICEF reported 187,484 infections and 1,002 deaths from measles in Bangladesh. The US CDC has designated it the world's largest measles outbreak, caused by a vaccination gap during 2024-2025 political unrest.
DRC Ebola Reaches 6,686 Confirmed Cases and 3,226 Deaths; WHO Emergency Ongoing
Ebola caused by the Bundibugyo virus has spread across 6 provinces in DRC including Ituri and North Kivu, with 6,686 confirmed cases and 3,226 deaths. WHO continues to maintain an international public health emergency.
Russia Launches Progress 96 Cargo Ship with 3 Tons of Supplies Toward ISS
The unmanned cargo vessel Progress 96 was launched on a Soyuz rocket from Baikonur Cosmodrome in Kazakhstan on September 9, carrying approximately 3 tons of food, fuel, and supplies to the International Space Station.
NASA Nancy Grace Roman Space Telescope Completes Coronagraph Activation, Enters Commissioning
The Nancy Grace Roman Space Telescope, launched on a Falcon Heavy on August 30, completed coronagraph instrument activation and entered the commissioning phase. The wide-field survey instrument is expected to begin operations within weeks.
DRC Ebola: record 6,604 confirmed cases, 3,175 deaths โ outbreak spreads across 6 provinces
The Bundibugyo virus Ebola outbreak in the DRC has reached a record 6,604 confirmed cases and 3,175 deaths. According to the ECDC, 851 people are in isolation and the outbreak has spread to 54 health zones across 6 provinces including Ituri.
FDA grants conditional approval to AstraZeneca's camizestrant for ESR1-mutated breast cancer
The FDA conditionally approved AstraZeneca's oral SERD camizestrant in combination with a CDK4/6 inhibitor for ESR1-mutated HR-positive, HER2-negative metastatic breast cancer, according to STAT News.
Oxford-BGU team achieves first experimental verification of Einstein equivalence principle in quantum realm
Researchers split ultracold rubidium atoms into two paths, allowing one to free-fall, and directly observed that Einstein's equivalence principle holds for quantum objects. The findings were published in Science Advances.
ESA-JAXA BepiColombo begins Mercury orbit insertion after 8-year journey
The ESA-JAXA joint Mercury explorer BepiColombo began entering Mercury's orbit on September 9, completing an 8-year journey since its October 2018 launch. The spacecraft will split into two orbiters to study Mercury's magnetic field and interior structure.
DRC-Uganda Ebola: 6,604 confirmed, 3,175 dead โ record outbreak
Ebola cases caused by the Bundibugyo virus reached 6,604 confirmed and 3,175 deaths as of Sep 5. The latest report recorded 82 new cases and 41 new deaths, with 851 in isolation. The outbreak has spread to 54 health zones across 6 provinces including Ituri, making it the largest Ebola outbreak in DRC history.
US measles hits 3,134 cases โ highest in 30 years; 38 clusters, MMR vaccination rate drops
As of Sep 3, 2026, US measles cases reached 3,134, with 95% of cases linked to 38 clusters. Pennsylvania reported its first 2 measles deaths in 35 years, and kindergarten MMR vaccination rates dropped to 92.4%, below the 95% herd immunity threshold.
Asteroid 2026 RW1 burns up over Indian Ocean just 7 hours 22 minutes after discovery
Asteroid 2026 RW1 entered Earth's atmosphere over the Indian Ocean (northwest of Australia) at 16:07 UTC on Sep 6 and disintegrated. ESA estimated its diameter at 0.6-1.3 m. The impact occurred 7 hours and 22 minutes after discovery, making it the 13th predicted Earth impactor in history.
NOAA issues G1 geomagnetic storm watch as multiple CMEs forecast to arrive Sep 8-9
NOAA's Space Weather Prediction Center issued a G1 geomagnetic storm watch at 12:30 UTC on Sep 7 after forecasting the arrival of multiple CMEs from sunspot AR4524. Solar wind peaked at 434 km/s with IMF at 18 nT; aurora sightings reported possible for Sep 8-9.
DRC Ebola Hits Record 6,342 Confirmed Cases, 3,072 Deaths โ Spread Across 6 Provinces
The DRC Bundibugyo Ebola outbreak has reached 6,342 confirmed cases and 3,072 deaths (48.1% fatality rate) across 60 health zones in 6 provinces. No approved vaccine or treatment is available; WHO's Public Health Emergency of International Concern remains in effect.
Korea Flu Cases Jump 45% Week-over-Week; COVID Hospitalizations Surge 79%
The KDCA reported that week 35 influenza-like illness rate reached 13.3 per 1,000 โ up 44.6% from the prior week's 9.2, and more than double the same period last year. COVID-19 hospitalizations also jumped from 61 to 109, a 78.7% increase.
Korea Adopts Whole-Genome Sequencing (WGS) to Trace Tuberculosis Cluster Transmission
Korea has officially adopted whole-genome sequencing technology for tracing tuberculosis cluster transmission. The system analyzes TB bacterial genomes to precisely map infection links and enable earlier detection of cluster outbreaks.
Germany's Isar Spectrum Rocket Achieves First-Ever Orbit from European Mainland
Isar Aerospace's Spectrum rocket launched from Norway's Andoya Space Center on September 5 and reached orbit in approximately 7 minutes. It is the first rocket launched from the European mainland to achieve orbit, and successfully deployed 5 CubeSats.
NASA Adds New 34m DSS-23 Antenna at Goldstone to Strengthen Deep Space Network
NASA's Deep Space Network added a new 34-meter antenna, DSS-23, at its Goldstone complex in California. It is the 5th of 6 planned antennas and has been operational since August 3.
SpaceX Launches 27 Starlink V2 Mini Sats โ 103rd Falcon 9 Mission of 2026
SpaceX launched 27 Starlink V2 Mini satellites from Vandenberg on September 6, the year's 103rd Falcon 9 mission. First-stage booster B1088 (its 19th flight) successfully landed on the drone ship.
DRC Ebola Reaches Record 6,342 Confirmed Cases and 3,072 Deaths
As of September 3, the DRC Ebola outbreak had grown to 6,342 confirmed cases and 3,072 deaths - the largest on record. The outbreak has spread across 54 health zones in 6 provinces, with 770 patients in isolation care.
Five Chronic-Fatigue Diseases Including Long COVID and PTSD Share a Common Gene Network Disruption
A University of East Anglia research team published in the Journal of Translational Medicine that long COVID, PTSD, rheumatoid arthritis, ME/CFS, and multiple sclerosis all disrupt a common genetic network.
Higher Pre-Pregnancy Vitamin B12 in Both Parents Linked to Lower Rate of Birth Defects
A Fudan University team analyzed 3,032 couples and reported in Annals of Internal Medicine that higher vitamin B12 levels in both parents before conception were associated with a lower rate of birth defects, primarily cardiac malformations.
NASA Roman Space Telescope Begins Commissioning While Traveling to L2 Lagrange Point
The Roman telescope, launched August 30, is traveling to the Sun-Earth L2 Lagrange point. It completed antenna and sunshield deployment on September 1. With a field of view 100 times wider than Hubble, first images are planned for early 2027.
NASA and SpaceX Delay Crew-13 ISS Launch After Oxidizer Leak Found on Dragon
An oxidizer (NTO) leak was detected during pre-launch checks on the Dragon spacecraft's propulsion system, forcing a delay of the September 12 launch. NASA said repairs were expected to take two to four weeks.
NASA Swift Telescope Rescue Fails; Reentry Now Inevitable Before Year-End
Catalyst's LINK satellite approached within 15 km of the Swift telescope on September 4 but withdrew due to insufficient fuel. With attitude control lost and no orbital reboost possible, Swift is expected to reenter and burn up before year-end.
DRC Ebola Reaches Record 6,342 Cases and 3,072 Deaths
According to WHO and ECDC, DRC's Ebola outbreak reached its largest-ever scale as of September 4. A single day saw 92 new confirmed cases; Ituri Province accounts for 82% of all cases, with 770 patients in isolation.
US West Nile Virus Hits 407 Cases Across 40 States โ Worst Season Since 2003
As of September 1, 407 cases were confirmed across 40 states, with 285 (71%) being neuroinvasive. CDC reports this season's outbreak pace is roughly 5 times the historical baseline โ the worst since the 2003 peak.
Man Dies in India's Navi Mumbai After Receiving Expired IV Fluid
A 50-year-old man in Navi Mumbai, Maharashtra died after being administered expired intravenous fluid. Two nurses and a pharmacist at the hospital were suspended, and authorities launched an investigation.
India's ISRO Successfully Places Earth Observation Satellite EOS-05 in GEO for First Time
ISRO successfully launched Earth observation satellite EOS-05 (2,367 kg) to geostationary orbit aboard a GSLV Mark II rocket on September 3 โ a first for India. The satellite entered its target orbit approximately 18 minutes after launch, marking India's third orbital mission of 2026.
NASA's Hubble Officially Confirms 10-Sided Atmospheric Wave 'Decagon' at Saturn's South Pole
An international research team officially confirmed a 10-sided atmospheric wave โ the 'decagon' โ encircling Saturn's south pole using Hubble data, publishing in Science Advances. Distinct from the north polar hexagon, the structure is reportedly still growing.
NASA Selects Blue Origin to Build Mars Communications Orbiter for Up to $700M
NASA selected Blue Origin to develop and operate a next-generation Mars telecommunications orbiter under a contract worth up to $700M. Blue Origin will develop and deploy the satellite by late 2028, targeting Mars operations by 2030.
COVID-19 Hospitalizations Hit 61 in Week 34, Rising for 4 Consecutive Weeks
COVID-19 hospitalizations at hospital-level facilities reached 61 in Week 34 per KDCA sentinel surveillance, rising for 4 consecutive weeks. The virus detection rate also climbed to 11.3%, prompting calls to review testing and treatment criteria for high-risk groups.
HIRA Applies AI Medical Imaging to Health Insurance Claims Review for First Time
The Health Insurance Review and Assessment Service (HIRA) applied deep-learning AI imaging analysis results to medical claims review for the first time, starting with knee osteoarthritis. The scope is planned to expand to spine and urinary stones; final decisions remain with human reviewers.
Study Finds Mental Health Disorders After Physical Trauma Linked to Higher Cardiovascular Risk
A study found that patients who develop mental health disorders following physical trauma have a significantly higher risk of cardiovascular disease compared to those who do not.
Study Confirms Most Cognitive Decline After COVID Omicron Infection Is Reversible
A study found that cognitive decline following COVID-19 Omicron infection is largely reversible over time.
ESA-JAXA BepiColombo Enters Mercury Arrival Phase After Nearly 8-Year Journey
The ESA-JAXA BepiColombo spacecraft began its Mercury arrival phase on September 3. The two orbiters separated from the transfer module; Mercury orbital insertion is scheduled for November 21, with science operations set to begin in April 2027.
Scientists Confirm Up to 400ยฐC Temperature Gap Between Mars Northern and Southern Interiors
Analysis of archived gravity data from 3 NASA Mars spacecraft found that the southern hemisphere interior may be up to 400ยฐC hotter than the northern hemisphere and potentially in a partially molten state.
NASA Roman Space Telescope Successfully Activates Coronagraph Instrument
The NASA Roman Space Telescope, launched on a Falcon Heavy on August 30, successfully activated its coronagraph instrument. It is traveling to the L2 point for dark energy and exoplanet research.
MD Anderson: BRAF Cancer-Targeting Protein Amplifies Chronic Pain in Spinal Cord
Researchers at UT MD Anderson Cancer Center revealed that the BRAF protein activates NMDA receptors in the spinal cord following nerve injury, amplifying chronic pain. Inhibiting BRAF reduces pain sensitivity, suggesting potential for repurposing existing cancer drugs for neuropathic pain treatment.
Dietary Fiber Types Like Arabinoxylan and Pectin Critical to Childhood Gut Microbiome Development
Research combining data from 256 children aged 6-36 months with fermentation experiments showed arabinoxylan, xyloglucan, and pectin differently affected short-chain fatty acid production and intestinal barrier protection. Higher pectin intake correlated with greater gut microbiome diversity.
One Month of Home HEPA Air Purifier Use Improves Cognitive Function by 12% in Adults Over 40
In a randomized crossover clinical trial with 119 adults aged 30-74, participants over 40 who used HEPA air purifiers for one month completed executive function and mental flexibility tests 12% faster than when using fake purifiers. Researchers attributed the improvement to reduced fine particulate exposure.
NASA's Roman Space Telescope Successfully Launches Aboard SpaceX Falcon Heavy
Launched from Kennedy Space Center aboard SpaceX's Falcon Heavy. With a primary mirror identical to Hubble's size, it will observe 100 times wider sky areas and conduct dark energy and exoplanet research. Total budget of $4.3 billion was invested.
NASA and ESA Female Astronauts Complete ISS's Historic Sixth All-Female Spacewalk
On September 1, NASA astronaut Jessica Meier and ESA astronaut Sophie Adeney completed a 6-hour 49-minute spacewalk. They replaced a retroreflector and prepared the AMS for maintenance, with Meier now ranking third among women in most spacewalks.
SpaceX Crew-13 Launch Indefinitely Delayed Due to Dragon Propulsion System Oxidizer Leak
A leak in the Dragon spacecraft's propulsion system oxidizer was detected during standard pre-launch checks, canceling the September 12 target launch date. The Crew-13 mission, consisting of four U.S., Canadian, and Russian astronauts, has no new launch date set.
Novartis Remibrutinib Hits Primary Endpoints in Relapsing MS Phase 3 Trials
Novartis's BTK inhibitor remibrutinib significantly reduced annualized relapse rates and brain MRI lesions versus teriflunomide in the REMODEL-1/2 Phase 3 trials, with a favorable safety profile and no hepatotoxicity signal.
Sleep Apnea Pill AD109 Cuts Breathing Pauses by 44% in Phase 3 Trial
In the SynAIRgy Phase 3 trial across 69 US and Canadian sites with 646 patients, once-daily AD109 reduced sleep-related breathing pauses by 44% and improved oxygen saturation, demonstrating potential as an oral alternative to CPAP.
Eli Lilly to Acquire Autoimmune Biotech Merida Biosciences for Up to $2.875B
Eli Lilly agreed to acquire Merida Biosciences, developer of the selective autoantibody-degrading pipeline asset MER511, for up to $2.875 billion. MER511 is currently in Phase 1 trials targeting Graves' disease and thyroid eye disease.
Zanidatamab Extends Overall Survival in 1L HER2+ Gastroesophageal Cancer
The second interim analysis of the HERIZON-GEA-01 Phase 3 trial found that zanidatamab plus chemotherapy statistically significantly improved overall survival versus trastuzumab plus chemotherapy in HER2-positive gastroesophageal adenocarcinoma in the first-line setting.
ISS Completes Historic 6th All-Female Spacewalk Over 6.5 Hours
NASA's Jessica Meir and ESA's Sophie Adenot conducted a 6.5-hour spacewalk outside the ISS on September 1, replacing navigation reflectors, servicing the Alpha Magnetic Spectrometer, and swapping a high-definition camera โ the 6th all-female spacewalk in history.
NASA's Swift Telescope Resumes Observations After Failed Private Rescue โ 1โ2 Months Remain
After a private orbital-raising mission failed, the Swift telescope resumed science observations with its UV and X-ray instruments. Atmospheric drag continues to lower its orbit and NASA expects the mission to end within 1โ2 months, followed by atmospheric reentry.
Rocket Lab Successfully Deploys Japanese Synspective SAR Satellite Strix to Low Earth Orbit
Rocket Lab launched an Electron rocket from Mahia Peninsula, New Zealand on September 2, successfully deploying Synspective's Strix synthetic aperture radar satellite to low Earth orbit. The satellite enables day-and-night, all-weather Earth observation and is part of a planned 30-satellite constellation.
Eli Lilly announces acquisition of Merida Biosciences for up to $2.88 billion
On August 31, Eli Lilly announced the acquisition of Merida Biosciences, which holds autoantibody-selective degradation technology, for up to $2.88 billion. The lead pipeline candidate MER511 is currently in Phase 1 clinical trials for Graves' disease and thyroid eye disease, marking Lilly's 12th M&A deal this year.
BioNTech and Genentech terminate Phase 2 personalized colorectal cancer mRNA vaccine trial early
The autogene cevumeran mRNA vaccine trial BNT122-01 was terminated early on August 28 following a recommendation from the safety monitoring committee due to an imbalance with more deaths in the treatment group than the control group. BioNTech's U.S.-listed stock price plunged approximately 9%.
FDA approves first RAS inhibitor daraxonrasib (Rasonque) for metastatic pancreatic cancer
Revolution Medicines' daraxonrasib (Rasonque) received FDA accelerated approval. The randomized clinical trial showed median overall survival extended from 6.7 months with conventional chemotherapy to 13.2 months.
NASA Roman Space Telescope separates from Falcon Heavy, begins independent flight and commissioning
The Roman Space Telescope, with a field of view 100 times wider than Hubble, separated from Falcon Heavy and is flying toward the L2 orbit. After solar panel and sunshield deployment, the telescope has begun initial commissioning.
ISS Expedition 75 to conduct 284th spacewalk...6.5 hours of scheduled work
NASA announced ISS Expedition 75's scheduled 284th spacewalk. The mission includes navigation auxiliary unit replacement, space radiation detector upgrade preparation, and data relay jumper cable installation, approximately 6.5 hours of work.
SETI and NASA clarify seven-stage meteorite formation process...vaporization theory revised
A team from SETI Institute and NASA Ames Research analyzed 75 meteorite impact videos to clarify the seven-stage process of space rocks passing through the atmosphere. Melting and fragmentation, rather than vaporization, were identified as the key mechanisms, published in the Meteoritics and Planetary Science journal.
August 2026 ยท 146
FDA Approves Daraxonib (Lasonkib), First-Ever Targeted Therapy for Metastatic Pancreatic Cancer
Revolution Medicines' daraxonib received FDA approval as the first RAS inhibitor for metastatic pancreatic cancer, reducing risk of death 60% versus chemotherapy and achieving a median overall survival of 13.2 months.
Pfizer-BioNTech XFG-Adapted COVID-19 Vaccine Receives FDA Approval, Begins Shipping
The 2026-27 COVID-19 vaccine targeting the XFG (Stratus) variant โ responsible for 79% of new US infections โ received FDA approval on August 27 and immediately began shipping.
NASA Nancy Grace Roman Space Telescope Successfully Launches on Falcon Heavy
The Roman Space Telescope launched at 7:26 a.m. EDT on August 30 from Kennedy Space Center, completed second-stage separation, and is now en route to its L2 orbit roughly 1.5 million km from Earth.
Turkey Becomes 71st Country to Sign Artemis Accords
At a signing ceremony at NASA Headquarters in Washington on August 31, Turkey joined the Artemis Accords as the 71st nation, committing to international norms for lunar and deep-space exploration.
10 National University Hospitals Hold Symposium on Cooperation Ahead of Essential Care Law
Seoul National University Hospital hosted the 2nd National University Hospital Public Sector Symposium with 170 participants on August 28. Data showed 70% of regional emergency transfers are due to staff and equipment shortages; cooperation models including Chungnam's FASTLINK app were shared.
Chonnam National University Hospital Signs Medical Tourism MOUs with China, Russia, Vietnam Agencies
Chonnam National University Hospital signed medical tourism agreements with Baixiang Holdings (China), Interclinic (Russia), and VK One-Stop (Vietnam) on August 24. The hospital subsequently hosted a facility tour for 10+ overseas referral agency representatives from eight countries.
NASA Roman Space Telescope Mated to Falcon Heavy, Aug. 30 Launch Locked In
The $4 billion Nancy Grace Roman Space Telescope was mated to SpaceX's Falcon Heavy on August 29, with launch set for August 30 at 07:26 EDT. It will survey dark energy, dark matter, and exoplanets with a field of view 100 times wider than Hubble.
Curiosity Rover Reaches 1km Elevation on Mars After 14 Years
NASA's Curiosity rover achieved a cumulative elevation gain of 1 kilometer on Mars, ascending from Gale Crater toward Mount Sharp over 14 years. A panorama composed of 323 images was released.
Campylobacter Food Poisoning Cases Double in One Week โ Health Authorities Issue Warning
Korean health authorities warned that confirmed Campylobacter food poisoning cases doubled in a single week. They urged extra care with refrigeration and kitchen hygiene as summer heat and humidity accelerate bacterial growth.
Ministry of Health to Open AI-Ready National Bio Big-Data to Public in Second Half of 2026
Korea's Ministry of Health and Welfare announced it will begin releasing its 770,000-person integrated bio big-data in an AI-accessible format in the second half of 2026. Medical data vouchers for AI startups and SMEs will expand from 8 to 40 projects in 2026.
International Space Summit 2026 Opens in Daejeon โ Global Space Leaders Convene
The International Space Summit 2026 opened in Daejeon, South Korea, bringing together leaders from space agencies and private space companies worldwide. Topics included space exploration, launch vehicles, satellite technology, and international cooperation frameworks.
MOHW holds first consultation with young healthcare workers on training and policy
Deputy Minister Lee Hyung-hoon met on Aug. 23 with 10 young healthcare workers โ including residents, pharmacists, and nurses โ to discuss improving training environments and expanding policy participation.
Life-sustaining treatment directive family-sharing feature launches Aug. 25 at 8 p.m.
MOHW held its advance directive writing contest awards ceremony on Aug. 25, drawing 405 entries โ more than double the prior year. The same evening at 8 p.m., a new feature allowing advance directives to be shared with family members went live.
MOHW reports primary care pilot โ multidisciplinary team model for ages 50+ โ to launch as early as September
MOHW presented an update to its primary care innovation pilot to the Health Insurance Policy Review Committee on Aug. 25. Targeting adults 50 and older, multidisciplinary teams will provide comprehensive care under a bundled payment model, with launch expected as early as September.
SpaceX's 100th Falcon 9 launch of 2026; booster B1067 sets 37-flight reuse record
SpaceX completed its 100th Falcon 9 launch of 2026 on Aug. 25. Booster B1067 flew for the 37th time, a company record, and deployed 29 Starlink satellites into low Earth orbit.
NASA's Roman Space Telescope encapsulated in Falcon Heavy fairing ahead of Aug. 30 launch
NASA's Nancy Grace Roman Space Telescope has been enclosed in a Falcon Heavy rocket fairing. It is scheduled to launch from Kennedy Space Center on Aug. 30 and will observe the universe with a field of view 100 times wider than Hubble.
NASA and ESA astronauts complete 98th U.S. spacewalk, replacing ISS communications antenna
NASA astronaut Anil Menon and ESA astronaut Sophie Adenot conducted a spacewalk on Aug. 25 outside the International Space Station, successfully replacing a ground-to-space communications antenna.
KDCA Study: Practicing 3 or More Healthy Habits Cuts Fatty Liver Risk by 28.6%
The Korea Disease Control and Prevention Agency's National Institute of Health analyzed 23,111 adults using national health survey data. Those practicing three or more of four healthy habits โ healthy diet, physical activity, non-smoking, and adequate sleep โ had a 28.6% lower risk of metabolic-dysfunction-associated fatty liver disease.
Korean Maternal Deaths from Direct Obstetric Causes Rising 0.9pp Per Year Since 2011
A Korea University preventive medicine team published analysis in JKMS showing that hemorrhage and embolism accounted for 42.8% of Korean maternal deaths from 2009 to 2023, with the share of deaths from direct obstetric causes rising again since 2011.
ESO Discovers S301, Closest-Known Star to Sgr A*, Opening Path to Measuring Black Hole Spin
The European Southern Observatory announced the discovery of S301, the closest star yet found orbiting the Milky Way's central black hole Sagittarius A*, with an orbital period of 8.7 years and peak speed of 25,000 km/s. It is noted as a key to the first direct measurement of the black hole's spin.
Ministry of Health reviews extending telemedicine drug delivery to all patients ahead of December formalization
The Ministry of Health and Welfare decided to discuss expanding telemedicine drug delivery from limited groups โ remote islands, people with disabilities โ to all telemedicine patients ahead of the December formalization. Amendments to the Pharmacy Act and Medical Act are also under consideration.
Nature study: latent herpesviruses reactivated in 47.9% of COVID-19 inpatients
A study published in Nature found that latent viruses including herpesviruses (EBV, CMV, HSV-1) were reactivated in 47.9% of COVID-19 inpatients, with an association also observed with increased disease severity.
DRC Ebola: 5,021 confirmed cases, 2,378 deaths, 47.4% case fatality rate
The Bundibugio Ebola virus has reached 5,021 confirmed cases and 2,378 deaths, with a case fatality rate of 47.4%. The outbreak is spreading three times faster than the 2014-2016 West Africa epidemic, and no approved vaccines or treatments exist.
Rocket Lab Electron's 93rd launch successfully places iQPS SAR satellite in 575km orbit
An Electron rocket launched from Rocket Lab's New Zealand facility and deployed Japan's iQPS SAR Earth observation satellite into a 575km low Earth orbit. It was Rocket Lab's 14th launch of the year and the 9th consecutive successful mission for iQPS.
Two M-class flares from solar region AR4513 trigger G1 geomagnetic storm and high-latitude auroras
Two M-class solar flares โ M1.9 and M1.0 โ erupted from newly emerged active region AR4513 on Aug 20. Combined with a coronal hole solar wind stream, they triggered a G1 geomagnetic storm and aurora observations in high-latitude regions including Scotland and Alaska.
Moderna and Merck mRNA skin cancer treatment vaccine confirms positive clinical trial results
Moderna and Merck reported positive results from clinical trials of a skin cancer treatment vaccine using the same mRNA technology as COVID-19 vaccines. More than 30 hospitals have joined the cancer vaccine clinical platform, with over 200 patients being treated in Europe.
NOACs blood thinners slow cognitive decline in Alzheimer's and atrial fibrillation patients
Analysis of 7,308 individuals from Sweden's cognitive impairment registry found that the NOACs group showed significantly slower cognitive decline than those taking warfarin or no anticoagulants. Risks of death, stroke, blood clots, and fractures were also lower.
Breast cancer rates rising rapidly among Asian American women, with sharpest increases in younger patients and aggressive tumors
Breast cancer incidence among Asian American women is rising rapidly, with the most severe increases seen in younger women and in aggressive or advanced-stage cancers, according to recent research.
China's LandSpace Zhuque-3 becomes world's third private rocket to land a booster on second flight
Chinese startup LandSpace's Zhuque-3 successfully landed its first-stage booster vertically on its second flight on Aug 18. The booster touched down in Minqin County, Gansu Province approximately 8 minutes after launch, making it only the third private rocket to recover a booster after SpaceX and Blue Origin.
NASA's Perseverance rover captures first-ever recording of Earth disappearing behind Mars' moon Phobos
NASA's Perseverance rover used its Mastcam-Z to capture footage of Earth disappearing behind Mars' moon Phobos. It is the first time in human history that Earth has been recorded being occulted by another celestial body from the surface of another planet.
Sophie Adenot completes first French female spacewalk lasting 6 hours 23 minutes
NASA's Anil Menon and ESA's Sophie Adenot conducted a 6-hour 23-minute spacewalk on Aug 18. Adenot was recorded as the first French woman to perform a spacewalk. They successfully removed a faulty antenna but ran out of time for the replacement installation, with an additional spacewalk scheduled.
US prescription drug prices fall 3.1% in July โ biggest annual decline since 1963
US consumer prices for prescription drugs fell 3.1% year-over-year in July 2026, the largest annual decline since 1963. Medicare drug price negotiations, expanded generic and biosimilar competition, and discounted GLP-1 obesity drugs were cited as key factors.
โฆ RELATED STORYLINELow-fat vegan diet: 16-week trial shows average 5.9kg weight loss without calorie restriction
A 16-week randomized clinical trial published in JAMA Network Open found that participants on a low-fat vegan diet consumed 357 fewer calories per day without intentional restriction, losing an average of 5.9kg. Researchers attributed this to reducing dietary energy density by approximately 30%.
Study reveals how triple-negative breast cancer hijacks macrophages to evade immune defenses
Researchers identified a mechanism by which triple-negative breast cancer tumors recruit M2 macrophages to neutralize immune responses. A PKM2 nuclear translocation pathway that promotes lymphatic metastasis was also confirmed, pointing to a potential new therapeutic target.
SpaceX completes its 100th mission of 2026 with Falcon 9 Starlink launch
SpaceX launched 24 Starlink satellites from Vandenberg Space Force Base on Aug 18, marking its 100th mission of 2026. It was the 97th Falcon 9 flight, with booster B1097 landing successfully for its 12th reuse.
JWST maps water ice and CO2 atmosphere on Jupiter's moon Callisto for the first time
The James Webb Space Telescope's NIRSpec instrument detected water ice patterns and a tenuous carbon dioxide atmosphere on Callisto. A Caltech-led international team published the findings in the Planetary Science Journal, confirming Callisto is more geologically dynamic than expected.
ESA astronaut Sophie Adenot completes 6.5-hour ISS spacewalk โ first French woman to do so
ESA astronaut Sophie Adenot conducted a 6.5-hour spacewalk outside the ISS on Aug 18 alongside NASA's Anil Menon. Adenot became the first French woman and only the second European woman in history to perform a spacewalk.
Hubble and James Webb team up to reveal composite image of the Black Eye Galaxy M64
Hubble and the James Webb Space Telescope combined data spanning ultraviolet to mid-infrared wavelengths to release a new image of Messier 64 (Black Eye Galaxy), located 17 million light-years away. The galaxy is notable for its outer gas disk rotating opposite to its inner stars.
Moderna's mFlusiva Becomes First mRNA Flu Vaccine to Win FDA Approval for 50+
The FDA approved Moderna's mRNA influenza vaccine mFlusiva for adults 50 and older: full approval for ages 50-64, accelerated approval for 65+. It is now the fourth mRNA drug approved in the United States.
US 2026 Measles Cases Top 2,566 โ Highest Since 1991; CDC Reviews Elimination Status
CDC's weekly update confirmed US measles cases reached 2,566 this year, the highest since 1991, with 38 active outbreaks tracked. An expert panel is reviewing US elimination status this month; PAHO will announce the determination in November 2026.
Aging Gait Decline Explained: Simultaneous Ankle Muscle Contraction Cuts Efficiency
A Flinders University study analyzing 107 adults aged 26-86 found older adults simultaneously contract ankle muscles to gain stability but at the cost of walking efficiency and faster fatigue onset. Researchers recommended Tai Chi and lower-body strength training.
Low-Fiber Diet Causes Gut Bacteria to Digest Mucin, Producing Harmful Metabolites
Research confirmed that when dietary fiber is insufficient, gut bacteria break down the mucin proteins in the gut lining, increasing harmful phenolic metabolites. Dietary fiber suppresses this process; indigestible plant proteins also help generate beneficial metabolites.
SpaceX Sets New Record With Dual Falcon 9 Launches Just 38.5 Minutes Apart
SpaceX launched a Falcon 9 from Cape Canaveral at 01:12 UTC on August 16 carrying 8 Globalstar satellites, then launched a second from Vandenberg 38.5 minutes later for a US Space Force mission โ setting the shortest dual-launch interval on record.
NASA COFFIES Team Uses AI to Predict Solar Active Regions Up to 12 Hours in Advance
NASA's COFFIES team developed a machine learning model that predicts the location of solar active regions up to 12 hours before they emerge. The model analyzes acoustic variation patterns using Solar Dynamics Observatory data and Ames supercomputers; results are published in JGR.
US CDC: 2,566 confirmed measles cases in 2026โฆhighest record in 35 years
The US CDC announced that confirmed measles cases in 2026 reached 2,566, recording the highest figure in 35 years. 93% of cases involved unvaccinated individuals and 169 were hospitalized.
Stanford confirms blood immune cells entering aging human brain for first timeโฆpublished in Nature
Stanford researchers confirmed that blood immune cells cross the blood-brain barrier and convert into microglia in the brain starting from middle age. Published in Nature as a uniquely human phenomenon not found in mice or primates.
โฆ RELATED STORYLINEFDA grants accelerated approval to Genvecksus, first CELMoD therapy for multiple myeloma
FDA granted accelerated approval for BMS's iberdomide (Genvecksus) combined with daratumumab and dexamethasone for relapsed/refractory multiple myeloma. It showed superiority with 41% MRD-negative complete response rate versus 21% in the control group.
โฆ RELATED STORYLINEJames Webb discovers 'black hole star' MoM-BH*-1 for first time 6.6 billion years after Big Bang
A study published in Nature found a new type of celestial body, 'black hole star' MoM-BH*-1, in the early universe. Analysis reveals a structure with a black hole 100,000 times the Sun's mass wrapped in a massive gas cloud.
Astronomy community warns of 'light pollution catastrophe' from Reflect Orbital mirror satellite
A study showed that a single 54-meter class reflective satellite would create light pollution brighter than a full moon by 4 magnitudes, making star observation impossible beyond 30km. The international astronomy community is demanding the plan be withdrawn.
โฆ RELATED STORYLINEAtmospheric CO2 increase confirmed to raise blood bicarbonate 7% over 20 years
Analysis of 20 years of US NHANES health data confirmed that blood bicarbonate increased approximately 7%, from 23.8 to 25.3 mEq/L, proportional to atmospheric CO2 rise.
โฆ RELATED STORYLINETrump Signs Executive Order for Separate MMR Vaccine Doses โ Medical Community Pushes Back Hard
President Trump signed an executive order on Aug 10 recommending that the combined MMR vaccine be administered as three separate shots. As no individual vaccines currently exist, clinical trials would be required. Public health experts stated there is no scientific basis for the claimed link to autism and opposed the order.
โฆ RELATED STORYLINEWomen with Endometriosis Face 46% Higher Risk of Type 2 Diabetes
A George Mason University research team analyzed medical records of approximately 3 million people over 25 years and found that women diagnosed with endometriosis had a 46% higher risk of developing Type 2 diabetes than those without. The association was most pronounced in premenopausal and non-obese women.
โฆ RELATED STORYLINETHC Drug Eliminates PTSD Nightmares Completely in Over a Third of Patients โ Published in Nature Medicine
A Charite Berlin research team reported in Nature Medicine that dronabinol was administered to 170 PTSD patients for 10 weeks. More than half reported reduced nightmares, and over a third experienced complete elimination of nightmares. The team stated that long-term studies are needed.
โฆ RELATED STORYLINEJames Webb Telescope Discovers 'Black Hole Star' โ A New Type of Cosmic Object
An MIT research team discovered an object designated 'MoM-BH*-1' in James Webb Space Telescope data. The team reported it is a new type of cosmic object โ a structure with a black hole of about 100,000 solar masses wrapped in hydrogen โ emitting 100 billion times more energy than any ordinary star.
โฆ RELATED STORYLINESDSS-V Releases Over 3 Million New Spectra โ First Southern Hemisphere Optical Data Included
The Sloan Digital Sky Survey Phase 5 (SDSS-V) released over 3 million new spectra in Data Release 20 (DR20). Data from Las Campanas Observatory in Chile was included for the first time, containing hundreds of thousands of rare stars, nebulae, X-ray sources, and supermassive black hole observations.
โฆ RELATED STORYLINECardiometabolic Index Independently Predicts Type 2 Diabetes Mortality Risk
A US cohort study found that the cardiometabolic index (CMI), combining waist-to-height ratio and triglyceride/HDL ratio, independently predicts all-cause and cardiovascular mortality risk in type 2 diabetes patients.
Tissue-Free ctDNA Test Predicts TNBC Recurrence Risk 27-Fold
UK c-TRAK phase 2 trial showed blood-based ctDNA can track triple-negative breast cancer recurrence without tissue biopsy. ctDNA positivity was associated with 27-fold higher recurrence risk, confirming its utility as an early surveillance tool.
IL-6 Receptor Inhibitors Outperform Steroids in Refractory Polymyalgia Rheumatica
IL-6 receptor inhibitors showed superior outcomes compared to conventional immunomodulatory therapy in polymyalgia rheumatica (PMR) patients refractory to or relapsing on glucocorticoids, according to reported research.
James Webb Captures Strongest Evidence Yet for 'Black Hole Stars'; Published in Nature
A US-led research team discovered 'black hole stars' using Webb telescope data from 660 million years after the Big Bang. The solar-system-sized object is 100 billion times brighter than ordinary stars and harbors a black hole 100,000 times the sun's mass, the team reported.
Spain's First Total Eclipse in 121 Years Featured in NASA APOD
A total eclipse passed over Greenland, Iceland, and Spain on August 12, 2026. Spain witnessed its first total eclipse since 1905. NASA selected a photo of the eclipse reflected in Zaragoza's Ebro River as the August 13 Astronomy Picture of the Day.
62 new drugs added to health insurance in H1, 142,495 patients to benefit
A total of 62 drugs were newly listed or had expanded reimbursement criteria under Korea's national health insurance in January-July 2026. Projected annual fiscal impact is KRW 749.4 billion, with an estimated 142,495 patients benefiting.
AstraZeneca's Breztri receives additional asthma indication approval in Korea
AstraZeneca Korea's triple-combination inhaler Breztri Aerosphere received regulatory approval from the MFDS for maintenance treatment of asthma in patients aged 12 and older. The approval follows FDA authorization.
MFDS initiates consultation to add liver injury adverse reaction to 21 diabetes combos
Korea's MFDS launched a harmonized consultation to add cholestatic, hepatocellular, and mixed liver injury as post-marketing adverse reactions to 21 products including sitagliptin-metformin combination drugs.
Europe's first total solar eclipse in 27 years draws millions of observers
A total solar eclipse passed through Greenland, Iceland, and Spain on Aug 12, marking Europe's first since 1999. In Spain, 350 official observation sites were set up for the first mainland totality in 121 years, with the moon fully covering the sun for up to 2 minutes.
Perseid meteor shower peaks Aug 13 under ideal new-moon conditions
The Perseid meteor shower reaches its peak on Aug 13, coinciding with the new moon to provide optimal dark-sky viewing conditions with up to 100 meteors per hour possible. The meteors are produced by debris from Comet Swift-Tuttle entering the atmosphere.
NASA deploys WB-57 high-altitude aircraft to study solar corona during eclipse
A NASA WB-57 aircraft flew at 50,000 feet to photograph the solar corona during the Aug 12 eclipse. Teams in Iceland and Spain also launched science-instrument balloons along the eclipse path to measure changes in the atmosphere caused by the sudden loss of sunlight.
Oral GLP-1 Aleniglifron Achieves Up to 12.1% Weight Loss in 36 Weeks
In a Phase 2b trial of 230 participants, once-daily oral GLP-1 receptor agonist aleniglifron (120mg) showed up to 12.1% body weight reduction versus placebo. Results published in Nature Medicine; can be taken regardless of meals.
โฆ RELATED STORYLINEStudy Confirms Legumes Improve Gut Health, Blood Sugar, and Lipid Levels
A 10-year research review in Nutrients found lentils, chickpeas, and other legumes contribute to gut health, blood sugar control, and lipid improvement, with lower environmental impact than animal protein, per Medical Dialogues.
UK Issues Class 2 Recall for ChloraPrep Applicators and Melatonin Oral Solution
Patient.info reported that as of August 11, field safety notices include a Class 2 drug recall for ChloraPrep applicators and KidNaps melatonin oral solution.
Total Solar Eclipse and Perseid Meteor Shower Occur Simultaneously โ First Time in 21st Century
On August 12, a total solar eclipse crossed Europe while the Perseid meteor shower peaked under new moon conditions, enabling up to 90+ meteors per hour in dark skies. This simultaneous occurrence is the first in the 21st century.
James Webb Telescope Releases High-Resolution Images of Lion Nebula NGC 2392
The NASA/ESA/CSA James Webb Space Telescope released NIRCam and MIRI images of planetary nebula NGC 2392, showing the central white dwarf forming the nebula over thousands of years.
NASA Conducts Eclipse Path Observations Using WB-57 Aircraft and Weather Balloons
NASA's WB-57 high-altitude aircraft photographed the solar corona from 50,000 feet, while Iceland and Spain teams launched science instrument balloons along the eclipse path to observe atmospheric boundary layer changes.
H2 Medical Resident Recruitment of 2,540 Begins...Application Deadline Aug. 12
The Ministry of Health and Welfare began recruiting 2,540 medical residents on August 10, including 1,830 interns and 710 first-year residents. Application submission deadline is 5 p.m. on August 12.
Oral GLP-1 Obesity Drug Aleniglipron Achieves 12.1% Weight Loss in 36 Weeks
Structure Therapeutics' oral small-molecule GLP-1 receptor agonist aleniglipron achieved maximum 12.1% weight reduction in the highest dose group (120mg) over 36 weeks in phase 2b clinical trials. Results were published in Nature Medicine.
โฆ RELATED STORYLINEElevated Lp(a) Levels Associated with 64% Higher Stroke Risk Even After Standard Treatment
Analysis of three NIH studies involving over 20,000 subjects found that patients with Lp(a) levels of 175 nmol/L or higher face 64% higher stroke risk and 49% higher cardiovascular mortality risk even after standard treatment. Results were presented at the 2026 SCAI Academic Conference.
Europe's First Total Solar Eclipse in 121 Years to Cross Spain's Mainland Aug. 12
A total solar eclipse will traverse Greenland, Iceland, and northern Spain on August 12. It is the first total solar eclipse to cross mainland Spain since 1905, with cities like Bilbao and Valencia experiencing up to 2 minutes 18 seconds of totality.
NASA Astronauts Complete Spacewalk for Final ISS Solar Panel Installation
Jessica Meyer and Anil Menon completed a 6-hour 27-minute spacewalk (EVA 96) on August 6, installing mounting hardware for the rollout solar panel on the 3B power channel. This marks the final stage of ISS power configuration before the station's planned 2030 deorbit.
NASA Roman Space Telescope to Launch Aug. 30 on Falcon Heavy
The Roman Space Telescope, featuring a 2.4-meter mirror identical to Hubble with a 100-times-wider field of view and 300-megapixel capability, will launch on August 30 from Kennedy Space Center. Primary missions include mapping dark energy and searching for exoplanets.
SK Biopharmaceuticals Posts Record Q2 Operating Profit; Cenobamate U.S. Sales Up 45%
SK Biopharmaceuticals recorded all-time quarterly highs in Q2 2026, with revenue of KRW 247.4B and operating profit of KRW 97.1B. U.S. sales of epilepsy treatment cenobamate (Xcopri) reached KRW 224.4B, up 45.6% year-on-year.
GC Biopharma Publishes mRNA-LNP Vaccine Precision Analysis Research in Pharmaceutical Research Journal
GC Biopharma published findings on physicochemical stability analysis of mRNA-LNP vaccines in a SCIE-indexed journal. The research demonstrated changes in mRNA purity and LNP structure under stress conditions, establishing a quality control foundation for commercialization.
ABL Bio Receives Additional MFDS Approval for Amended Phase 1 IND for Bispecific Antibody ABL503
ABL Bio received additional approval from the Ministry of Food and Drug Safety for an amended Phase 1 clinical trial plan for ABL503, a PD-L1/4-1BB bispecific antibody. The trial will evaluate monotherapy and combination therapy in patients with advanced solid tumors at 8+ institutions in the U.S. and Korea.
Korea's Danuri Captures World-First Images of SpaceX Falcon 9 Lunar Impact
Korea's lunar orbiter Danuri captured before-and-after images of a Falcon 9 upper stage (approximately 4.9 tons) striking near Einstein Crater at 2.43 km/s. With ground-based telescopes failing to capture evidence, Danuri was confirmed as the sole observational asset.
Second Spaceport Race Narrows to Jeonnam-Gwangju vs. Jeju; Final Decision in October
The Korea AeroSpace Administration's open call for a second launch site received bids from Jeonnam-Gwangju Integrated Special City and Jeju Special Self-Governing Province. Launch facilities and reusable rocket landing infrastructure will be built from 2028 to 2034, with the final selection announced in October.
KASA Unveils Heliospheric Exploration Plan at COSPAR, Discusses Cooperation With NASA and ESA
The Korea AeroSpace Administration presented a heliospheric exploration plan for observing the space environment between Earth and the Moon at COSPAR 2026 in Florence, Italy, and discussed cooperation with NASA and ESA. The goal is to build a multi-point network to supplement solar storm warnings at L1.
FDA Approves World's First mRNA Flu Vaccine 'mFlusiva' for Adults 50+
Moderna's mRNA-1010 (mFlusiva) received FDA approval on August 5 for adults 50 and older. Clinical trials showed approximately 27% higher efficacy than conventional flu vaccines, with supply planned for the 2026-2027 flu season.
DRC Ebola: 3,802 Cases, 1,707 Deaths โ Second Largest Outbreak on Record
Ebola caused by the Bundibugyo virus has spread to five provinces in the DRC, with 3,802 confirmed cases and 1,707 deaths recorded, making it the second largest Ebola outbreak on record. The WHO is maintaining its highest alert level.
Jalapeno Salmonella Outbreak Spreads to 27 US States, 345 Infected
The CDC is investigating a multistate Salmonella Javiana outbreak linked to Mexican-grown jalapeno peppers. 345 people have been infected and 36 hospitalized. Chipotle and QDOBA suspended service of the affected product.
FDA Approves Tumor-Dissolving Virus Therapy 'Tudriqev' for Melanoma
On August 6, the FDA approved Tudriqev, a genetically modified oncolytic virus therapy, in combination with nivolumab for the treatment of advanced cutaneous melanoma.
SpaceX Falcon 9 Upper Stage Confirmed to Have Struck Moon Near Einstein Crater
A SpaceX rocket upper stage traveling at 8,700 km/h struck the Moon on August 5, generating a sodium and lithium gas plume. Orbiters from multiple nations are now racing to photograph the impact crater.
NASA Repurposes Gateway HALO Hardware for Lunar South Pole Survival Demos
Power and thermal control components from the canceled Gateway HALO module will be deployed in Northrop Grumman's LID-1 through LID-3 missions to demonstrate survival through the 14-day lunar polar night by 2029.
Scientists Observe Solar Micro-Vortices Just 20 km Wide for First Time
Scientists observed tiny plasma vortices just 20 km wide across the solar surface for the first time, analyzing that these structures twist the magnetic field and can store energy for small solar flares.
SpaceX Falcon 9 Crashes into Moon โ Sodium and Lithium Spectra Observed for 5-10 Minutes
At 06:35 UTC on August 5, the upper stage of a Falcon 9 rocket impacted near Einstein Crater on the Moon's far side at 8,700 km/h. The collision generated a dust cloud several kilometers high, and sodium and lithium gas spectra were observed for 5-10 minutes.
NASA and Northrop Grumman to Repurpose Gateway Components for Three Lunar Base Demonstration Missions
After NASA canceled the Lunar Gateway program in March 2026, it decided to repurpose Northrop Grumman's HALO module components for three lunar south pole survival technology 'Lunar Infrastructure Demonstration (LID)' missions. Key test targets include systems for surviving polar night on the Moon and shared power infrastructure.
August 12: Total Solar Eclipse and Perseid Meteor Shower Coincide โ Rare Astronomical Double Event
The August 12 total solar eclipse path passes through northern Russia, Greenland, Iceland, and northern Spain. The Perseid meteor shower also peaks on the same day, offering a rare opportunity to observe both phenomena simultaneously under dark skies due to the new moon.
Solar Wind Strips Mars Atmosphere via Kelvin-Helmholtz Waves โ Planet Unprotected Without Magnetic Field
Analysis of MAVEN and Tianwen-1 data revealed that solar wind creates rolling waves at the outer edge of Mars's atmosphere, stripping atmospheric particles at approximately 100 grams per second as plasma clouds. Mars, which lacks a magnetic field, is defenseless against this process.
FDA Approves First mRNA-Based Flu Vaccine mFLUSIVA โ Platform Expands Beyond COVID-19
The FDA approved the mRNA-based influenza vaccine mFLUSIVA on August 5. It marks the first extension of the mRNA platform to flu prevention, and is expected to enable faster production than traditional egg-based methods.
FDA Grants Accelerated Approval to Tudriqev for Treatment-Resistant Melanoma โ One in Four Patients Responds
The FDA granted accelerated approval to Replimune's Tudriqev on August 6, in combination with nivolumab, for adult patients with unresectable advanced cutaneous melanoma that progressed after anti-PD-1 therapy. One in four patients responded in clinical trials, with a median duration of response of approximately 14 months.
US Cyclospora Infections Exceed 22,000 โ 2 Deaths Confirmed
According to the US CDC, the cyclospora outbreak has spread to 45 or more states, with confirmed and pending cases exceeding 22,700. As of August 6, 279 people have been hospitalized and 2 deaths have been confirmed in Michigan.
Once-Weekly HIV Pill Confirms Viral Suppression in Phase 3 Trial
Phase 3 results from the ISLEND-1 and -2 trials presented at AIDS 2026 showed that a once-weekly single pill combining islatravir (Merck) and lenacapavir (Gilead) demonstrated equivalent viral suppression to daily regimens. More than 93% of participants maintained viral suppression at week 48.
ESO Telescope Captures Chemical Fingerprint of SpaceX Rocket's Moon Crash
ESO's Very Large Telescope captured sodium and lithium spectral lines for 5-10 minutes in the lunar dust plume generated immediately after a Falcon 9 upper stage (4 tonnes) crashed into the Moon on August 5. Sodium is attributed to lunar soil and lithium to the rocket body.
NASA Astronauts Conduct ISS Spacewalk 96 for Solar Array Expansion
Jessica Meir and Anil Menon performed US Spacewalk 96 outside the ISS on August 6 to prepare the 3B power channel for a future rollout solar array installation. The excursion lasted approximately 6.5 hours.
Curiosity Discovers Largest Known Honeycomb Crack Field on Mars
NASA's Curiosity rover photographed 4-8 cm polygonal cracks extending to the horizon in the Valle Grande valley of Gale Crater. Dried mud or freeze-thaw cycles are the suspected cause, drawing attention as potential evidence of past water activity on Mars.
Imported Jalapeรฑo Salmonella Outbreak: 345 Sick Across 27 States, 36 Hospitalized
CDC and FDA announced on August 6 that Salmonella Javiana was detected in jalapeรฑos from Sinaloa, Mexico, sickening 345 people and hospitalizing 36 across 27 states. 93% of cases involved diners at Mexican-style restaurants like Chipotle and QDOBA; the product has been recalled.
Prebiotic Inulin Supplement Reduces Knee Arthritis Pain in Clinical Trial
A University of Nottingham team published 6-week clinical results (117 participants) in Nutrients showing the inulin group had significantly reduced knee pain, pain sensitivity, and improved grip strength compared to placebo, with a lower dropout rate than the exercise therapy group.
Soy-Based Bioactive Gum Cuts HPV by 93%, Showing Head and Neck Cancer Prevention Potential
Penn researchers published a study in Scientific Reports showing a soy-based gum containing natural antiviral protein FRIL reduced HPV in oral samples from head-and-neck cancer patients by 93%. Adding antimicrobial peptides nearly eliminated two cancer-associated bacteria.
SpaceX Launches AST BlueBird Satellites 11-13 on Falcon 9
A Falcon 9 rocket launched BlueBird 11, 12, and 13 from Cape Canaveral on Aug. 5, bringing the total to 13 satellites and accelerating the build-out of direct-to-smartphone satellite connectivity.
Falcon 9 Upper Stage Strikes Moon Near Einstein and Bell Craters
A Falcon 9 rocket second stage tracked by NASA from a commercial mission struck the lunar surface near the Einstein and Bell craters on Aug. 5. Surface change analysis is planned.
NASA Astronauts Meir and Menon Complete ISS Spacewalk
NASA astronauts Meir and Menon conducted a spacewalk outside the International Space Station beginning at 8:35 a.m. ET on Aug. 6.
World-First NK Cell Therapy ZI-MA4-1 Administered to Advanced Ovarian Cancer Patient
The Christie Hospital in the UK administered ZI-MA4-1, a natural killer (NK) cell therapy targeting the MAGE-A4 protein, to an advanced ovarian cancer patient on Aug. 5 in the first-ever administration of this Phase 1 clinical trial.
Gastric Cancer CAR-T Therapy satri-cel Availability Announced for Solid Tumors
Shanghai SinoUnited Hospital announced on Aug. 5 the availability of satri-cel, the world's first approved CAR-T therapy for solid tumors, for patients with Claudin18.2-positive advanced gastric cancer.
FDA Sets Aug. 17 PDUFA Date for Multiple Myeloma Drug Iberdomide
Bristol Myers Squibb's iberdomide (IberDd combination therapy) received priority review designation for relapsed/refractory multiple myeloma. The FDA decision date is August 17, 2026.
SpaceX Successfully Launches 24 Additional Starlink Satellites on Falcon 9
SpaceX launched 24 satellites into low Earth orbit on the Starlink 17-53 mission from Vandenberg Space Force Base on August 4 using a Falcon 9 rocket. It was the 90th Falcon 9 launch of the year, with the Starlink constellation now exceeding 10,800 satellites.
ISS Expedition 75 Completes Spacewalk Procedure Review
Expedition 75 astronauts completed a review of procedures for the next spacewalk on August 3. NASA also officially introduced the crew for the SpaceX Crew-13 mission, scheduled to launch on September 12.
Hand, Foot, and Mouth Disease Cases Surge 33-Fold in 12 Weeks; KDCA Urges Children to Stay Home
Korea Disease Control and Prevention Agency sentinel surveillance data shows the ratio of suspected hand, foot, and mouth disease cases surged 33-fold over 12 weeks, reaching 48.3 per 1,000 outpatient visits among children aged 0-6. Parents are advised to keep sick children home from daycare and kindergarten.
Dementia Management Primary Care Program Expands to 92 Cities and Counties Starting August 3
The Ministry of Health and Welfare expanded the dementia management primary care pilot program from 42 to 92 cities and counties. Participating physicians also increased from 315 to 417, strengthening integrated community-based dementia care.
Government Plans to Release National Bio Big Data of 770,000 People in H2
The Ministry of Health and Welfare announced plans to gradually release national integrated bio big data covering 770,000 people starting in H2 2026, and to expand data access support grants of up to 400 million KRW for AI startups from 8 to 40 cases.
Asteroid Nysa Confirmed as Solar System's First Triple-Lobed Body
Asteroid (44) Nysa has been confirmed as the solar system's first triple-lobed asteroid, connected by three lobes. It is approximately 75 km in diameter and also has a 1-km satellite.
NASA Selects Rocket Lab to Launch Aspera Space Telescope
NASA selected Rocket Lab Electron as the launch vehicle for the shoebox-sized Aspera space telescope. Aspera will map the distribution of hot gas around galaxies through EUV observations.
Mounjaro Surpasses 1.5 Million Prescriptions 10 Months After Korean Launch
GLP-1 obesity drug Mounjaro surpassed 1.5 million prescriptions 10 months after domestic launch. Those in their 20s and 30s account for over half, with teen prescriptions surging; discussions on designating it a misuse-concern drug have begun.
Thermage, Ultherapy and Others Refuse to Supply Skin Devices to Oriental Medicine and Dental Clinics
Major skin beauty device companies including Thermage and Ultherapy officially announced they will not supply products to oriental medicine clinics and dental offices, responding to backlash from the medical community.
Generic Drug Prices Cut to 45% of Originals; Phased Implementation Begins August
The Korean government is phasing in revisions to generic drug pricing, lowering standards from 53.55% to 45% of original drugs. The goal is annual savings of 2.4 trillion won.
Korea's First Domestic CAR-T 'Limcapo' Passes Key Health Insurance Coverage Review
Curocel's first Korean CAR-T treatment Limcapo passed a key checkpoint in the national health insurance coverage review for adult lymphoma treatment.
Solar CME Strikes Earth, Triggers G2 Geomagnetic Storm
A coronal mass ejection (CME) launched from the Sun on July 30 reached Earth on August 2, triggering a maximum G2 (moderate) geomagnetic storm. NOAA forecast impacts to continue through August 3.
NASA Roman Telescope Fueled, Launch Set for August 30
NASA completed loading 290 gallons of hydrazine fuel into the Nancy Grace Roman Space Telescope. It is scheduled to launch August 30 on a SpaceX Falcon Heavy, with a mirror the same size as Hubble's but providing 100 times the field of view.
Dark Matter Self-Interaction Shows Paradoxical Result in New Study
Researchers at the Perimeter Institute for Theoretical Physics published findings that self-attractive forces among dark matter particles paradoxically make dark matter lighter during cosmic expansion, contrary to standard cosmological predictions. Verification through observatories is planned.
World's First All-Optical Photonic Time Crystal Demonstrated
A joint team from Ecole Polytechnique and HZDR demonstrated the world's first all-optical photonic time crystal operating at terahertz frequencies. Applications in ultrafast computing, communications, and medical imaging are expected.
Korea's Telepix Wins First US Export Contract for AI Satellite Camera
Korean space AI company Telepix signed a contract to supply an AI satellite payload integrating a 4.8m-resolution electro-optical camera and GPU-based onboard AI system to US company Antaris Space, marking the first US export of AI satellite payload by a Korean space startup.
Dementia Primary Care Pilot Expands to 92 Cities and Counties Today
The Ministry of Health and Welfare's dementia primary care pilot program expanded from 42 to 92 cities and counties starting August 3. Participating physicians also increased from 315 to 417.
Moderna mRNA Flu Vaccine FDA Approval Decision Due August 5
The FDA's decision date for Moderna's mRNA-based seasonal flu vaccine mFLUSIVA is August 5. An FDA advisory panel unanimously recognized its benefits for adults 50 and older.
Domestic CAR-T Limkato Clears Cancer Drug Review, Reimbursement Process Underway
Curocell's domestic first CAR-T therapy Limkato cleared the HIRA Cancer Disease Review Committee for relapsed/refractory diffuse large B-cell lymphoma. Price negotiations and other procedures are underway targeting second-half 2026 reimbursement listing.
KMA-NHIS Fee Negotiations Intensify Ahead of 2027 Medical Fees
Negotiations over 2027 medical fees have escalated, with the Korean Medical Association demanding guaranteed legal strike rights if talks break down while the National Health Insurance Service insists it has no room for increases due to deficits this year.
BMS Iberdomide FDA Approval Target Date August 17
BMS's new cancer drug iberdomide has an FDA approval target date of August 17. As the first CELMoD-class candidate, it significantly improved MRD-negative rates versus standard therapy in the phase 3 EXCALIBER-RRMM trial.
Roman Space Telescope Fueled and Ready; Falcon Heavy Launch Set for August 30
NASA moved the Nancy Grace Roman Space Telescope into its final pre-launch phase and completed fueling with 290 gallons of propellant. It is scheduled to launch toward the L2 orbit on a SpaceX Falcon Heavy rocket on August 30.
Fossil Discovered in Australia Shows Three-Tier Predation: Pterosaur, Ichthyosaur, Plesiosaur
A fossil revealing a three-tier predation chain โ a pterosaur caught by an ichthyosaur, which was in turn caught by a plesiosaur โ was excavated from the Eromanga Sea formation in northwestern Queensland. The findings were published in Gondwana Research.
NASA Madrid Deep Space Antenna Survives Spanish Wildfires โ No Structural Damage
The Madrid Deep Space Communications Complex (DSN) was evacuated due to wildfires but confirmed no structural damage to its antennas. Some cable damage was reported, and operational control was temporarily transferred to Goldstone and Canberra.
Indoor Heat Illness Rates Double During Extreme Heat Above 38ยฐC
Analysis by the National Disaster Management Research Institute found that on days when the daytime high exceeds 38ยฐC, the proportion of heat illness cases occurring indoors or at home more than doubles from the usual 6% to over 12%. Authorities strongly recommended active use of cooling appliances.
Heat-Related Deaths Reach 13, Including Victims in Their 20s
The number of heat-related deaths this summer rose to 13, now including victims in their 20s. Uiyakeilbo reported that the extreme heat has expanded beyond the elderly and vulnerable populations to threaten all age groups.
81 Heat Illness Patients and 32,000 Livestock Deaths in North Chungcheong
North Chungcheong Province recorded 81 heat illness patients and approximately 32,000 livestock deaths due to the heat wave. Health authorities stated that the heat wave danger level 4 will be maintained through August 3.
43 Advanced Nursing Practice Roles Finalized; Full Implementation Begins in August
The Ministry of Health and Welfare officially finalized 43 authorized tasks for advanced practice nurses and began implementing the system in August. Covered procedures include wound suturing, arterial line insertion, and drafting medical records, with a minimum of three years of clinical experience required.
ESO Directly Images Betelgeuse's Companion Star for First Time in 100 Years
The ESO Very Large Telescope succeeded in directly imaging Betelgeuse's companion star 'Betelgeuse B.' French researcher Miguel Montarges stated 'a century of searching has reached its conclusion.'
NASA Roman Space Telescope Fueling Complete ... Falcon Heavy Launch Set for August 30
The Nancy Grace Roman Space Telescope, set to be carried on SpaceX's Falcon Heavy, completed loading 290 gallons of hydrazine propellant. Launch is scheduled for 7:26 AM ET on August 30, targeting the Sun-Earth L2 orbit.
NASA Opens New 'Flight Dynamics Research Facility' at Langley, First in 40 Years
NASA opened the 25,000 square-foot Flight Dynamics Research Facility (FDRF) at Langley Research Center in Virginia on July 31. The 20-foot diameter vertical wind tunnel will be used for testing flight characteristics of aircraft, spacecraft, and parachutes.
Thermal Camera Technique Can Boost LIGO Gravitational Wave Sensitivity by Up to 31%
A UC Riverside research team developed a technique using commercial thermal cameras to reconstruct nanometer-scale thermal deformations in LIGO mirrors. The method can improve LIGO A+ sensitivity by up to 31%, they reported.
Heat Illness Deaths Reach 13, Including a Person in Their 20s ... KDCA Calls It 'Very Unusual'
As of July 31, this summer's cumulative heat illness patients totaled 1,701 with an estimated 13 deaths. A man in his 20s with an underlying condition in Busan collapsed with heat illness symptoms at home and died after emergency transport. The KDCA called it 'very unusual.'
Dizziness in Summer Heat May Signal Stroke, Not Just Heat Illness ... Doctors Warn
According to Korea University Guro Hospital, heat-season cerebral infarction patient numbers over the past three years have matched or exceeded winter-season numbers. Blood thickens from dehydration in extreme heat, raising clot risk; paralysis or speech difficulty warrants immediate emergency care.
Ministry of Health Distributes Tattoo Procedure Guidelines ... Removal and Correction at Tattoo Parlors Prohibited
The Ministry of Health and Welfare distributed standard tattoo procedure guidelines to tattooists on July 30, prohibiting removal and correction of tattoos at tattoo parlors. Hepatitis B, C, and HIV carriers must submit a medical certificate before procedures, effective with the Tattooist Act in October 2027.
July 2026 ยท 118
SpaceX Successfully Launches NRO Classified Satellite NROL-95 on Falcon 9
SpaceX launched the U.S. National Reconnaissance Office (NRO) classified satellite NROL-95 on Falcon 9 at 3:10 AM EDT on July 30 from Cape Canaveral. The first-stage booster successfully landed approximately 8.5 minutes after launch.
U.S. Space Force Signs $1.6 Billion Contract with SpaceX for 18 Falcon 9 Launches
The U.S. Space Force signed an approximately $1.6 billion contract with SpaceX for 18 Falcon 9 launches on July 30. Launches will be conducted from Vandenberg Space Force Base through the end of 2027.
โฆ RELATED STORYLINENASA Opens New 'Flight Dynamics Research Facility' ... First New Wind Tunnel in 40 Years
NASA held a dedication ceremony for the 'Flight Dynamics Research Facility (FDRF)' at Langley Research Center in Virginia on July 31. NASA's first new wind tunnel in 40 years, it supports Artemis lunar exploration program research.
Medical License Exam Pass Rate at 90.8% ... 1,631 of 1,797 Applicants Pass
The pass rate for the 91st Medical License National Examination in 2026 was 90.8%, up 14.9 percentage points from the previous 90th session at 75.9%. Park Si-hyung from Kyung Hee University and Son Da-bin from Inje University tied for top score.
Health Insurance Review and Assessment Service: 112 First-Grade Acute Stroke Facilities Nationwide
The Health Insurance Review and Assessment Service released 2024 acute stroke appropriateness evaluation results. Of 268 medical institutions, 112 (41.8%) received a first-grade rating. Timely mechanical thrombectomy implementation rate was 95.1%.
GangStem Biotech's Osteoarthritis Treatment OSCA Confirms Efficacy in Phase 2a Trial
GangStem Biotech confirmed significant improvements in pain and joint function versus placebo at week 24 in Phase 2a trials of its osteoarthritis treatment OSCA in both medium and high doses. The OMERACT-OARSI responder rate was approximately twice that of the placebo group.
Korean Medical Association Officially Opposes Medical Accident History Disclosure System
The Korean Medical Association formally opposed implementing a medical accident history disclosure system for medical professionals. The association cited concerns about high-risk patient avoidance and defensive medicine, proposing enhanced professional self-regulation as an alternative.
Interstellar Comet 3I/ATLAS Passes Saturn's Orbit โ China's Probe Successfully Photographs It
The third interstellar object, comet 3I/ATLAS, is passing through Saturn's orbit in July. China's Tianwen-1 orbiter captured images of the comet's tail and coma, and NASA's JWST is continuing observations to determine its origin.
Government to Fully Introduce AI at Public Health Centers and Emergency Rooms โ AI Packages from 2027
The Ministry of Health and Welfare and the Ministry of Science and ICT announced their 'AI Basic Medical Strategy.' AI packages will be distributed to public health centers nationwide starting in 2027, and a public medical AI high-speed network will be connected to 72 responsible medical institutions by 2029.
UNAIDS: HIV Funding Hits 20-Year Low, 1.2 Million New Infections in 2025
A report released by UNAIDS on July 28 warned that global HIV response funding has fallen to $7.3 billion, a 20-year low, and that 1.2 million new infections occurred in 2025.
Stanford Uses AI to Discover Body-Produced Peptide BRP That Suppresses Appetite in Animal Tests
Stanford researchers used AI to discover BRP, a naturally produced peptide in the body. Animal experiments showed that a single injection before meals reduced food intake by up to 50%.
CRISPR RNA Editing Found to Improve Immunotherapy Response in Prostate Cancer
A research team at the University of Rochester used CRISPR-based RNA editing to restore immune cell recognition markers on prostate cancer cells, improving immunotherapy response rates. The findings were published in Nature Biomedical Engineering.
First Direct Evidence Published That Genetic Background Shapes Cancer Development
Cambridge University researchers published direct evidence in Nature showing that identical carcinogens produce different tumor development patterns depending on genetic background in mouse studies.
FDA Approves Centanafadine (Symtario), First New ADHD Drug Class in Decades
The FDA approved Otsuka's centanafadine (Symtario) on July 24 for ADHD in patients 6 and older. As a triple norepinephrine-dopamine-serotonin reuptake inhibitor, it is the first approval in this drug class.
Lancet Study: 90% of Countries Overprescribe Antibiotics
A Lancet Public Health analysis of 186 countries found 90% overuse resistance-inducing antibiotics. India prescribes at 9.3 DID compared to the recommended 6 DID benchmark.
Critical Brain Immune Cell Transition Determining Alzheimer's Progression Identified
Researchers identified a critical turning point for Alzheimer's progression: when brain microglia shift from early inflammation to antigen-presenting states, cognitive decline accelerates. Published in Nature Medicine.
CRISPR Technology Successfully Boosts Prostate Cancer Immunotherapy Response
RNA-targeting CRISPR-Cas13 restored immune detection in prostate cancer cells and significantly improved checkpoint therapy response, opening a new path against immunotherapy resistance in 'immune desert' tumors.
Cyclosporiasis Outbreak Across 9 US States: 1,947 Cases, 98 Hospitalized
Cyclospora-contaminated Mexican iceberg lettuce infected 1,947 people across 9 states and hospitalized 98. The CDC and FDA recommended a recall of Taylor Farms Mexico products.
NASA Astronaut Chris Williams Returns from ISS After 241 Days
NASA astronaut Chris Williams and two Russian cosmonauts parachuted down in Kazakhstan's Steppe on July 26 aboard Soyuz MS-28. They completed 3,856 orbits and traveled over 106 million miles during the mission.
Oral Antiviral Confirmed to Block Airborne Transmission of Measles-Like Virus
A Georgia State University team published findings in Nature Microbiology showing oral antiviral candidate GHP-88310 blocked both airborne and contact transmission of a measles-like virus in ferret models.
Sulfur-Based Compound LASSS Improves Aged Muscle Recovery Over Twofold
A Kyushu University research team published findings in Scientific Reports showing the trisulfide compound LASSS enhances the c-Met binding affinity of muscle repair protein HGF over twofold and increases oxidative damage resistance.
Prebiotic Fiber Supplement Improves Knee Osteoarthritis Pain and Strength
The INSPIRE clinical trial at the University of Nottingham reported that knee osteoarthritis patients taking inulin fiber supplements for 6 weeks experienced reduced pain, improved grip strength, and decreased pain sensitivity.
Samsung Biologics Posts Record Q2 Revenue of 1.3209 Trillion Won
Samsung Biologics disclosed Q2 2026 revenue of 1.3209 trillion won and operating profit of 586.4 billion won. Revenue and operating profit rose 30.2% and 23% year-on-year, respectively, maintaining an operating margin of 44%.
Kolon TissueGene's TG-C Fails U.S. Phase 3 Clinical Trial
Kolon TissueGene's osteoarthritis cell and gene therapy TG-C failed to achieve statistical significance versus placebo in its first U.S. Phase 3 clinical trial.
Hanmi Pharmaceutical Identifies Obesity Drug Candidate Using AI Platform
Hanmi Pharmaceutical announced on July 24 that it has identified a muscle-building obesity drug candidate compound using its in-house AI platform HARP-pSAR. Research results were presented at ISMB 2026 in the U.S., where a U.S. Phase 1 clinical trial is underway.
MFDS Publishes Pre-Announcement of Sub-Regulations for CDMO Special Act
The Ministry of Food and Drug Safety published a pre-announcement on July 24 for the enforcement decree and enforcement rules of the special act supporting bio-pharmaceutical CDMO regulatory support. The regulations cover facility standards for export-purpose operations and GMP certification procedures, with a scheduled effective date of December 31.
South Korea Life Expectancy 83.7 Years All-Time High...Fewest Doctors in OECD
OECD Health Statistics 2026 shows South Korea's life expectancy reached 83.7 years, above the OECD average of 81.2 years. Doctors per 1,000 people: 2.6, lowest in OECD. Suicide rate: 23 per 100,000, highest in OECD.
Semiconductor Fund Makes First Biotech Investment: 323 Billion Won in LigaChem Bio
Korea's government semiconductor fund selected LigaChem Biosciences, an antibody-drug conjugate (ADC) specialist, as its first biotech investment, committing $323 million (approx. 323 billion won).
Hugel Officially Launches Botulinum Toxin 'Letybo' in Indian Market
Hugel officially launched botulinum toxin 'Letybo' in the Indian market at the Global Aesthetics Summit in Goa, India. It conducted hands-on workshops with Indian partner Aakar Medical through July 24.
Starship Flight 13 Launch Aborted Due to Raptor 3 Engine Ignition Failure
SpaceX attempted to launch Starship Flight 13 on July 23 (local time) but the launch was automatically aborted when a Raptor 3 engine preburner failed to ignite. Elon Musk said two booster engines need replacement.
Milky Way Disk Flipped Over 90 Degrees After Dwarf Galaxy Collision 10 Billion Years Ago
Durham University researchers presented simulations at NAM 2026 showing the Milky Way disk flipped over 90 degrees after a head-on collision with the Gaia-Sausage-Enceladus dwarf galaxy ~10 billion years ago. The overturn process took hundreds of millions of years.
First Atmosphere Confirmed Around Habitable Zone Rocky Exoplanet LHS 1140 b
Helium escaping from rocky super-Earth LHS 1140 b, 48 light-years away, was detected via Magellan Telescope observations. This is the first confirmed atmosphere around a rocky exoplanet in the habitable zone.
Samsung Biologics pursues all-cash $1.8 billion acquisition of Swiss CDMO PolyPeptide
Samsung Biologics announced on July 19 a tender offer for Swiss contract manufacturer PolyPeptide at CHF 1.46 billion in full cash. The goal is to build GLP-1 and peptide drug production capacity โ the largest overseas acquisition by a Korean biotech company.
โฆ RELATED STORYLINEBMS and NVIDIA announce AI drug discovery factory built on DGX SuperPOD
Bristol Myers Squibb announced on July 20 an AI infrastructure expansion based on NVIDIA DGX SuperPOD. The system delivers up to 10x better performance per megawatt versus prior infrastructure and has already cut drug candidate clinical preparation time by 20-30%.
Eli Lilly to acquire psychedelic drug maker AtaiBeckley for up to $3.8 billion
Eli Lilly announced on July 16 it will acquire AtaiBeckley for up to $3.8 billion. The lead asset is BPL-003, a DMT-based nasal spray for treatment-resistant depression currently in Phase 3 trials.
Biogen's Alzheimer's tau therapy diranasen misses primary endpoint in CELIA study
Biogen presented Phase 2 CELIA trial results for diranasen at AAIC on July 14. The CDR-SB primary endpoint was not met, but the 60 mg cohort showed a 50-65% reduction in CSF tau protein and other biomarker improvements.
Celcuity wins FDA approval for gedatolisib in HR+/HER2- breast cancer
Celcuity announced on July 14 that gedatolisib received FDA approval for adults with PIK3CA-mutation-negative hormone receptor-positive, HER2-negative metastatic breast cancer โ the first approved pan-PI3K/mTOR inhibitor.
SpaceX Starship Flight 13 rescheduled for July 23 after engine replacement
SpaceX set the relaunch of Starship Flight 13, which auto-aborted on July 16, for 6:45 PM EDT on July 23. At least three Raptor 3 engines on Booster 20 were replaced, and a propellant loading test was conducted at the launch pad on July 22, per Space.com.
Starship Flight 13 to carry 20 Starlink V3 satellites for the first time
Starship Flight 13 plans to deploy 20 next-generation Starlink V3 satellites into orbit for the first time. The satellites will deploy solar panels and antennas and attempt high-capacity laser links with a South African ground station, per Space.com.
NASA awards approximately $590 million for 4 lunar cargo landings
NASA awarded contracts totaling approximately $590 million to Astrobotic, Firefly Aerospace, and Intuitive Machines for four lunar cargo landing missions carrying navigation, dust, and radiation instruments to support lunar base construction planned for late 2028.
James Webb Telescope discovers third exoplanet in Beta Pictoris system
NASA's James Webb Space Telescope used its NIRSpec infrared spectrograph to discover a third exoplanet in the Beta Pictoris star system. The research team confirmed the planet by analyzing the system's chemical composition, per Space.com.
NASA Exploration Science Forum 2026 covers Moon, asteroids, and Mars moons
The NASA Exploration Science Forum at Ames Research Center (July 21-23) featured invited talks and poster presentations on the Moon, near-Earth asteroids, and Mars moons. Lunar surface resource utilization and next-generation exploration mission directions were discussed, per NASA SSERVI.
Eli Lilly acquires AtaiBeckley for up to $3.8 billion in record psychedelic drug deal
Lilly agreed to acquire AtaiBeckley, which has a 5-MeO-DMT-based treatment for treatment-resistant depression, for $2.8 billion upfront (up to $3.8 billion total). It is reported as the largest psychedelic pharmaceutical deal on record.
FDA approves Lipendla, the first oral PCSK9 inhibitor
FDA approved Enriched (Lipendla) on July 16 as a treatment for adult high cholesterol. Unlike existing injectable PCSK9 inhibitors, it is the first available in oral form.
Taco Bell-linked Cyclosporiasis outbreak spreads to 34 states, 1,645 cases
CDC confirmed 1,645 Cyclosporiasis cases across 34 US states since May 1. Mexican iceberg lettuce distributed through Taco Bell was identified as the source, with 141 hospitalizations reported.
Dyne Therapeutics receives FDA priority review for DMD drug BLA
FDA granted priority review for Dyne Therapeutics' z-rostudirsen BLA with a PDUFA target date of January 21, 2027. It is an accelerated approval application for exon 51-skippable DMD patients.
SpaceX and Northrop Grumman launch robotic arm satellite servicer to geostationary orbit
Northrop Grumman's MRV and three MEP satellites launched on Falcon 9 on July 21. MRV directly docks with geostationary satellites via dual robotic arms, extending satellite lifespan by up to 6 years for repairs and repositioning.
โฆ RELATED STORYLINESpaceX Falcon 9 successfully launches Starlink after previous abort
SpaceX Falcon 9, which aborted at the last second on July 20, successfully launched Starlink satellites from Vandenberg Space Force Base in California on July 21.
Starship Flight 13 targets July 23 relaunch after engine replacement
Starship Flight 13, which auto-aborted just before Raptor engine ignition on July 20, is targeting a July 23 relaunch after replacing two engines and improving the startup sequence. It will carry 20 V3 Starlink satellites for the first time.
Atmosphere detected for first time around rocky habitable-zone exoplanet
An atmosphere was confirmed for the first time around rocky planet LHS 1140b, 48 light-years away. Helium escape was detected, suggesting a stable atmosphere maintained for billions of years, opening new avenues for studying potential habitability.
Scientists recreate cosmic dust in lab, providing clues to life's origins
Researchers successfully created cosmic dust in a glass tube simulating the space environment. Complex carbon molecules containing essential elements for life were detected in the generated dust.
Dinosaur-extinction asteroid identified as rare CO chondrite type
Scientists determined that the asteroid that wiped out the dinosaurs 66 million years ago was an extremely rare CO chondrite type originating from the outer solar system, providing new clues for research on asteroid origins.
India's Skyroot achieves first successful orbital launch with Vikram-1
Skyroot Aerospace's Vikram-1 rocket launched from Sriharikota on July 18 and reached a 450 km low Earth orbit in 17 minutes. India became the third country with a private company capable of orbital launches.
Congo Ebola death toll surpasses 930 in record-breaking outbreak
Ebola deaths in the DRC surpassed 930, with 37 additional deaths in 24 hours. With 2,344 confirmed cases, it achieved the fastest breakthrough to 2,000 cases on record, spreading across 5 provinces.
HLB subsidiary doses first patient in triple-negative breast cancer mRNA vaccine Phase 1
Immunomic Therapeutics, HLB's US subsidiary, dosed the first patient in the VITAL-TNBC Phase 1 trial of self-amplifying mRNA vaccine ITI-5000. The trial evaluates safety and immune activation as monotherapy and in combination with Keytruda.
ICMR survey finds 87% of Indian adults have dyslipidemia
The Indian Council of Medical Research's nationwide survey found 87.3% of Indian adults have abnormal lipid levels. Cardiovascular risk factors including high LDL and low HDL are widely prevalent across the country.
India's Skyroot Achieves First Successful Orbital Launch with Vikram-1
Skyroot Aerospace's Vikram-1 rocket launched from Sriharikota on July 18 and reached a 450 km low Earth orbit in just 17 minutes. This makes India only the third country after the US and China where a private company has achieved orbital launch capability.
China's Tianwen-2 Begins Close-Proximity Study of Asteroid Kamooalewa at 20 km
China's Tianwen-2 spacecraft closed to within 20 km of near-Earth asteroid 469219 Kamooalewa and began analyzing its shape, material composition, and internal structure.
Exoplanet Beta Pictoris d Sets New Record as Faintest Directly Imaged from Earth
Two independent research teams simultaneously announced a third planet in the Beta Pictoris system. With a mass 2.4 times that of Jupiter and an orbital period of 91 years, it is now the faintest exoplanet ever directly imaged from the ground.
FDA Formalizes Shift to Single Pivotal Trial for New Drug Approvals
The FDA officially finalized a policy reducing the standard for new drug approval from two pivotal clinical trials to one trial plus supplementary evidence. The agency noted this will affect the pace of drug development in oncology and rare disease.
WHO: Up to 45% of Global Dementia Cases Are Preventable
New guidelines published by the WHO on July 17 state that up to 45% of dementia cases worldwide could be delayed or prevented through interventions targeting modifiable risk factors.
Merck's Oral PCSK9 Inhibitor Lipfendra Wins First-Ever FDA Approval
Merck's enlicitide (Lipfendra) received FDA approval on July 16, becoming the world's first oral PCSK9 inhibitor. It is indicated for reducing LDL cholesterol in adults with hypercholesterolemia.
Creatine Found to Fuel T Cells and Suppress Tumor Growth
Research published on July 19 confirmed that creatine supplies energy to T cells and suppresses tumor growth. The findings suggest potential applications for creatine as an adjunct to immunotherapy cancer treatments.
India's Vikram-1 Becomes First Successful Private Orbital Rocket Launch
Skyroot Aerospace's Vikram-1 lifted off from Sriharikota on July 18 and reached a 450km low Earth orbit. The four-stage small rocket carries up to 350kg, making India the third country with private orbital launch capability.
LHC Observes 'Diffusion Wake' in Quark-Gluon Plasma for First Time
CERN's Large Hadron Collider confirmed the first experimental observation of diffusion wakes in ultra-hot quark-gluon plasma during lead-nucleus collisions. The phenomenon was theorized over 20 years ago; findings are accepted in Physical Review Letters.
ESA Mars Express Reveals Metallic-Looking Dunes on Mars
ESA's Mars Express orbiter released new images of unusual wave-shaped dunes on the Martian surface with a metallic appearance. Scientists plan to use the imagery to study Mars' wind erosion and landform formation processes.
FDA Approves Merck's Oral PCSK9 Inhibitor LipfendraโA First in Class
The FDA approved Merck's enlicitide (Lipfendra) on July 17 as the first once-daily oral PCSK9 inhibitor for adults with hypercholesterolemia. Phase 3 trials showed a 56-59% LDL-C reduction vs. placebo; all prior PCSK9 inhibitors required injection.
Eli Lilly to Acquire Psychedelic Drugmaker Ataibeckley for $2.8B
Eli Lilly announced on July 16 an agreement to acquire Ataibeckley at $6.75 per share for a total of $2.8B. Lilly's lead pipeline asset BPL-003 (a mebufotenin analog) is in Phase 3 for treatment-resistant depression.
Novartis Iptacopan Gains Full FDA Approval for IgA Nephropathy
Novartis' iptacopan (Fabhalta) received traditional FDA approval on July 16 for slowing kidney function decline in primary IgA nephropathy. As the first and only complement inhibitor for the indication, Phase 3 data showed 48% slower decline vs. placebo at 24 months.
Biogen's Tau-Targeting Diranersen Shows Cognitive Benefit at 18 Months in Phase 2
Biogen presented Phase 2 CELIA data for diranersen (BIIB080) at AAIC 2026. All dose groups reduced CSF total tau by 50-65%, and the 60mg group showed slowed cognitive decline at 18 months. Biogen decided to advance to Phase 3.
NASA-backed LOXSAT launches on Rocket Lab Electron from New Zealand
NASA-backed cryogenic fluid management satellite LOXSAT 1 launched July 17 from Mahia, New Zealand on a Rocket Lab Electron rocket. It will validate 11 liquid oxygen storage and transfer technologies over nine months.
Hubble discovers four hidden white dwarfs within 65 light-years
Hubble Space Telescope identified four white dwarfs within 65 light-years through near-ultraviolet spectroscopy. G 203-47 was confirmed as the 9th nearest white dwarf to the Sun after 27 years of uncertainty.
FDA approves first oral PCSK9 inhibitor Lipfendra
Merck's Lipfendra 20mg tablet received FDA approval on July 16. It is the first and only once-daily oral PCSK9 inhibitor that reduces LDL-C by up to 59% compared to placebo in adults with hypercholesterolemia.
Taco Bell-linked cyclosporiasis outbreak tops 400 cases
Over 400 cyclosporiasis cases have been confirmed across four states including Michigan and Ohio, with 94 hospitalizations. CDC and FDA identified Mexican shredded lettuce supplied to Taco Bell as the source and are recalling Taylor Farms products.
NASA Launches LOXSAT Cryogenic Fuel Technology Demo Satellite
The LOXSAT satellite, jointly developed by NASA and Eta Space, launched July 17 from the Mahia Peninsula, New Zealand aboard a Rocket Lab Electron rocket. It will demonstrate orbital storage and transfer of cryogenic liquid oxygen for use in future crewed lunar and Mars missions.
Hubble UV Observations Reveal 4 Previously Hidden White Dwarfs Near Red Dwarfs
Astronomers using Hubble Space Telescope ultraviolet observations identified four previously unknown nearby white dwarfs that had been hidden by their bright red dwarf companions. The discovery adds important cases to the study of stellar evolution's final stages.
FDA Grants Early Approval to Breast Cancer Drug Gedatolisib (Revtorpyk)
The FDA approved Celcuity's gedatolisib for HR+/HER2- PIK3CA wild-type metastatic breast cancer on July 14. In triple combination, the median progression-free survival was 9.3 months versus 2.0 months in the control arm, a 76% reduction in disease progression or death risk.
U.S. Measles Cases Surpass 2,231 โ CDC Warns of Risk to Elimination Status
CDC data shows 2,231 cumulative measles cases in 2026, with 32 new outbreaks. 93% of confirmed cases were unvaccinated or had unknown vaccination status, and the MMR vaccination rate of 92.5% falls below the 95% herd immunity threshold.
Korea's Ministry of Health and Welfare to Restructure on July 21
The Ministry of Health and Welfare announced it will implement an organizational restructuring on July 21, aimed at building a sustainable healthcare system and strengthening regional, essential, and public medical services.
NASA astronaut successfully docks with ISS aboard Soyuz
NASA astronaut Anil Menon and two Russian cosmonauts launched aboard Soyuz on July 14 and joined the ISS Expedition 74 crew.
Stellar-mass black hole confirmed in Omega Centauri globular cluster for the first time
Researchers announced the first identification of a stellar-mass black hole within the globular cluster Omega Centauri, based on analysis of Hubble and James Webb telescope data.
Ministry of Health holds joint meeting on preventing 'taeum' workplace bullying in medical institutions
The Ministry of Health and Welfare held a joint meeting with healthcare organizations on July 14 to address workplace bullying in medical institutions, moving to establish prevention and management frameworks including evaluation metric integration.
AstraZeneca's 'Wainua' fails phase 3 trial for ATTR cardiomyopathy
AstraZeneca's Wainua was reported on July 14 to have failed a large-scale phase 3 trial for ATTR cardiomyopathy.
FDA approves injectable formulation of Alzheimer's drug Leqembi
The FDA approved an injectable formulation of Alzheimer's drug Leqembi (lecanemab) on July 14, broadening patient access compared to intravenous administration.
China's Long March 10B Successfully Recovers First-Stage Booster with World-First Sea Net Capture
On July 10, China successfully captured the first-stage booster of the Long March 10B rocket on its maiden flight using a net structure aboard a sea vessel. Capture by net without landing legs is a world first, realizing a new approach to reusable rocket technology.
NASA Chandra Captures Evidence That Milky Way's Outer Spiral Arms Are Wider Than Previously Estimated
NASA's Chandra and ESA's XMM-Newton used X-ray echoes from gamma-ray bursts to measure distances to the Milky Way's outer spiral arms. The Perseus, Outer, and Scutum-Centaurus arms were confirmed to extend more broadly than previously estimated.
U.S. Parasite Infections Surge โ Over 4,000 Cases Across 32 States
Cyclospora parasite infections causing severe diarrhea have spread to 32 U.S. states, with more than 4,000 cases reported as of July 13. The figure already exceeds the full-year total of 2,700 for 2025, and the source of infection has not yet been identified.
Blood Pressure Drug Telmisartan Found to Significantly Enhance Efficacy of Cancer Drug
Researchers published findings that the common blood pressure drug telmisartan can meaningfully enhance the efficacy of the cancer drug olaparib. The results drew attention as they open up potential applications even in patients without BRCA gene mutations.
U.S. Measles Hits 32 Outbreaks in 2026 โ Elimination Status Review Announced
After the number of measles outbreaks reached 32 this year, U.S. health authorities announced they would review whether the country can maintain its national measles elimination status. The CDC is set to formally re-evaluate whether elimination criteria are being met.
HLB Science Shareholder Meeting Approves HLB Merger with 99% Approval
HLB Science's shareholders voted 99% in favor of merging with HLB. The combined entity will unify drug pipelines and R&D infrastructure to boost competitiveness.
Samsung BioLogics Signs $188.95M CMO Contract with European Pharma
Samsung BioLogics announced a $188.95 million biopharmaceutical contract manufacturing agreement on July 13. Contract term runs through March 2032 with counterparty name undisclosed.
Health Insurance Rates Overhauled for First Time in 20 Years, $3.6T to Regional and Essential Care
The Health Insurance Policy Committee approved major rate increases for regional and essential care. Non-capital surgery fees rise 10%, community clinics initial visit fees increase 6%, with phased rollout starting December.
Korea's First CAR-T Therapy 'Limcato' Clears NHI Coverage's First Hurdle
Curocell's Limcato passed the Severe Disease Deliberation Committee on July 8, entering the National Health Insurance listing process โ roughly two months after receiving MFDS approval in April.
Manual Therapy Moves to Managed Benefits Tier from July 1 โ Up to 15 Sessions per Year
The Ministry of Health and Welfare announced that from July 1, manual therapy is reclassified as a managed benefit, with NHI applying at โฉ43,850 per session (95% co-pay), capped at twice a week and 15 sessions per year.
Type 1 Diabetes Patients Can Now Register as Pancreatic Disability โ First Expansion in 23 Years
From July 1, the Ministry of Health and Welfare added pancreatic disability as a new disability category, allowing patients with insulin secretion deficiency to register. This is the first expansion of disability categories since 2003.
MFDS Officially Approves Rare Disease Drug Zoenxa on July 10
The Ministry of Food and Drug Safety approved Zoenxa (leniolisib phosphate), an imported rare disease drug for patients with PI3K-delta syndrome, on July 10. Designated as the 27th product under the Global Innovative Products Fast Track, it is the first treatment option for patients who previously had none.
HLB Rivoceranib FDA PDUFA Date Set for July 23 โ Third Attempt
HLB resubmitted its NDA for the hepatocellular carcinoma drug rivoceranib in combination with camrelizumab, with a PDUFA date of July 23. The two prior complete response letters stemmed from manufacturing facility issues at partner Hengrui Pharmaceuticals; resolution of those issues is the critical variable.
LegaChem Biosciences Unveils 2035 ADC Roadmap and AI Research Strategy at R&D Day
LegaChem Biosciences held an R&D Day at the Conrad Hotel in Seoul on July 8, presenting its 2035 ADC roadmap, AI-driven research strategy, and updates on clinical progress with global partners.
Eli Lilly oral GLP-1 outperforms oral semaglutide on all Phase 3 metrics
Eli Lilly's oral GLP-1 orforglipron showed superior blood sugar and weight loss outcomes compared to oral semaglutide in Phase 3 trials, according to ScienceDaily.
โฆ RELATED STORYLINEFDA grants accelerated approval to Vera's IgA drug Trutakna
The U.S. FDA granted accelerated approval on the 7th to Vera Therapeutics' atacicept (Trutakna) for treating IgA nephropathy in adults. Clinical trials confirmed 46% reduction in proteinuria.
Manual Therapy Managed-Benefit Rules Take Effect in July โ Korean Manual Medicine Society Demands Immediate Reversal
Starting in July, manual therapy was reclassified as a managed benefit, capping sessions at KRW 43,850 per visit, 95% patient co-pay, twice a week, and a maximum of 24 sessions per year. The medical community responded with fierce opposition, and a wave of clinic closures was already underway.
National Health Insurance Service and Medical Associations Begin 2027 Fee Negotiations
The National Health Insurance Service and heads of medical associations began negotiations over 2027 healthcare reimbursement fees. Demands for fee increases to address medical workforce shortages and strengthen essential medical services emerged as the core agenda.
New Rule Exempts Radiation Workers from Repeat Health Checkups After Job Change โ Effective July 9
Starting July 9, workers handling radiation-generating devices no longer need to undergo a new health examination when they change jobs or shift to different duties. The rule change addresses complaints that requiring repeat checkups at every job change caused inconvenience for workers and administrative burdens.
US FDA grants accelerated approval to Vera's IgAN drug Trutakna
According to GlobeNewswire, the US FDA granted accelerated approval to Vera Therapeutics' atacicept (brand name Trutakna) to reduce proteinuria in adults with primary IgA nephropathy. The first dual-target therapy inhibiting both BAFF and APRIL, given as a once-weekly subcutaneous injection, it showed a 42% reduction in proteinuria versus placebo at week 36.
FDA expands Casgevy approval to children age 2+ with sickle cell disease
FDA approved Casgevy (exagamglogene autotemcel) from Vertex and CRISPR Therapeutics on July 1 for children age 2 and older with sickle cell disease and transfusion-dependent beta-thalassemia. The age requirement lowered from 12+.
Korea MFDS approves Serplulimab for extensive-stage small cell lung cancer treatment
The Korea Ministry of Food and Drug Safety approved Serplulimab from Alvogene Korea on July 1 as a rare drug for first-line treatment of extensive-stage small cell lung cancer in adults combined with carboplatin and etoposide.
Korea's national growth fund makes first biotech investment of 323B won in LigaChem
The 150 trillion won national growth fund made its first biotech bet, investing $323 million (approximately 323B won) in ADC specialist LigaChem Biosciences, according to the Financial Services Commission.
US Medicare Begins Offering GLP-1 Obesity Drugs at $50 per Month
Starting July 1, CMS launched a pilot program providing GLP-1 obesity drugs such as Wegovy and Zepbound at $50 per month to Medicare Part D enrollees who meet obesity criteria. The program runs through the end of 2027.
โฆ RELATED STORYLINEKorea Tightens Catastrophic Medical Expense Support from July, Excluding Minor Conditions
From July 1, 2026, medical costs related to minor conditions such as hypertension, diabetes, and the common cold are excluded from the catastrophic medical expense support calculation. Hospital room charges for non-critical conditions in semi-private and private rooms were also removed from eligible expenses.
FDA Set to Review Gedatolisib Breast Cancer Drug Approval on July 17
The FDA has set July 17 as the PDUFA date to review Celcuity's gedatolisib for approval. The drug is a once-weekly subcutaneous injection for patients with HR+/HER2- PIK3CA wild-type advanced breast cancer.
Manual therapy now a managed benefit: 43,850 won per session, 15-session annual cap
Manual therapy was reclassified from non-covered to managed-benefit status on July 1. Clinic rate fixed at 43,850 won, 95% patient co-pay, maximum 15 sessions per year (2 per week).
Nationwide family-doctor pilot launches; targets adults 50 and older first
The Ministry of Health and Welfare started a three-year family-doctor model pilot in July 2026. Year one focuses on adults 50+, providing integrated chronic-disease management and preventive care.
Hanmi, JW Pharma, HK Inno.N accelerate Korean GLP-1 race
Hanmi Pharmaceutical filed MFDS approval for efpegerglucagon; JW Pharmaceutical plans domestic phase 3 of bofanglutide in 2026; HK Inno.N completed phase 3 enrollment for its GLP-1 candidate.
โฆ RELATED STORYLINEFDA sets July 7 PDUFA date for atacicept in IgA nephropathy
The FDA granted Priority Review to atacicept's BLA for adult IgA nephropathy, with a PDUFA action date of July 7, 2026.
LigaChem Bio Secures 500 Billion Won from Korea's State Growth Fund
The Korea National Growth Fund invested 500 billion won in ADC specialist LigaChem Biosciences via convertible preferred shares and bonds โ the fund's first direct investment in a listed biotech.
SK Biopharma & Insilico Medicine Sign $2.5B AI Drug Discovery Deal
SK Biopharma and Insilico Medicine signed an AI-based drug discovery collaboration for neuroimmune CNS disorders with total potential milestones of up to $2.5 billion.
MOHW Launches Pilot to Cut Rare Disease Drug Listing Time to 100 Days
Korea's Ministry of Health and Welfare began recruiting participants for a fast-track health insurance listing pilot from July 1, targeting a reduction of the current 240-day process to within 100 days.
Korea Night at BIO USA 2026 Draws Record 1,200 Global Attendees
The Korea Night event held during BIO USA 2026 drew more than 1,200 domestic and international attendees. Overseas participants accounted for 55% of attendees โ the highest ratio on record.
June 2026 ยท 114
SK Biopharmaceuticals Signs AI CNS Drug Development Deal with Insilico
SK Biopharmaceuticals signed a joint research agreement with generative AI drug developer Insilico Medicine to expand its central nervous system (CNS) pipeline, according to Innobiolab.
Yuhan's Lazertinib Retains Insurance Coverage via RSA Re-contract
Yuhan Corporation's non-small cell lung cancer drug Lazertinib (Rybrevant) retained National Health Insurance coverage through a risk-sharing agreement re-contract at approximately 35.3% below the current list price, according to Innobiolab.
MFDS and EMA Complete First Joint Bio-Drug Review
Korea's Ministry of Food and Drug Safety and the European Medicines Agency completed their first joint review of a domestic biopharmaceutical product, conducted via simultaneous submission, according to Innobiolab.
Korean Biotech Global Technology Transfer Contracts Surpass 13 Trillion Won in First Half
According to TheBio, domestic pharmaceutical and biotech companies' accumulated global technology transfer (L/O) contracts in the first half of 2026 totaled approximately 12.858 trillion won ($8.6 billion). With eight deals including Hanmi Pharmaceutical and Oscotec already closed, the sector has already exceeded half of last year's full-year performance.
DRC Ebola Bundibugyo Virus: WHO Maintains International Health Emergency
The International Public Health Emergency of Concern (PHEIC) declared by WHO in May remains in effect. WHO reports 515 confirmed cases and 91 deaths in Congo, 19 confirmed cases in Uganda, with no approved vaccines or treatments.
US Measles Cases Reach 2,134 with Outbreaks in 41 States
According to the CDC, as of June 25, US measles cases have reached 2,134 across 41 states, with 93% linked to outbreak clusters. The unvaccinated share stands at 92%.
FDA Approves Utebzi, First Oral Carbapenem Antibiotic for Complex UTIs
The FDA approved the oral carbapenem antibiotic Utebzi (tebipenem pivoxil) for complex urinary tract infections on June 17. It marks the first US approval of an orally administered carbapenem-class drug.
Ebola Bundibugyo Virus: 1,118 Confirmed, 291 Deaths in DRC
With WHO having declared a PHEIC on May 17, the DRC reported 1,118 confirmed cases and 291 deaths as of June 25. One imported case was confirmed in France, and no licensed vaccines or treatments exist for this variant.
U.S. Measles Cases Reach 2,134 โ 30th Outbreak Confirmed
U.S. measles cases totaled 2,134 as of June 25, according to the CDC. There have been 30 outbreaks this year, with 1,982 cases โ 93% of the total โ linked to outbreak clusters.
Biopharma M&A Tops $134B in H1 2026 โ Already Exceeds Full-Year 2025
H1 2026 pharma and biotech M&A volume has already surpassed the full-year 2025 total, according to STAT News. There were 33 biotech acquisitions above $1 billion, totaling approximately $134 billion.
FDA PDUFA Review Target Date for Sobi's Gout Drug NASP Is Today
The FDA's PDUFA target review date for Swedish biotech Sobi's nanocapsulated sirolimus and pegadricase combination therapy (NASP) is June 27, 2026. NASP is a combination therapy designed to lower uric acid levels in patients with refractory gout.
FDA Approves Keytruda + Trodelvy as First-Line Triple-Negative Breast Cancer Treatment
On June 25, the FDA approved the combination of Keytruda and Trodelvy as a first-line treatment for PD-L1-positive metastatic triple-negative breast cancer, based on ASCENT-04 trial data. It is the first combination approval of its kind in this class.
AbbVie to Acquire Apogee for $10.9B, Adding Atopic Dermatitis and Asthma Pipeline
AbbVie entered into an agreement on June 22 to acquire Apogee Therapeutics, which holds IL-13-targeting monoclonal antibody zumlilokibart, for $135.11 per share totaling $10.9 billion.
Psilocybin Drug Receives FDA Commissioner's National Priority Review Voucher
Compass Pathways' synthetic psilocybin COMP360 received an FDA Commissioner's National Priority Review Voucher, shortening the review timeline. Both Phase 3 trials COMP005 and COMP006 for treatment-resistant depression met their primary endpoints.
National Bio Big Data of 770,000 People to Open Gradually in Second Half of 2026
The government will open its national integrated bio big data of 770,000 people starting in the second half of 2026. AI medical startup support vouchers will also expand dramatically from 8 to 40, accelerating AI-driven healthcare innovation.
Severe Alopecia Areata Treatment Covered by National Health Insurance from June
The Ministry of Health and Welfare began covering the severe alopecia areata treatment 'Olumiant (baricitinib)' under national health insurance from June 1. A public forum on extending coverage to youth with general hair loss is also scheduled for July.
South Korea Joins International Clinical Trial Network โ Strengthening Pandemic Response
Four hospitals including Seoul National University Bundang Hospital are participating in a multi-national RAPID clinical trial targeting antibiotic-resistant bacteria. Linked with the NIH-led STRIVE program, the effort raises South Korea's infectious disease response capabilities to international standards.
Semaglutide Slows Biological Aging by 9%, First RCT Confirms
A UC San Diego team published in Nature Communications showing weekly semaglutide reduced epigenetic aging speed by 9% versus placebo โ the first randomized controlled trial to confirm an anti-aging effect from a GLP-1 drug.
โฆ RELATED STORYLINEIvonescimab Cuts Lung Cancer Mortality by 34% โ ASCO Plenary
Akeso and Summit Therapeutics bispecific antibody ivonescimab combined with chemo reduced death risk by 34% in advanced squamous NSCLC as first-line therapy, per the HARMONi-6 trial presented at ASCO.
Wegovy Pill Surpasses 3 Million Prescriptions in 5 Months
Novo Nordisk announced at ADA 2026 that its oral semaglutide 25mg tablet has exceeded 3 million prescriptions, with over 80% going to patients who had never previously received GLP-1 therapy.
โฆ RELATED STORYLINEAbbVie seals $10.9B all-cash Apogee Therapeutics deal
AbbVie sweeps up Apogee Therapeutics for $135.11/share, $10.9B cash. Lead asset zumilokibart (IL-13 target) shores up immunology portfolio post-Humira cliff.
FDA okays first oral carbapenem, Utebzi, for resistant UTIs
Tebipenem pivoxil gets green light for complicated UTI treatment. First oral carbapenem ever. Landmark for antibiotic resistance: serious infections now have oral option.
MoonLake posts Week 52 sonelokimab data; 67% hit HiSCR75
IL-17A/F nanobody sonelokimab: 67% achieved HiSCR75 response in hidradenitis suppurativa; 25%+ full remission. BLA target 2026.
WHO flags AI policy risks; human-in-loop critical, algorithm audit urged
Discussion paper unpacks how AI reshapes evidence-based health policy beyond clinical. Mandatory algorithmic impact assessments, human validation loop, deployment readiness checks recommended.
APG273 dual IL-13/TSLP inhibitor gains attention from Apogee deal
Alongside single-target zumilokibart, Apogee's APG273 blocks both IL-13 and TSLP cytokines in one long-acting antibody. Dual blockade shows asthma severity edge over monotherapy.
K-Pharma-Biotech H1 Technology Transfer Breaks 13 Trillion Won
With Oscotec's autoimmune disease therapy technology transfer to US Azios at up to 1 trillion won scale and other deals, domestic biotech companies' first-half 2026 global licensing-out exceeded 13 trillion won, rebounding versus the same period last year.
Korea's First Advanced Regenerative Medicine Therapy Approved for Rare Lymphoma Patients
The Ministry of Health and Welfare approved a treatment plan for EBV-positive rare NK/T-cell lymphoma patients using autologous immune cell injection as the first approved advanced regenerative medicine therapy. The first approval 14 months after system implementation raises access to rare disease treatment.
HLB Ribociclib FDA Decision Date Confirmed July 23 for Liver Cancer Indication
HLB's FDA decision date for ribociclib and camrelizumab combination therapy co-filed with Antengene Pharma is confirmed for July 23. After two Requests for Additional Information, the third attempt is underway, with HLB Chair Jin Yang-gon expressing hopes for simultaneous approval of two anti-cancer drugs in the second half.
FDA issues Complete Response Letter to cytisinicline โ approval delayed
The FDA sent a Complete Response Letter to cytisinicline on its June 20 PDUFA date, declining to approve the smoking cessation drug due to manufacturing facility GMP issues. Developer Achieve Life Sciences plans to refile in Q4 2026 with a new manufacturing partner.
Ebola Bundibugyo PHEIC drags on โ Korea tightens border screening at arrival gates
The WHO-declared Public Health Emergency of International Concern for Ebola Bundibugyo continues, with 837 confirmed cases and 196 deaths across DRC and Uganda as of June 15. Korea's KDCA is maintaining a 'Watch' alert and conducting universal screening at arrival gates for travelers from the affected countries.
GLP-1 users walk 560 fewer steps per day โ exercise still essential alongside the drugs
A study presented at ENDO 2026 found that people taking GLP-1 weight-loss drugs such as Ozempic and Wegovy walked an average of 560 fewer steps per day and spent 5.7 fewer minutes in moderate-intensity activity. Experts are urging patients to maintain resistance training to prevent muscle loss.
Cytisinicline FDA PDUFA today โ first new quit-smoking drug in 20 years
Achieve Life Sciences' cytisinicline hits its FDA PDUFA deadline today (6/20). Phase 3 trials ORCA-2 and ORCA-3 demonstrated significant smoking cessation rates vs placebo in over 2,000 participants. It would be the first new mechanism since varenicline.
Wegovy pill tops 3 million prescriptions โ oral GLP-1 market explodes
Novo Nordisk's Wegovy pill hit 3 million prescriptions and Q1 revenue of $355M โ twice the forecast โ just 5 months after launch. Eli Lilly's orforglipron (Foundayo), approved in April, is intensifying competition in the oral GLP-1 space.
โฆ RELATED STORYLINEFDA's June oncology relay โ KRAS and AKT1 targeted therapies surge to the fore
In June, the FDA is reviewing expanded approval of the KRAS-targeted pancreatic cancer drug daraxonirasiB and fast-track status for the AKT1 inhibitor TER-2013 in HR+ breast cancer. Q2 2026 is shaping up as a turning point for the oncology landscape.
Ebola cases in DRC reach 837 confirmed, 196 deaths, WHO activates emergency response as Uganda spread confirmed
Bundibugyo virus Ebola outbreak expanded to three provinces in DRC โ Ituri, North Kivu, and South Kivu โ with 837 confirmed cases and 196 deaths as of June 15. 19 cases confirmed in Uganda, with WHO and U.S. CDC mobilizing emergency response plans exceeding $500 million as no designated treatments or vaccines exist.
New smoking cessation drug in 20 years imminent...FDA decision on cytisinicline tomorrow
The FDA PDUFA decision date for Achieve Life Sciences' plant-derived smoking cessation drug cytisinicline is June 20. Upon approval, the first new smoking cessation treatment since varenicline 20 years ago will be born. ORCA-2 and ORCA-3 trials confirmed meaningful smoking cessation rate improvements over placebo.
AstraZeneca's oral GLP-1 elecoglipron achieves 10.5% weight loss in 26 weeks, Phase III underway
Elecoglipron 75mg presented at ADA 2026 achieved 10.5% weight loss in 26 weeks (placebo 0.6%), with results published in Lancet. As a once-daily oral small molecule GLP-1 receptor agonist with no food or fasting restrictions, EMBOLD and ELUMINATE Phase III trials have officially begun.
โฆ RELATED STORYLINEDRC Ebola reaches 782 cases and 181 deaths, WHO maintains PHEIC as Uganda hit
The DRC's Ebola Bundibugio virus outbreak has reached 782 confirmed cases and 181 deaths as of June 14. Ituri Province accounts for 717 cases and Uganda has reported 19 additional cases. The WHO, which declared a PHEIC on May 17, continues its emergency response.
Smoking cessation drug cytisinicline heads for FDA decision D-3 on June 20
The FDA PDUFA review date for cytisinicline โ a plant-derived alkaloid smoking cessation drug โ is June 20. The first novel cessation therapy since varenicline, it demonstrated significantly higher quit rates than placebo in Phase 3 ORCA-2 and ORCA-3 trials and holds FDA Breakthrough Therapy designation.
Oral GLP-1 elecoglipron achieves 10.5% weight loss at 26 weeks, enters Phase 3
At ADA 2026, AstraZeneca's oral small-molecule GLP-1 receptor agonist elecoglipron 75mg achieved 10.5% body weight reduction at 26 weeks. 88.8% of participants lost at least 5% versus placebo; results were published in The Lancet and the drug has advanced to Phase 3 EMBOLD.
โฆ RELATED STORYLINEEbola Cases Surge to 782 in DRC โ WHO Warns PHEIC to Continue
The Ebola Bundibugyo virus outbreak in the Democratic Republic of Congo has worsened to 782 confirmed cases and 181 deaths as of June 14. Ituri Province accounts for 717 cases and Uganda reported 19. WHO, which declared a PHEIC on May 17, is warning of further regional spread if the trend continues.
Oral GLP-1 Drug Delivers 10.5% Weight Loss in Trial โ Potential Obesity Game-Changer
At the ADA annual conference, AstraZeneca's oral GLP-1 receptor agonist elecoglipron delivered meaningful blood sugar reduction and 10.5% weight loss over 26 weeks in a type-2 diabetes trial. Eli Lilly's orforglipron also proved superior in three Phase 3 trials, heralding an era of injection-free obesity treatment.
โฆ RELATED STORYLINEFirst New Smoking Cessation Drug in 20 Years, Cytisinicline, Faces FDA Decision D-4
The plant-derived nicotine receptor partial agonist cytisinicline faces its FDA PDUFA date on June 20. Phase 3 ORCA-2 and ORCA-3 trials showed significantly higher quit rates than placebo; FDA already granted Breakthrough Therapy designation. Approval would be the first new smoking cessation drug since varenicline in 2006.
WHO Ebola PHEIC: 676 Cases, 136 Deaths in DRC and Uganda
WHO declared Ebola Budibugyo virus a Public Health Emergency of International Concern on May 17. As of June 10, there are 676 confirmed cases and 136 deaths. The Africa CDC and WHO have launched a $518 million emergency response plan.
FDA Approves Belzutifan + Pembrolizumab as First Adjuvant for Renal Cell Carcinoma
On June 12, the FDA approved the belzutifan + pembrolizumab combination as adjuvant therapy for high-risk clear-cell renal cell carcinoma after radical nephrectomy, based on the LITESPARK-022 trial (1,841 patients). The first dual HIF-2ฮฑ/PD-1 inhibition approval.
Cytisinicline, First New Smoking-Cessation Drug in 20 Years, Faces FDA Decision June 20
The plant-derived alkaloid cytisinicline demonstrated significant quit rates vs. placebo in the ORCA-2 and ORCA-3 Phase 3 trials. Its FDA PDUFA date is June 20. If approved, it would be the first new smoking-cessation drug since varenicline in 2006.
China's JUNO Neutrino Observatory Publishes First Results on Nature Cover
The JUNO observatory, which holds 20,000 tonnes of liquid 700 meters underground, successfully reduced uncertainty in neutrino oscillation parameters by 1.6x compared to previous measurements using 59 days of data. The results were published as the cover paper in the June 10, 2026 issue of Nature.
Finerenone Shows Cardio-Renal Protection in Non-Diabetic CKD; Published in 3 Journals Simultaneously
Clinical studies published simultaneously in NEJM, JAMA, and The Lancet showed finerenone reduced the risk of kidney failure and cardiovascular death in non-diabetic chronic kidney disease patients by 23%. This opens a new treatment option for millions who had limited choices.
Stanford Successfully Regenerates Knee Cartilage by Blocking Aging Protein 15-PGDH
A Stanford Medical School research team successfully regenerated damaged knee cartilage in elderly mice and prevented arthritis by blocking the aging protein 15-PGDH. An oral drug has already entered clinical trials.
WHO declares Ebola Bundibugyo PHEIC; 635 confirmed, 127 dead in DRC
The WHO declared the Ebola Bundibugyo virus outbreak in the DRC and Uganda a Public Health Emergency of International Concern on May 17, 2026. As of June 10, the DRC alone reports 635 confirmed cases and 127 deaths, with no approved vaccine or treatment.
US measles reaches 2,073 cases across 40 jurisdictions in 2026
As of June 11, the US 2026 measles total stands at 2,073 cases across 40 jurisdictions, led by South Carolina (668). Some 92% of confirmed cases involve unvaccinated individuals, and 72% are children and adolescents.
Eli Lilly retatrutide hits 28.3% weight loss in TRIUMPH-1 Phase 3 โ a new record
Eli Lilly announced TRIUMPH-1 Phase 3 results in May 2026: weekly 12mg retatrutide over 80 weeks produced an average 28.3% body weight reduction (~32 kg), with 45% of participants losing more than 30%, setting a new obesity drug benchmark.
โฆ RELATED STORYLINENovo Nordisk CagriSema under FDA review; 22.7% weight loss in pivotal trial
Novo Nordisk submitted its CagriSema NDA to the FDA in December 2025, with an H2 2026 decision expected. The REDEFINE 1 Phase 3 showed 22.7% weight reduction and REIMAGINE 2 showed 1.91 percentage-point HbA1c improvement in diabetes patients.
โฆ RELATED STORYLINEFDA approves 4 drugs in May 2026, including rare blood cancer and COVID-19 prevention
The FDA approved Gilead's decnupazab for BPDCN, a hepatitis B/D treatment (Hepcludex), a triple-negative breast cancer therapy (DATROWAY), and Shionogi's COVID-19 prevention agent Xocova in May 2026.
Orforglipron wins FDA nod as the first GLP-1 pill with no food or timing limits
The FDA approved Lilly's orforglipron for adult obesity on April 1. Unlike oral semaglutide, it can be taken any time without food or water, promising better adherence, and ADA 2026 phase-3 data showed double-digit weight loss over 72 weeks.
โฆ RELATED STORYLINEBundibugyo Ebola hits 635 cases across DRC and Uganda; WHO declares a PHEIC
The Bundibugyo outbreak has spread across 18 health zones in DRC's Ituri and into Uganda, with 635 cases and 127 deaths as of June 9. The WHO declared a PHEIC on May 17; with no approved vaccine and a 30-50% fatality rate, response gaps are exposed.
US measles tops 2,030 cases, with elimination loss called 'highly likely'
US measles reached 2,030 cases by June 4, near the highest since 1991, with 30 large outbreaks across Florida, Pennsylvania and Virginia as MMR coverage slipped to 92.5%. CIDRAP calls a fall loss of elimination status highly likely.
Retatrutide phase 3 cuts A1C 2.0 points and sleep apnea 61% at ADA 2026
At ADA 2026, the triple agonist retatrutide cut baseline A1C of 7.9% by up to 2.0 points, reduced sleep-apnea events 60.6% and knee-osteoarthritis pain 73.1%, proving broad comorbidity benefit and shifting Lilly's obesity pipeline.
โฆ RELATED STORYLINECytisinicline FDA decision due June 20, the first new quit-smoking drug in 20 years
The plant-derived nicotine-receptor partial agonist cytisinicline faces a June 20 PDUFA date; approval would mark the first new smoking-cessation drug since varenicline in 2006. ORCA-2 and -3 showed higher quit rates, and the FDA granted priority review.
Bundibugyo Ebola at 598 cases in DRC, WHO/Africa CDC mount 500M response
As of June 8, the DRC reported 598 Bundibugyo Ebola cases and 115 deaths, with Uganda at 19 and 2. WHO and Africa CDC unveiled a 518-million-dollar joint response, and CEPI committed 60 million to three vaccine candidates.
Lilly's retatrutide sets record with 28.3% average weight loss at 80 weeks
Lilly's triple agonist retatrutide delivered an average 28.3% (about 31.9 kg) weight loss at 80 weeks in the 12mg arm of the TRIUMPH-1 Phase 3. It is the best obesity-drug result yet, with an FDA filing targeted for late 2026.
โฆ RELATED STORYLINENovo CagriSema REIMAGINE Phase 3 proves HbA1c and weight cuts
Novo's CagriSema achieved a 1.8-point HbA1c drop and 13.8% weight loss at 40 weeks in the 2.4mg arm of the REIMAGINE Phase 3 presented at ADA 2026. It met all primary and secondary endpoints, proving combination potential in diabetes.
โฆ RELATED STORYLINEUS measles tops 2,030, elimination status at risk after 26 years
As of June 4 US measles cases reached 2,030 across 30 outbreaks, with 93% unvaccinated. CIDRAP warned it is 'highly likely' the US loses its elimination status at this fall's PAHO review, ending a 26-year run.
Oral GLP-1 orforglipron's diabetes data debuts at ADA 2026
Diabetes trial data for orforglipron, the oral GLP-1 the FDA approved April 1, debuted at ADA 2026 in June. As the first non-peptide oral agent taken without food restrictions, it showed up to 12.4% weight loss at 72 weeks.
โฆ RELATED STORYLINELilly's retatrutide sets record with 28% average weight loss
In the TRIUMPH-1 phase 3 unveiled at ADA 2026, Lilly's triple agonist retatrutide cut weight 28.3% on average at 80 weeks in the 12mg arm. 45.3% lost 30%-plus, a new high for obesity drugs.
โฆ RELATED STORYLINENovo's CagriSema REIMAGINE phase 3 hits all primary endpoints
Novo Nordisk's CagriSema met all primary endpoints in the REIMAGINE 1, 2 and 3 phase 3 trials presented at ADA 2026. Trial 2 showed a 1.91-point HbA1c drop and 14.2% weight loss at 68 weeks.
โฆ RELATED STORYLINEBundibugyo Ebola emergency: over 530 cases in DRC and Uganda
The Bundibugyo Ebola outbreak, declared a WHO emergency on May 17, rose to 515 cases in DRC and 19 in Uganda by early June. Deaths reached about 90, with no approved vaccine or therapy, leaving only supportive care.
US measles tops 2,030, risking elimination status after 26 years
US measles cases reached 2,030 as of June 4, with 30 new outbreaks reported. Falling MMR coverage fueled spread, and officials warned the US could lose its elimination status at a November PAHO review.
FDA approves oral post-exposure COVID drug Xocova in May
On May 29 the FDA approved Shionogi's ensitrelvir (Xocova) as the first oral antiviral for post-exposure COVID-19 prevention. The 3CL protease inhibitor can be taken within 72 hours of exposure.
Lilly's retatrutide sets record with 30% average weight loss in Phase 3
Per ADA 2026, Lilly's triple agonist retatrutide in the TRIUMPH-1 Phase 3 trial achieved 28.3% average weight loss at week 80 in the 12mg arm, and 30.3% (about 38.6kg) at week 104 for BMI 35+, a new obesity-drug record.
Novo's CagriSema fails non-inferiority vs Zepbound at week 84 head-to-head
In the REDEFINE 4 head-to-head trial unveiled at ADA 2026, Novo's CagriSema 2.4mg posted 23% weight loss at week 84 but failed its primary endpoint of non-inferiority versus tirzepatide 15mg. A US FDA decision is expected by year-end.
DRC-Uganda Bundibugyo Ebola spreads to 400 cases, 66 deaths
The Bundibugyo Ebola outbreak, declared a PHEIC by the WHO on May 17, persisted into June, reaching 381 cases and 64 deaths in the DRC and 19 cases and 2 deaths in Uganda per a June 4 tally. No vaccine or treatment exists for this strain.
US measles tops 2,030 cases, elimination status at risk after 25 years
Per the CDC, US measles cases in 2026 topped 2,030 as of June 4, with 30 new outbreaks reported. 92% of patients were unvaccinated and 6% hospitalized. A November PAHO review is likely to revoke the elimination status earned in 2000.
Novo's zenagamtide, a GLP-1/amylin combo diabetes drug, shows 14.6% weight loss
Per Phase 2 results of Novo's zenagamtide (amycretin) at ADA 2026, the top dose achieved 14.6% weight loss and a 1.71-point A1C improvement at week 36 in 262 type 2 diabetes patients. The company plans to begin Phase 3 in the second half.
Ebola Bundibugyo variant declared PHEIC; spread continues despite response
The WHO declared the Bundibugyo ebolavirus outbreak in the DRC and Uganda a PHEIC on May 17. As of June 3, the DRC reported 381 confirmed cases and 64 deaths, with existing treatments proving ineffective and contact tracing at only 45%, hampering containment efforts.
โฆ RELATED STORYLINEUS measles cases exceed 2,030; elimination status at risk by fall
Cumulative measles cases in the US have exceeded 2,030 across 40 states, with 30 outbreaks reported. Over 92% of confirmed cases involved unvaccinated individuals, raising alarm that the nation may lose its measles-free status by fall as MMR vaccination rates decline.
ADA 2026: Novo's Cagrisema achieves 23% weight loss at 84 weeks
At ADA 2026 (June 5-8, New Orleans), Novo Nordisk presented Cagrisema phase 3 results. The drug achieved 23% weight loss at 84 weeks, falling short of Eli Lilly's Zepbound (25.5%).
โฆ RELATED STORYLINEFDA approves Eli Lilly's oral GLP-1 Orforglipron for obesity treatment
The FDA approved Eli Lilly's oral GLP-1 obesity treatment Orforglipron on April 1. As the world's first non-peptide oral GLP-1, taken once daily without food restrictions, phase 3 trials showed average weight loss exceeding 12%.
โฆ RELATED STORYLINEOral Wegovy pills launch in US at 149 dollars monthly, transforming GLP-1 access
Novo Nordisk's oral semaglutide (Wegovy pills) launched in the US market starting January. At 149 dollars per month, superior accessibility compared to injections is expected to reshape the GLP-1 landscape, with extensive data presented at ADA.
โฆ RELATED STORYLINEUS measles cases hit 2,030 this year, nearing 2025 record, shaking elimination status
As of June 4, US measles cases this year reached 2,030, nearing the record 2,288 of 2025. Over 92% of patients are unvaccinated and 6% (127) were hospitalized; 30 new clusters across four states threaten elimination status.
Innovent's IBI343 meets Phase 3 primary endpoint in gastric cancer; China NDA accepted
On June 4 Innovent Biologics said its CLDN18.2-targeting ADC IBI343 met the primary endpoint in an international Phase 3 trial for advanced refractory gastric cancer. China's NMPA accepted the NDA; it is the first CLDN18.2 ADC under regulatory review worldwide.
FDA approves oral Covid post-exposure prophylactic ensitrelvir (Xocova)
On May 29 the FDA approved Shionogi's ensitrelvir (Xocova) for Covid-19 post-exposure prophylaxis (PEP). A Phase 3 trial showing significantly lower onset risk by day 10 versus placebo was the basis; it is the first oral option for PEP.
First smoking-cessation drug in 20 years: cytisinicline FDA decision by June 20
An FDA decision on the plant-derived alkaloid smoking-cessation drug cytisinicline is due by June 20. Phase 3 trials ORCA-2 and ORCA-3 showed significantly higher quit rates versus placebo; if approved it would be the first new cessation drug in about 20 years.
FDA approves Lilly's oral obesity drug orforglipron, its fastest NME ever
The FDA approved the oral obesity drug orforglipron (Foundayo) as the first new molecular entity under the National Priority Voucher program. The decision came 50 days after filing and 294 days ahead of the PDUFA date, the fastest NME approval since 2002.
โฆ RELATED STORYLINEWHO and Africa CDC unveil a joint $518M six-month Ebola response plan
WHO and Africa CDC unveiled a joint six-month continental plan to fight Bundibugyo Ebola on June 5, targeting a $518 million budget for June-November 2026.
Ebola: DRC 381 cases, Uganda 19; WHO DON605 updates the latest status
Per WHO DON605 dated June 5, the DRC has 381 confirmed cases (64 deaths) and Uganda 19 (2 deaths), with Ituri province accounting for all 359 cases as cross-border spread continues.
Abemaciclib delivers first phase 3 liposarcoma win, PFS 9.7 months in SARC041
Presented in an ASCO 2026 plenary, the phase 3 SARC041 showed abemaciclib cut progression or death risk 62% in advanced dedifferentiated liposarcoma, with median PFS of 9.7 months versus 1.5 on placebo, the first positive phase 3 in the tumor type.
FDA accepts ivonescimab BLA, PDUFA Nov 14; first US review for PD-1/VEGF bispecific
The FDA accepted ivonescimab's (a PD-1/VEGF bispecific) BLA for second-line-plus EGFR-mutated non-small-cell lung cancer and set a review date of November 14, 2026, after the phase 3 HARMONi cut progression risk 48%.
ADA 2026 opens; Novo Nordisk unveils full CagriSema phase 3 data on June 7
The American Diabetes Association 2026 sessions opened June 5 in New Orleans. Novo Nordisk will present full CagriSema REIMAGINE phase 1-3 data on June 7, after REIMAGINE 2 showed a 1.91-point HbA1c drop and 14.2% weight loss.
โฆ RELATED STORYLINEPancreatic drug daraxonrasib doubles survival in second line
In the ASCO 2026 plenary, the phase 3 RASolute 302 trial (500 patients) showed daraxonrasib doubled median overall survival to 13.2 months vs 6.7 for chemo (HR 0.40), with simultaneous NEJM publication, likely a new 2nd-line standard.
Ivonescimab improves survival in first-line squamous lung cancer
In the 532-patient HARMONi-6 phase 3, the PD-1/VEGF bispecific ivonescimab plus chemo cut death risk 34% vs tislelizumab plus chemo (HR 0.66). It is the first China-originated cancer drug chosen for an ASCO plenary.
Galleri blood test misses primary endpoint but cuts stage IV 26% in first RCT
In the 142,250-person NHS-Galleri study over three years, the primary endpoint for stage III/IV diagnoses missed significance. But stage IV diagnoses fell 26% by year three, suggesting earlier detection, with fewer emergency diagnoses.
Abemaciclib scores first phase 3 win in rare liposarcoma, cutting risk 62%
In the 108-patient SARC041 phase 3, the CDK4 inhibitor abemaciclib extended median PFS in dedifferentiated liposarcoma to 9.7 months vs 1.5 for placebo, a 62% risk cut (HR 0.38) โ the first positive phase 3 in the disease.
CEPI puts $62M into Ebola PHEIC, fast-tracking three vaccines
With Bundibugyo Ebola spreading in Congo and Uganda (900+ suspected, 220+ deaths), the WHO declared a PHEIC on May 16. On June 1, CEPI announced $62M total to fast-track three vaccines from Moderna, IAVI and Oxford.
Daraxonrasib nearly doubles pancreatic-cancer survival, ASCO ovation
In the RASolute 302 phase 3, daraxonrasib lifted median survival in pretreated metastatic pancreatic cancer to 13.2 months (chemo 6.7), cutting death risk 60%. Presented at ASCO June 1, published simultaneously in NEJM.
Ivonescimab plus chemo beats PD-1 on survival in squamous lung cancer
In HARMONi-6, ivonescimab combo lifted first-line squamous NSCLC survival to 27.89 months vs tislelizumab's 23.69, cutting death risk 34% (HR 0.66). It is the first China-developed drug picked for an ASCO plenary.
Abemaciclib delivers first phase-3 win in liposarcoma, 62% risk cut
In SARC041, abemaciclib achieved progression-free survival of 9.7 months (placebo 1.5) in advanced dedifferentiated liposarcoma, cutting progression/death risk 62% โ the first positive phase 3 in this rare sarcoma.
โฆ RELATED STORYLINEGalleri multi-cancer blood test cuts stage-IV diagnoses up to 26% in first RCT
In the 142,942-person NHS-Galleri trial, stage-IV diagnoses fell 9%, 22% and 26% across three screening rounds, with stage-I/II diagnoses up 16% โ the first randomized controlled trial of multi-cancer early detection.
โฆ RELATED STORYLINEDRC-Uganda Ebola PHEIC: CEPI accelerates 3 vaccines with $62M
On May 17 the WHO declared the Bundibugyo Ebola outbreak a PHEIC. On June 1 CEPI urgently accelerated three vaccine programs with $50m to Moderna, $8.6m to Oxford and $3.2m to IAVI.
Daraxonrasib lifts metastatic pancreatic OS to 13.2 months
In the RASolute 302 Phase 3, daraxonrasib delivered median overall survival of 13.2 months, nearly double chemotherapy's 6.7 months. It headlined the ASCO 2026 plenary with an NEJM publication.
FDA approves vepdegestrant, the world's first PROTAC cancer drug
Arvinas and Pfizer's vepdegestrant won FDA approval May 1 for ESR1-mutated ER-positive, HER2-negative metastatic breast cancer, the first-ever PROTAC-class drug.
Bundibugyo Ebola declared a PHEIC in DRC and Uganda
The WHO declared the DRC-Uganda Bundibugyo Ebola outbreak a public health emergency on May 17. As of June 2 there are 336 confirmed cases and 49 deaths, with no approved vaccine.
Oral Wegovy pill launches in US, speeding GLP-1 access
Novo Nordisk's oral semaglutide launched in the US after FDA approval. The OASIS 4 trial showed 16.6% weight loss, and a $149 monthly price sharply widens access.
โฆ RELATED STORYLINEKEYNOTE-522 final analysis: early-TNBC 7-year survival 85%
KEYNOTE-522 final data at ASCO 2026 showed 85.1% 7-year overall survival in the pembrolizumab arm versus 77.2% for placebo, reaffirming the standard of care for early TNBC.
โฆ RELATED STORYLINEPancreatic daraxonrasib doubles OS to 13.2 months at ASCO plenary
Revolution Medicines' oral RAS inhibitor daraxonrasib extended median OS for previously treated metastatic pancreatic cancer to 13.2 months versus chemotherapy's 6.6 in the RASolute 302 trial, presented at the May 31 ASCO plenary and published in NEJM.
TNBC pembrolizumab reaffirms standard with 85.1% 7-year survival
KEYNOTE-522's final analysis showed a 7-year overall survival of 85.1% for the pembrolizumab combo in high-risk early triple-negative breast cancer, versus 77.2% for placebo (8pp gain). Follow-up was 93.8 months across 1,174 patients, presented at ASCO 2026.
FDA approves first PROTAC cancer drug, vepdegestrant, for breast cancer
On May 1 the FDA approved Arvinas and Pfizer's vepdegestrant for ESR1-mutated, ER-positive, HER2-negative advanced breast cancerโthe world's first approved protein-degrading PROTAC drug, based on the VERITAC-2 trial.
WHO declares Bundibugyo Ebola in Congo, Uganda a PHEIC
On May 17 the WHO declared the Bundibugyo Ebola outbreak in the DRC and Uganda a PHEIC. Cases surged to 282 as of June 1, and with no approved vaccine or therapy, concern is spreading.
GRAIL's Galleri multi-cancer blood test boosts detection up to 6.5x
GRAIL's 35,878-participant PATHFINDER 2, presented at ASCO 2026, showed the Galleri multi-cancer early-detection blood test raised cancers found up to 6.5x over standard screening, with 60.3% positive predictive value and 71% of new cancers at stages 1-3.
Daraxonrasib pancreatic OS 2x, ASCO plenary grand slam
RAS inhibitor daraxonrasib showed in Phase 3 RASolute 302 that median overall survival in metastatic pancreatic cancer reached 13.2 months vs chemotherapy's 6.7 monthsโdoubling itโwith 60% death-risk reduction (HR 0.40) across 500 patients in six countries.
Akeso/Summit ivonescimab squamous lung cancer -34% death risk
Dual PD-1/VEGF antibody ivonescimab in Phase 3 HARMONi-6 cut first-line squamous NSCLC death risk 34% vs tislelizumab plus chemotherapy and extended survival ~4 months. Presented May 31 with US partner Summit benefit.
Lilly selpercatinib early RET lung cancer recurrence risk -83%, NEJM
Phase 3 LIBRETTO-432 showed selpercatinib adjuvant therapy cut early RET-fusion NSCLC recurrence or death risk 83% in 151 patients across 22 countriesโfirst proof in a non-targeted therapy population with simultaneous NEJM publication and ASCO plenary.
WHO Bundibugyo Ebola PHEIC, DRC 125 confirmed, no vaccine
WHO declared May 17 a Public Health Emergency of International Concern for Bundibugyo Ebola across DRC and Uganda. As of May 28, DRC reports 125 confirmed, 17 deaths, 906 suspected; Uganda 9 confirmed with no approved vaccine or treatment.
FDA late-May approvalsยทdecitabine, boxpendi, durvalumab
FDA approved May 27 CD123-targeted ADC decitabine for BPDCN, May 18 first aldosterone synthase inhibitor boxpendi for hypertension, and May 28 durvalumab plus BCG for high-risk non-muscle-invasive bladder cancer.
May 2026 ยท 131
ASCO 2026 Chicago opens 5/29 ยท 7,000 abstracts ยท 35,000 oncologists for Day 1 launch
ASCO's annual meeting opens 5/29 at McCormick Place in Chicago. With 7,000 abstracts, 200+ sessions, and 35,000 oncologists gathering, next-generation immuno-oncology, bispecific antibody, and precision-medicine data simultaneously emerge at weekend plenaries โ a decisive oncology market inflection point activates.
Revolution Medicines pancreatic daraxonrasib RASolute 302 OS ~2x improvement looms
Revolution Medicines's pancreatic cancer drug daraxonrasib RASolute 302 OS data will be unveiled at the weekend plenary. A preliminary signal of roughly 2x overall survival improvement is being priced and a $10B market-cap jump scenario already reflected โ Day 1 oncology sector momentum ignites.
Summit / Akeso bispecific ivonescimab HARMONi-6 lung first-line treatment data unveiled
Summit Therapeutics / Akeso's bispecific antibody ivonescimab HARMONi-6 lung first-line data is placed at the ASCO plenary. As a PD-1รVEGF dual-target next-generation immuno-oncology best-in-class candidate, global immuno-oncology hegemony begins diffusing from Merck Keytruda's near-monopoly.
Lilly Retevmo / Verzenio double plenary ยท LIBRETTO-432 / Sarc041 precision-treatment punch
Lilly grabs Day 1 ASCO momentum with the Retevmo LIBRETTO-432 and Verzenio Sarc041 double plenary. RET-mutant lung and osteosarcoma precision-treatment data emerge simultaneously, with the next stage of oncology precision medicine in view and Merck, BMS, MRNA big-pharma PD-1 diversification competition intensifying.
WHO Bundibugyo Ebola PHEIC spreads ยท DRC 121 cases / 17 deaths ยท Uganda 7, no vaccine
WHO's Bundibugyo Ebola PHEIC, declared 5/17, has spread to DRC 121 confirmed / 17 deaths / 1,077 suspected and Uganda 7 confirmed as of 5/26. Absence of a Bundibugyo-specific vaccine and treatment is the core challenge, with Oxford / Serum Institute's ChAdOx1 monovalent vaccine pushing for clinical entry in 2-3 months.
WHO Bundibugyo Ebola PHEIC escalates; DRC 121 confirmed, Uganda 7; vaccine gap persists
The Bundibugyo Ebola outbreak, declared a PHEIC on 5/17, has escalated to 121 confirmed cases in the DRC with 17 deaths and 1,077 suspected cases as of 5/26, plus seven confirmed in Uganda. The absence of a Bundibugyo-specific vaccine remains the critical bottleneck.
ASCO 2026 annual meeting opens 5/29 in Chicago McCormick Place; 35,000 oncologists, 7,000 abstracts convene
The American Society of Clinical Oncology's annual conference opens 5/29 at McCormick Place. With 35,000 oncologists and 7,000 abstracts across 200+ sessions, next-generation immunotherapy and cancer-care data will move markets in a single week.
FDA approves Novo Nordisk oral semaglutide 25mg for weight loss; first GLP-1 pill with MACE reduction data
Novo Nordisk's oral semaglutide 25mg won FDA approval for obesity and cardiovascular risk reduction, marking the first approved GLP-1 oral. OASIS 4 data showed average 16.6% weight loss. Uninsured pricing begins at $149/month.
โฆ RELATED STORYLINEDOJ appeals ACIP vaccine-policy ruling; RFK Jr.'s board picks flagged with first-circuit appeal filed
The Department of Justice filed an appeal to the First Circuit on the March 16 Murphy ruling that voided Kennedy's ACIP board appointments. The DOJ simultaneously proposes adding toxicology, pediatric neurodevelopment, and vaccine-adverse-event expertise to the councilโa direct collision with pediatric-society standards.
H5N1 human infections surpass 1,000 cumulative cases globally; fatality rate 48%
The CDC has updated cumulative HPAI A(H5N1) human infections across 25 countries since 1997 to over 1,000 cases, with roughly 48% fatality rate. Q1 2026 saw 13 new cases: one pediatric death in Bangladesh, three in Cambodia. WHO has escalated monitoring status.
WHO Bundibugyo Ebola PHEIC, 105 confirmed, 906 suspected, expanding
DRC reported 105 confirmed and 906 suspected cases (223 suspected deaths), Uganda 7 confirmed cases as of 5/26. Spread across Ituri, North Kivu, South Kivu, while Italy's suspected case tested negative showing some partial calming signal.
Oxford Bundibugyo-specific ChAdOx1 vaccine to enter trials in 2-3 months
Oxford University and Serum Institute will accelerate clinical trials of ChAdOx1 BDBV monovalent vaccine for Bundibugyo. However, GMP production requires additional 6-9 months, so immediate deployment is impossible, focusing on long-term response framework.
ASCO 2026 opens 5/29, daraxonrasib pancreatic cancer Phase 3 LBA5 in focus
ASCO 2026 opens 5/29 in Chicago. Revolution Medicines will present metastatic pancreatic cancer RASolute 302 OS unprecedented improvement at 5/31 plenary, Roche giredestrant lidERA 30% recurrence reduction also to be unveiled.
RFK Jr. HHS pushes ACIP appeal, contests 1st court invalidation
After 3/16 federal court invalidated Kennedy's 13 ACIP appointments and Hep B and COVID guideline downgrades, HHS is pursuing appeal at First Circuit. Vaccine policy uncertainty continues through June.
H5N1 California dairy farms infectious virus detected in air and wastewater
5/5 PLOS Biology study confirmed infectious virus in dairy cow breath, milking parlor air, and wastewater of 14 H5N1-positive farms. Many asymptomatic cows tested positive, first field evidence of airborne transmission risk.
WHO declares Bundibugyo Ebola PHEIC; 746 suspected cases, 176 deaths
WHO designated Bundibugyo Ebola in DRC and Uganda as PHEIC on 5/16. As of 5/21: 746 suspected cases, 176 deaths; 85 confirmed cases, 10 confirmed deaths with no approved vaccine or therapy.
FDA approves oral Wegovy: first GLP-1 obesity pill arrives
Novo Nordisk oral semaglutide 25mg received FDA obesity approval. OASIS 4 trial showed average 16.6% weight loss; uninsured launched in US at $149/month.
โฆ RELATED STORYLINELilly orforglipron gets FDA fast-track approval in 50 days
FDA approved Lilly's Foundayo (orforglipron) for obesity on 4/1. Fastest NME approval since 2002 at 50 days from application, with 36mg achieving 11.2% weight loss over 16 months.
โฆ RELATED STORYLINEDOJ appeals RFK Jr ACIP ruling to 1st Circuit
DOJ filed appeal in late April to the First Circuit Court of Appeals against Judge Murphy's 3/16 ruling voiding Secretary Kennedy's 13 ACIP appointments, continuing the vaccine policy overhaul.
H5N1 cumulative human cases pass 1,000; 48% fatality
CDC updated that HPAI A(H5N1) human infections since 1997 across 25 countries crossed 1,000 with ~48% deaths. Q1 2026 added 13 cases including a Bangladeshi pediatric death.
WHO Bundibugyo Ebola PHEIC: 746 suspected, 176 deaths
Bundibugyo Ebola spreading across DRC's Ituri province and Uganda. As of May 21: 746 suspected cases, 176 deaths, 85 confirmed cases, 10 deaths. No Bundibugyo-specific vaccine or treatment exists; 30-50% fatality concerns rising with 6-9 months until clinical trials.
Lilly oral GLP-1 'Foundayo' (orforglipron) FDA obesity approval
First-ever oral GLP-1 taken once daily without food/water restrictions. 72-week 12.4% weight loss exceeded oral semaglutide. With insurance $25/month, cash $149+ โ fully opening the pill era.
โฆ RELATED STORYLINEHHS appeals injunction blocking Kennedy vaccine policy
DOJ filed appeal against Judge Murphy's March injunction blocking RFK Jr. vaccine policies including ACIP restructuring. American Academy of Pediatrics and others sued for Administrative Procedure Act violations, with main proceedings expected to be prolonged.
MAHA secures 35% food industry artificial dye phase-out, coalition cracks
Walmart, Hershey, Nestle and 35% of US food industry join artificial dye removal. Child vaccine recommendations cut from 72 doses across 17 diseases to 10. MAHA coalition fractures emerging over glyphosate and vaccine positions.
FDA approves first anal cancer 1L treatment 'retifanlimab' and more oncology wins
PD-1 monoclonal retifanlimab approved as first 1L treatment for advanced anal cancer. Sonrotoclax (relapsed mantle cell lymphoma), atezolizumab (muscle-invasive bladder cancer adjuvant), and first PROTAC based on VERITAC-2 also approved in May โ strong oncology month.
WHO declares Congo-Uganda Bundibugyo ebolavirus PHEIC
On May 17 WHO declared Bundibugyo ebolavirus spreading in DRC and Uganda a public health emergency. 600 suspected cases with 139 deaths reported with no vaccine or treatment, leaving containment and supportive care as sole response.
HHS appeals court ruling blocking RFK vaccine policy changes
Health Department appealed Massachusetts federal court ruling blocking RFK's vaccine schedule changes. Fifteen states filed separate lawsuits challenging removal of seven vaccines from HHS recommendations.
Eli Lilly oral GLP-1 Foundayo approved, ushering pill era
Orforglipron (Foundayo) approved for obese and overweight adults. First oral GLP-1 taken without meal restrictions shows weight maintenance post-Ozempic/Zepbound conversion in Phase 3. April launch begins pill era.
โฆ RELATED STORYLINENovo Nordisk oral Wegovy gains EU approval recommendation
On May 22 EMA CHMP recommended EU approval for daily oral semaglutide 25mg. OASIS 4 Phase 3 showed average 16.6% weight loss. US launch saw 1 million patients start in 4 months.
โฆ RELATED STORYLINEFDA pilots AI real-time clinical trial monitoring
FDA launched pilot cloud and AI real-time monitoring of AstraZeneca and Amgen cancer drug trials. Early trial shortening of 20-40% possible with May 29 comment deadline and accelerated drug development ahead.
WHO declares Ebola Bundibugyo PHEIC; 600 suspected cases, 139 deaths
DRC and Uganda Bundibugyo ebolavirus reached 600 suspected cases and 139 deaths by May 20 after WHO's May 17 PHEIC declaration. No approved vaccine or therapeutic available.
Bundibugyo vaccine gap critical; clinical trials require 6-9 months minimum
Approved Ervebo vaccine targets Zaire strain only, proving useless against Bundibugyo variant. Two candidate vaccines exist but clinical entry requires 6-9 months minimum. 25-40% case fatality rate leaves only containment and supportive care.
15 state AGs sue to overturn RFK vaccine recommendation stripping
Connecticut, California and 13 other state attorneys general sued HHS Secretary RFK Jr. to overturn January 5 CDC decision memo removing rotavirus, meningococcal, hepatitis, and coronavirus vaccine recommendations for children.
Eli Lilly oral GLP-1 'Foundayo' FDA approved; pill era begins
Orforglipron (Foundayo) earned FDA approval April 1 as first oral GLP-1 with no food/water restrictions. ATTAIN-1 trial showed 72-week 12.4% weight loss. Launched April 6 via Lilly Direct.
โฆ RELATED STORYLINEGlobal big pharma M&A explodes; Q1 2026 deals hit $84B, double YoY
2026 Q1 biotech M&A surged to $84B from $44.4B YoY. Sun Pharma-Organon $11.75B, Bayer-Perfuse $2.45B lead deals. Full-year 2026 forecast $250B+
WHO Bundibugyo PHEIC official; 8 confirmed, 246 suspected, 80 dead
May 16 declaration. DRC, Uganda spread. 30-50% fatality, no vaccine, no cure.
CDC deploys international team to Uganda, DRC; WHO funding appeal issued
Kampala 2 confirmed reported. Ituri 3 health zones affected. Ghebreyesus May 20 briefing urgent.
15 states sue RFK Jr. to block RSV, hepatitis B, seven-vaccine removal
Connecticut, California lead. HHS appealing ACIP board-block ruling.
Medicare GLP-1 bridge fixed $50 copay July launch; muscle loss warning louder
1-in-8 US adults on GLP-1. Protein, strength training critical. Pricing war ignites.
โฆ RELATED STORYLINEFDA clears Lecanemab home injection; BeiGene sofocrelax MCL approval
Alzheimer's home access expands. BCL-2 market competition intensifies.
Bundibugyo PHEIC widens; 89 deaths tallied
DRC Ituri 9 districts log 10 confirmed, 336 suspected, 88 deaths; Uganda Kampala 2 confirmed, 1 dead. Bundibugyo strain eludes Ervebo, leaving treatment void.
Novo oral Wegovy 1.3M US prescriptions storm
Novo's oral Wegovy hit ~1.3M prescriptions Q1 post-Jan 5 US launch, record GLP-1 launch. Eli Lilly's April oral Foundaeo counterpunch heats duopoly war.
โฆ RELATED STORYLINECDC enhances US entry screening on ebola threat
CDC, DHS May 18 deployed reinforced quarantine, entry bars, health measures for US arrivals. Rapid response teams deployed, safe treatment centers opened, test infrastructure boosted.
RFK Jr. cuts child vaccines 18 to 11; 15 states sue
HHS dropped flu, COVID, rotavirus, hepatitis A/B, meningococcal from recommendations, Denmark-style. 15-state coalition sued; anti-vaccine groups infiltrated ACIP, sparking healthcare pushback.
FDA clears Boxspendi first-in-class aldosterone synthase inhibitor
FDA May 18 approved boxdrostat as first-in-class aldosterone synthase inhibitor for adult hypertension. Resistant hypertension market shifts on novel option.
Novo's Wegovy pill outpaces Lilly's Foundayo in early U.S. rollout
Four months in, oral Wegovy sees tens of thousands of prescriptions via telehealth. Lilly's Foundayo struggles with brand awareness and penetration stateside.
โฆ RELATED STORYLINEArvinas Veppanu wins FDA nod as first PROTAC to market
May 1 approval for protein degrader vepdegestrant targets ESR1-mutant ER+/HER2โ advanced breast cancer. Novel modality milestone.
Cytokinetics' aficamten meets Phase 3 goal in non-obstructive HCM
ACACIA-HCM trial success on KCCQ-CSS and peak VO2 (p=0.021, p=0.003). First non-obstructive win challenges BMS Camzyos monopoly.
BeiGene wins accelerated FDA nod for Beqalzi in relapsed MCL
May 13 approval for BCL-2 inhibitor in recurrent/refractory mantle-cell lymphoma. AbbVie Venclexta now faces new competition in hematologic oncology.
Samsung BioLogics added to Dow Jones ESG for fifth year running
May 5 index inclusion after Song-do Plant 5 ramps. CDMO capacity now 845,000L globally; market cap $60 billion puts firm in global biotech top tier.
Eli Lilly's Foundayo breaches 10,000 prescriptions weekly
IQVIA reported 10,248 Foundayo scripts for the week of May 8โup from 7,335 the prior week. Novo's oral Wegovy still leads early.
โฆ RELATED STORYLINEBayer buys Perfuse vision-implant developer for up to $2.45B
Bayer acquired Perfuse Therapeutics and PER-001, an intraocular implant. Deal: $300M upfront plus up to $2.45B in milestones. Targets glaucoma and diabetic retinopathy.
Regenxbio's RGX-202 Phase 3 trial hits primary endpoint
The AFFINITY DUCHENNE study met its primary endpoint on May 14. Two serious adverse events reported; CEO remains confident in FDA approval prospects.
United Therapeutics wins FDA approval for pig-heart clinical trial
United Therapeutics won FDA clearance May 15 to start the UHeart clinical trial for terminal heart failure patients. First formal pig-heart trial enrollment underway.
WHO tracking 13 avian and swine flu cases; no imminent pandemic signal
WHO documented 13 avian and swine influenza cases in Q1 2026, including an H5N1 death in a Bangladeshi child. CDC is monitoring U.S. dairy and poultry workers; public health risk assessed as low.
BeOne Beqalzi earns FDA accelerated approval for MCL; first BCL-2 inhibitor class
Sonrotoclax wins nod for relapsed/refractory mantle cell lymphoma. ORR 52%, response duration 15.8 months. Direct Venclexta challenge emerging.
Isomorphic Labs closes Series B at $2.1B; AlphaFold pipeline expands
DeepMind spinoff banks $2.1B Series B. AlphaFold-driven pipeline advances toward in-house clinical entry readiness.
CDC monitors 41 Americans across 16 states; hantavirus Hondius exposure
Antarctic cruise cluster confirmed 8 cases, 2 probable. U.S. isolation protocol triggers; six-week monitoring window commenced nationwide.
Angelini acquires Catalyst Pharma for $4.1B; enters U.S., expands rare disease
Italian Angelini pays $31.50 per share, $4.1B total. U.S. entry and rare-disease brain-health platform expansion. May's fourth major biotech deal.
Lilly ships Foundayo oral obesity drug; Novo pill competition heats up
Lilly launches three months after Novo oral GLP-1. Foundayo 17% weight loss trails Wegovy pill. Telehealth demand surges.
โฆ RELATED STORYLINEBMS inks $15.2B deal with Hengrui for 13-program oncology, heme, immunology pipeline
BMS fronts $600M, total deal value $15.2B across tumor, hematology, immunology programs. China R&D speed leverage signals big pharma mega-deal renaissance.
Novo oral Wegovy overpowers Lilly's Foundayo 6.7-to-1 in scripts, seizes market
Last week of April: Novo oral semaglutide 135K prescriptions vs Lilly Foundayo 20K. 17% weight loss vs 12% gap hands oral GLP-1 to Novo.
โฆ RELATED STORYLINEMV Hondius cruise Andes hantavirus cluster; five continents on alert
WHO, CDC notified 5/2 of Andes hantavirus clusterโ3 dead, 5 confirmed. Only human-transmissible hantavirus; eight nations launch joint response.
Moleculin MIRACLE AML Phase 2b/3 unblinding imminent; complete remission ~30%
Annamycin plus cytarabine in 45 R/R AML patients hits complete remission ~30% in blinded readoutโexceeds historical benchmark. Results due before 6/30.
Moderna Q1 beats with $389M revenue; flu vaccine PDUFA August 5
Q1 revenue $389M crushes consensus $236M. International revenue recovers to $311M. August 5 PDUFA for flu vaccine marks fifth commercial product milestone.
Lilly GLP-1 US market share tops 60%
Mounjaro and Zepbound combined Q sales $12.8B +56% YoY. Lilly now leads globally including ex-US vs Novo Nordisk.
โฆ RELATED STORYLINEPfizer BRAFTOVI colon cancer 64% response rate
BREAKWATER phase 3 Cohort 3: BRAFTOVI+cetuximab+FOLFIRI in BRAF V600E metastatic colorectal cancer achieved 64% ORR.
FDA Vyvgart seronegative gMG approval timeline set
argenx efgartigimod alfa-fcab PDUFA May 10 date, expands AChR-antibody-negative myasthenia gravis. Home-start option hoped.
Leqembi home-initiation dose FDA decision pending
Eisai-Biogen Leqembi starting dose home-use approval expected May. Alzheimer's access inflection point.
Seaport, Hemab combine $556M IPO, biotech momentum
Two companies debut together on $556M, year-to-date 10 public launches at $3.2Bโbiotech IPO market in recovery.
BMS signs up-to-$15.2B 13-pipeline megadeal with China's Hengrui
Bristol Myers Squibb signed a global licensing and co-development agreement with Hengrui on May 12 covering 13 early-stage oncology, hematology, and immunology programs. The deal includes a $600M upfront payment and up to $950M in near-term payments, with total potential value reaching $15.2B including milestones and royalties. Hengrui's Hong Kong-listed shares jumped more than 13%.
Roche Alzheimer's blood test pTau217 receives European CE mark
Roche announced on May 12 that its Elecsys plasma pTau217 test, co-developed with Eli Lilly, received the European CE mark. Unlike pTau181, it supports not only ruling out Alzheimer's pathology but also confirming it, reducing the burden of invasive CSF testing and brain imaging. CE-market launch is planned for July 2026.
Eli Lilly overtakes Novo Nordisk in ex-U.S. GLP-1 share
Q1 overseas Mounjaro revenue reached $8.7B, beating consensus and allowing Eli Lilly to overtake Novo Nordisk in non-U.S. GLP-1 market share for the first time. In oral GLP-1s, however, Novo's Wegovy pill launched first in January and appears to be seeing faster early uptake than Lilly's Foundayo, or orforglipron, launched in April.
โฆ RELATED STORYLINETrump administration MFN drug-pricing policy reaches voluntary deals with 17 pharma firms
The White House said in May 12 materials that its most-favored-nation drug-pricing policy has secured voluntary agreements with 17 global pharmaceutical companies and would save federal and state Medicaid programs $64.3B over ten years. Industry resistance continues, however, with list prices for 872 branded drugs rising a median 4% so far in 2026.
Rare-disease pipelines advance at AskBio and BridgeBio; telehealth Hims misses
AskBio dosed the first patient in a phase 1/2 gene-therapy trial for late-onset Pompe disease, while BridgeBio filed an FDA new-drug application for encaleret in autosomal dominant hypocalcemia type 1. Meanwhile, as telehealth competition in compounded GLP-1s intensified, Hims & Hers reported quarterly revenue below consensus on May 12 and shares weakened.
MV Hondius: 94 evacuated, WHO reassures
The Dutch cruise ship MV Hondius, carrying Andes hantavirus cases, docked in Canary Islands on May 10, disembarking 94 passengers from 19 countries. Three died, seven confirmed, nine suspected. Human-to-human transmission confirmed in some cases, but WHO Director Tedros said general public risk is low.
VYVGART PDUFA May 10; Intellia CRISPR shows gains
argenx VYVGART (efgartigimod) for seronegative generalized myasthenia hits May 10 PDUFA. Intellia's lonvo-z for hereditary angioedema showed 87% attack-rate cut vs. placebo in phase 3, with 60% remaining attack-free (vs. 11% placebo), signaling the first in vivo CRISPR path to approval.
Foundayo vs. Wegovy: GLP-1 oral duel
Lilly's oral Foundayo (orforglipron) saw 20,000+ patients begin dosing post-launch, 1,000 new scripts per day, 80% new-to-GLP1. Novo's Wegovy pill leads with tens of thousands on board in four months. Novo holds 2026 revenue/profit guidance at -5% to -13%.
โฆ RELATED STORYLINEH5N1 case in Bangladesh child; U.S. vigilant
WHO Q1 2026 report logged 13 zoonotic flu human infections including one Bangladesh child H5N1 death (unreported earlier). U.S. dairy and poultry worker exposures remain sporadic; no sustained human-to-human spread. CDC rates public risk 'low'.
Korean biosimilars' golden decade
Samsung Bioepis' Pyzchiva (Stelara equivalent) cracked U.S. top-3 ustekinumab market in one year. Celltrion's Steqeyma gains via Costco. Global pharma M&A races to bag biosimilar firms ahead of blockbuster patent cliffs.
MV Hondius hantavirus: 8 cases, 3 deaths, expanding response
WHO tallied eight Andes hantavirus (ANDV) cases, three deaths (38% fatality rate), and six lab confirmations as of May 8 aboard MV Hondius. The ship docked in Tenerife early May 10; 17 Americans were transferred to Nebraska's national quarantine facility. WHO assessed global risk as low while Argentina expedited 2,500 diagnostic kits to five nations.
Aficamten clears non-obstructive HCM trial, opening billions
Cytokinetics unveiled May 5 that aficamten (Myqorzo) hit its primary endpoint in ACACIA-HCM, a phase 3 trial in non-obstructive hypertrophic cardiomyopathy. This is territory BMS's Camzyos never entered, opening a multibillion-dollar market. Analysts call it 2026's top cardiovascular catalyst.
Daraxonrasib doubles pancreatic-cancer survival
Revolution Medicines' pan-RAS inhibitor daraxonrasib nearly doubled overall survival in metastatic pancreatic adenocarcinoma: 13.2 months combined versus 6.7 months chemotherapy alone in phase 3. FDA granted fast-track and expanded-access approval. Analysts view this as the inflection point for the first RAS inhibitor to reshape treatment standards.
Vyvgart expands to all myasthenia gravis serum types
Argenx won FDA approval May 8 for Vyvgart and Vyvgart Hytrulo to treat all adult generalized myasthenia gravis serum typesโAChR-positive, MuSK, LRP4, and seronegative. The label expansion broadens eligible patient populations significantly. PDUFA date was May 10.
Survodutide achieves 16.6% weight loss over 76 weeks
Boehringer Ingelheim and Xyvea's dual GLP-1/glucagon agonist survodutide showed 16.6% weight reduction in 76-week phase 3, data locked April. NIH separately published how oral small-molecule GLP-1s penetrate deep brain reward circuits to suppress appetite. Medicare begins $50/month GLP-1 options in July.
โฆ RELATED STORYLINEBiotech M&A blitz: seven deals in one week
BioCentury tallied seven biotech M&A announcements in early Mayโthree exceeding $1B. H1 2026 reached 19 deals; CareDx acquired liquid-biopsy firm Naveris as the sole US buyer. Momentum accelerates post-Q1's record $15.6B deal volume.
MV Hondius Hantavirus: 3 Deaths, 6 Confirmed as Ship Reaches Tenerife
WHO confirmed 6 of 8 suspected cases with 3 deaths (2 confirmed Andes variant) as of May 9. Over 100 passengers, including 17 Americans, began disembarkation in the Canary Islands with U.S. and UK deploying evacuation aircraft.
โฆ RELATED STORYLINEViridian Elegrobart Phase 3 REVEAL-2 Achieves 50% PRR in Chronic Thyroid Eye Disease
May 5 Phase 3 REVEAL-2 data showed 50% partial response rate (versus 15% placebo) for four-weekly elegrobart dosing, with eight-weekly achieving 54%, securing Q1 2027 BLA filing pathway.
CMS Launches July 2026 Medicare GLP-1 Obesity Pilot
May 6 CMS announced GLP-1 bridge model (July 2026โDecember 2027) offering discount coverage for Wegovy, Zepbound KwikPen, Foundayo tablets for Medicare enrollees with BMI 27+ (with comorbidities) or BMI 35+.
โฆ RELATED STORYLINEArvinas Veppanu Becomes First PROTAC FDA Approval for ESR1-Mutant Breast Cancer
May 1 FDA approval of Arvinas' vepdegestrant (Veppanu) for ER+/HER2โ/ESR1-mutant advanced/metastatic breast cancer marks first commercial PROTAC (heterobifunctional protein degrader) success.
Capricor Deramiocel Phase 3 HOPE-3 Meets Primary in Duchenne Muscular Dystrophy
Phase 3 HOPE-3 met PUL v2.0 primary endpoint, with reduced cardiac LGE progression (p=0.022) and improved LVEF (p=0.017). PDUFA date set for August 22, 2026.
โฆ RELATED STORYLINELilly Foundayo (orforglipron) Approved as First Non-Peptide GLP-1 Weight-Loss Pill
FDA approved Lilly's Foundayo on 4/1 for chronic weight management. As the first non-peptide GLP-1 receptor agonist oral formulation, it eliminates meal and water restrictions. CNPV priority review determined the action in 50 days.
โฆ RELATED STORYLINEVeppanu (vepdegestrant) Approved for ER+/HER2- Metastatic Breast Cancer
FDA approved Veppanu on 5/1 for advanced and metastatic ER+/HER2- breast cancer with ESR1 mutations. This marks the first success of the heterobifunctional protein degradation class.
Novo Nordisk Wegovy Oral Formulation; First GLP-1 Weight-Loss Tablet
FDA approved Novo Nordisk's Wegovy oral tablet as the first GLP-1 medication in pill form for weight loss. Tablet availability reduces patient reluctance versus injection therapy, accelerating market expansion.
โฆ RELATED STORYLINENuvation Bio Files IBTROZI sNDA for ROS1-Positive NSCLC
Nuvation Bio submitted a supplemental NDA on 5/6 for IBTROZI (taletrectinib) in advanced ROS1-positive NSCLC. Target action date: January 4, 2027.
FDA Authorizes Four Glas E-Cigarette Products; Total Approved ENDS Reaches 45
On 5/5, FDA approved four Glas electronic nicotine delivery system products through the PMTA pathway, bringing total authorized ENDS products to 45. The decision introduces new policy inflection in tobacco regulation.
โฆ RELATED STORYLINECMS Launches BALANCE Model for Medicaid GLP-1 Weight Management; Coverage Begins in May
The BALANCE model provides free GLP-1 therapy paired with lifestyle support programs, expanding Medicaid access to obesity treatment.
โฆ RELATED STORYLINEGLP-1 Users Face Greater Social Stigma Than Diet-Adherent Peers; Rice Study
A new Rice University study finds that individuals losing weight via GLP-1 face more negative social perception than those employing diet and exercise, or even individuals with untreated obesity, highlighting emerging social acceptance barriers.
WHO Guidelines Endorse GLP-1 Use for Adult Obesity Treatment
The World Health Organization's guidance published in JAMA establishes GLP-1 as standard-of-care therapy for eligible adults with obesity.
โฆ RELATED STORYLINEDiaMedica Updates Pipeline on May 7; Preeclampsia, Stroke Programs Featured
DiaMedica Therapeutics presented Q1 results and pipeline updates for preeclampsia, fetal growth restriction, and acute ischemic stroke candidates.
Vepdegestrant Approved May 1 for ER+/HER2- Advanced Breast Cancer
The FDA approved vepdegestrant as a targeted hormone therapy option, expanding the treatment arsenal for hormone receptor-positive breast cancer.
โฆ RELATED STORYLINEVeppanu FDA Approved; First-in-Class Protein Degrader for Breast Cancer
On May 1, FDA approved Veppanu for ER+/HER2-/ESR1-mutant advanced breast cancer. Protein degradation mechanism is key.
โฆ RELATED STORYLINENuvation Bio's IBTROZI sNDA Filed with FDA on May 6
Supplemental NDA for IBTROZI, for ROS1-positive advanced non-small cell lung cancer, submitted to FDA.
GLP-1 Associated with Reduced Depression, Anxiety, and Addiction Risk
Large cohort data show reduced depression, anxiety, and psychiatric hospitalization rates in semaglutide and other GLP-1 users.
โฆ RELATED STORYLINERice Study: GLP-1 Users Experience Greater Social Stigma Than Diet/Exercise Weight Loss
Research finds GLP-1 users report greater social stigma compared to those losing weight through diet and exercise, prompting policy discussions.
CMS BALANCE Model: Medicaid GLP-1 Coverage Begins May; Medicare Part D Follows July
Under the voluntary BALANCE model, Medicaid GLP-1 obesity treatment coverage launches May, with Medicare Part D coverage beginning July.
โฆ RELATED STORYLINEPfizer Q1 revenue $14.45B, +5% YoY
EPS $0.75 exceeds consensus $0.72; 2026 revenue guidance $59.5-62.5B reconfirmed.
โฆ RELATED STORYLINEVeppanu (vepdegestrant) first PROTAC FDA approval
Arvinas and Pfizer for ER+/HER2-/ESR1 mutation advanced breast cancer.
Yale-led breast cancer treatment technology receives first FDA approval
Yale-led technology receives first-ever FDA approval on May 7.
โฆ RELATED STORYLINEVYVGART antibody-negative indication PDUFA 5/10
Decision imminent for AChR antibody-negative patients.
โฆ RELATED STORYLINELEQEMBI IQLIK weekly loading dose PDUFA 5/24
Eisai and Biogen Alzheimer's early treatment decision pending.
MV Hondius Hantavirus: 3 Deaths, 5 Confirmed Cases as of May 6
As of May 6, the MV Hondius hantavirus outbreak has resulted in 3 deaths and 5 confirmed cases, with co-monitoring by WHO and CDC.
Twelve Countries Implement Passenger Tracking and Observation
Canada, Germany, the Netherlands, Singapore, the United Kingdom, the United States, Switzerland, and eight other nations are actively monitoring disembarked passengers.
Five U.S. States Launch Passenger Monitoring Programs
Five U.S. states have initiated monitoring protocols for individuals who entered the country after disembarking from MV Hondius.
Global Wellness Summit Identifies Ovarian Aging Arrest as Next-Generation Biotech Keyword
The Global Wellness Summit has designated ovarian stem cell therapy and targeted ovarian fibrosis treatment as core health trends for 2026.
End of Anti-Aging Era: 'Skin Longevity' Framework Emerges
The traditional anti-aging paradigm is shifting toward 'skin longevity,' combining biotech, AI diagnostics, and novel active ingredients in integrated care regimens.
Veppanu Approved for ER+ Breast Cancer
On May 1st, the FDA approved Veppanu (bepedegertrant) for advanced and metastatic ER+/HER2- breast cancer with ESR1 mutations.
First Non-Psychiatric Dementia Agitation Treatment Approved
On April 30th, the FDA cleared the first non-psychiatric class medication for agitation associated with dementia, reducing elderly psychiatric care burden.
Idvynso HIV Treatment Approved April 21st
The doravirine and islatravir combination Idvynso gained approval as an adult HIV-1 treatment, offering a once-daily alternative to existing antiretroviral therapies.
GLP-1 Reduces Psychiatric Hospitalization and Sick Leave by 42%
A 10-year longitudinal study of approximately 100,000 patients showed semaglutide reduced psychiatric hospitalizations and sick leave by 42%, depression risk by 44%, and anxiety by 38%.
Rybelsus Oral GLP-1 Launches in U.S. Starting May 4th
Novo Nordisk began full commercial distribution of oral Rybelsus in the U.S. on May 4th, reducing injection-related barriers and expanding the GLP-1 tablet market.
FDA Approves AUVELITY for Alzheimer's Agitation on April 30
AXS-05 (bupropion/dextromethorphan) approved for Alzheimer's dementia-related agitation indication.
FDA Approves Interchangeable Insulin Glargine 'Langlara' on April 29
Lantus biosimilar approved for diabetes treatment with interchangeable designation.
FDA Advisory Panel Reviews Camizestrant and Truqap on April 30
Proceedings for ER+/HER2- early breast cancer and PTEN-deficient metastatic hormone-sensitive prostate cancer underway.
Medicare GLP-1 Bridge Program Launch Set for July 1
Monthly $50 copay guarantee for obesity medications; pilot runs July 1 through December. Millions of beneficiaries expected to benefit.
NIH Clarifies Oral GLP-1 Small-Molecule Mechanism in Reward Circuitry
Orforglipron and similar compounds modulate brain reward pathways to suppress hedonic appetite, offering non-injectable, cost-effective advantages.
FDA Proposes Excluding GLP-1 from 503B Bulk Drugs (April 30)
Semaglutide, tirzepatide, and liraglutide removed from 503B bulk drug list proposal, signaling compounding era conclusion.
Medicare GLP-1 Bridge Program Launches July 1
$50 monthly copay benefit for Foundayo, Wegovy, and Zepbound KwikPen through December 31, 2027.
Medicaid GLP-1 Coverage Reductions Expanding
California, New Hampshire, Pennsylvania, and South Carolina reductions followed by Massachusetts and Rhode Island review proceedings.
GLP-1 Indication Expansion: Atrial Fibrillation, Alcohol Disorder, Depression, Diabetic Retinopathy
April clinical data releases documented efficacy beyond obesity across four additional therapeutic domains, initiating multi-indication era.
UCSF GLP-1 Synaptic Plasticity Research
GLP-1 may influence brain neural circuit rewiring, accelerating Alzheimer's and cognitive function drug candidate pipelines.
April 2026 ยท 150
FDA Approves Langlara (Insulin Glargine-aldy) as Lantus Interchangeable Biosimilar
Sanofi's insulin glargine-aldy (Langlara) approved April 29 as interchangeable Lantus biosimilar. Expands insulin options and reduces patient burden.
Gilead's Once-Daily HIV Therapy Granted Priority Review
Bictegravir plus lenacapavir once-daily NDA received priority review April 29. Potential paradigm shift toward simplified once-daily oral HIV management.
BeOne TEVIMBRA Wins Priority Review for HER2+ Gastric/Esophageal Cancer
BeOne Medicines' TEVIMBRA granted priority review for first-line HER2+ gastroesophageal adenocarcinoma. Expands immunotherapy first-line options.
Lilly Foundayo Launches at $149 Self-Pay, $25 Insured; Competes with Novo Wegovy Tablet
Oral GLP-1 Foundayo, approved in early April, launched via LillyDirect, pharmacies, and telehealth. Pricing: $149/month lowest dose self-pay, $25 commercial insurance. Competes against Novo Nordisk Wegovy tablet (600K March prescriptions).
Novo Nordisk Wegovy Tablet Hits 600K March Prescriptions; First-Mover Advantage
Novo Nordisk Wegovy oral formulation surpassed 600K prescriptions in March, ~3 months ahead of Lilly Foundayo launch. Price and access competition intensifying.
FDA Approves Langlara Insulin Glargine Biosimilar
On April 29, the FDA approved insulin glargine-aldy (Langlara), a Lantus-compatible biosimilar for long-acting insulin treatment of diabetes.
FDA Proposes Restricting Compounding of GLP-1 Active Ingredients
On April 30, the FDA proposed limiting outsourced facility bulk compounding of semaglutide, tirzepatide, and related GLP-1 compounds, targeting illicit market channels.
Gilead's Bictegravir-Lenacapavir Once-Daily HIV Regimen Granted Priority Review
Gilead's bictegravir-lenacapavir once-daily HIV therapeutic regimen has been designated for FDA priority review, signaling simplified treatment option expansion.
Eli Lilly's Oral GLP-1 Candidate Orforglipron Advances in Approval Pathway
Eli Lilly's oral GLP-1 compound orforglipron is advancing toward regulatory approval, positioning itself as a potential advantage over Novo Nordisk's oral semaglutide (Rybelsus).
Jaguar Health's Crofelemer Demonstrates Efficacy in Cancer Drug-Induced Diarrhea Trial
On April 29, Jaguar Health announced statistically significant efficacy of Canalevia-CA1 (crofelemer) in treating chemotherapy-induced diarrhea.
FDA Approves Daraxonrasib Expanded Access in Two Days โ 60% Mortality Reduction in Pancreatic Cancer
Revolution Medicines submitted 4/28; FDA approved 4/30. Based on clinical data showing 60% mortality risk reduction versus chemotherapy in previously treated metastatic PDAC.
Scancell iSCIB1+ Receives Fast Track 4/28 โ Advanced Melanoma
iSCIB1+ immunotherapy granted fast-track designation for advanced melanoma treatment. Follows Opna OPN-6602 (multiple myeloma) April 15 and NextCure SIM0505 (ovarian cancer) April 7 fast tracks.
Lilly Foundayo (Orforglipron) Approved April 1 โ Oral GLP-1
Once-daily GLP-1 tablet: $25 monthly with insurance; $149โ349 self-pay. Medicare starts summer at $50. Direct competition with Novo Wegovy pill (600,000 prescriptions in March).
FDA Otarmeni Accelerated Approval 4/23 โ OTOF Genetic Hearing Loss Gene Therapy
AAV vector-based lunsotogene parvec-cwha. Approvals same period: 4/21 Idvynso (HIV-1); 4/29 Langlara (insulin glargine biosimilar).
Tecartus (Brexu-cel) Full Approval โ Relapsed/Refractory MCL
FDA converted accelerated approval to standard approval. Long-term follow-up data supports durability. ADC 'I-DXd' receives priority review for advanced SCLC.
FDA Approves Lilly's Foundayo (Orforglipron)
Eli Lilly's once-daily oral GLP-1 Foundayo received FDA approval. It is the first oral GLP-1 requiring no dietary restrictions.
ATTAIN-1 Phase 3: Up to 12-Pound Weight Loss at Highest Dose
ATTAIN-1 Phase 3 results showed 12-pound average weight loss (12.4%) at the highest dose, compared to 16.6% with oral semaglutide.
Obesity Surpasses Oncology as Top Late-Stage Therapy
For the first time in 16 years, obesity treatment leads the late-stage pipeline value hierarchy. Obesity and diabetes now comprise 38% of late-stage pipeline commercial value.
Novel Approaches Beyond GLP-1 Target Emerging
Research published April 16 suggests emerging pharmacology approaches that bypass the GLP-1 target, challenging conventional obesity treatment paradigms.
Less Than 10% of Eligible Patients Use GLP-1
GLP-1 penetration among eligible patients remains below 10%, leaving significant room for multiple market participants.
AUVELITY Alzheimer's Agitation Indication Decision Due April 30
Axsome's AUVELITY faces FDA decision on April 30 for Alzheimer's-associated agitation indication. Approval would position it as a first-line oral option.
Wegovy Oral GLP-1 Approved; First Obesity Oral Medication
The FDA approved Novo Nordisk's Wegovy oral GLP-1 for obesity indication, marking the first oral GLP-1 for weight loss. Full U.S. market entry began in January, signaling a price decline and oral medication expansion cycle in 2026.
Beyond GLP-1: GIP and Glucagon Dual-Pathway Medications Emerge
STAT reported emergence of a new drug class targeting GIP and glucagon receptors, rather than GLP-1 itself, to reduce nausea side effects. Expansion across multiple disease indications is key.
FDA Posts April 27 Notice; May 28 VRBPAC Meeting on 2026-2027 COVID Vaccines
The FDA posted a Federal Register notice on April 27 announcing a May 28 Vaccines and Related Biological Products Advisory Committee meeting to discuss 2026-2027 COVID-19 vaccine composition.
FDA Direct-to-Consumer Conference Convenes in Boston
On April 21, FDA officials, industry representatives, and academics gathered in Boston for the DTC National Conference to discuss direct-to-consumer advertising and patient access issues.
Stanford's BRP Molecule โ 'Natural Ozempic' Discovered via AI
Suppresses appetite and reduces body fat without nausea or muscle loss; preclinical stage.
GLP-1 Resistance โ Approximately 10% Have Genetic Non-Response
Stanford researchers clarify mechanism of Ozempic and Wegovy non-responders.
Survodutide Phase 3 โ Average 16.6% Weight Loss
76-week trial shows overwhelming efficacy vs placebo (3.2%).
Down Syndrome CRISPR โ Chromosome 21 Overexpression 'Silenced'
Preclinical results promising; announced April 24.
GLP-1 'Target-Switching' Hypothesis โ GIP/Glucagon Pathway
Original researchers propose novel approach; potential to bypass side effects.
Eli Lilly's Orforglipron (Foundayo) Gains FDA Approval
72-week average weight loss: 12% vs. 0.9% placebo. First GLP-1 tablet without meal restrictions.
Eli Lilly Acquires Kelonia Therapeutics
Secures cancer-targeting gene therapy pipeline; deal announced April 24.
Foundayo Self-Pay Pricing Starts at $149/Month
Commercial insurance: $25/month. Medicare copay capped at $50 effective July 1.
FDA Moves to End GLP-1 Compounded Pharmacy Products
FDA negates clinical necessity; begins rulemaking to shut down compounded product sales channels.
Next-Generation GLP-1 Candidates Target Expanded Pathways
New drug candidates beyond GLP-1 targeting neurological and metabolic pathways emerging.
FDA Approves HIV-1 Treatment Idvynso on April 21
The FDA approved Idvynso (doravirine/islatravir combination) on April 21 for the treatment of adult HIV-1 infection.
Genetic Hearing Loss Gene Therapy Otarmeni Receives Accelerated Approval on April 23
Lunsotogene parvec-cwha (Otarmeni) received accelerated approval on April 23, marking the first gene therapy for inherited hearing loss.
Novo Nordisk Wegovy Oral Formulation Enters GLP-1 Pill Market
Novo Nordisk's Wegovy oral formulation gained market entry, with a starting dose of 1.5mg available at $149 monthly through pharmacies and telehealth channels.
Eli Lilly Foundayo Launches Three Months Behind Novo Nordisk
Eli Lilly's Foundayo entered the market three months after its competitor but is projected to capture 60% of the daily oral market by 2030.
Lantus Interchangeable Biosimilar Langlara Approved April 29
Insulin glargine-aldy (Langlara) received approval on April 29 as an interchangeable biosimilar to Lantus, adding pricing pressure to diabetes care.
Wegovy and Zepbound Each Lose Coverage for 12 Million
88% of remaining enrollees subject to prior authorization or BMI restrictions.
Eli Lilly Launches Foundayo (Orforglipron)
First small-molecule GLP-1 oral agent; 11% weight loss in clinical trials.
Wegovy Oral Formulation Expands Commercial Availability
Novo Nordisk begins pharmacy distribution nationwide.
Non-GLP-1 Obesity Hypothesis; GIP and Glucagon Targeting
Original researchers propose novel hypothesis: GLP-1 targeting unnecessary.
152 Million Americans Reside in Failing Air Quality Counties
Earth Day report highlights respiratory and cardiovascular risks.
GLP Diet app launches April 21; exceeds 2,500 reviews
Custom nutrition, 5-minute workouts, and progress tracking integrated for Ozempic and Mounjaro users officially launched.
Tom Brady, eMed partner to offer GLP-1 to healthcare workers at $25/month
Fixed employer cost of $25 per employee; employee copay $99 for GLP-1 solution.
GLP-1 indication broadens to atrial fibrillation, depression, diabetic retinopathy
April clinical updates hint at GLP-1 efficacy expansion to alcohol use disorder, depression, and diabetic retinopathy.
Stanford study: 10% of patients show GLP-1 resistance
One in ten patients on GLP-1 diabetes medications may experience diminished response. Next-generation targets needed.
NIH: oral small-molecule GLP-1 penetrates brain; suppresses cravings
Oral small-molecule GLP-1 drugs cross the blood-brain barrier to inhibit cravings, representing a next-generation obesity pharmacology candidate.
GLP-1 Oral Formulation Prescribed to 170K Patients in Six Weeks
The adoption curve for orals is outpacing injectables' initial trajectory, marking a paradigm shift in obesity treatment delivery.
Up to 40% of Weight Loss Attributable to Lean Muscle Depletion
Skeletal muscle loss accompanies 'Ozempic face' concerns, positioning muscle-preserving therapeutics as the next-generation priority.
FDA Approves Idvynso for Adult HIV-1 Infection on April 21
The fixed-dose combination of doravirine and islatravir expands antiretroviral options.
Otarmeni Receives Accelerated Approval for Hereditary Hearing Loss on April 23
FDA expedited lunsotogene parvec-cwha approval, broadening the gene-therapy footprint in rare diseases.
GLP-1 Drug Cycling Becomes Widespread Practice
Users frequently stop and restart medication; long-term cycling safety data remains scarce.
Eli Lilly's Foundayo Achieves Broad U.S. Distribution Post-FDA Approval (April 1)
Following April 1 FDA accelerated approval, Eli Lilly's Foundayo (orforglipron) began LillyDirect shipments April 6, then expanded to wide pharmacy and telehealth networks mid-April. It is the first oral GLP-1 formulation unrestricted by meal, water or timing.
UnitedHealth Raises 2026 Full-Year Guidance on Strong Q1 Performance
UnitedHealth posted Q1 revenue of $111.72B and adjusted EPS of $7.23, raising 2026 guidance from $17.75 to $18.25+. Medical benefit ratio of 83.9% beat consensus of 85.5%.
CMS Finalizes GLP-1 Bridge Program; Medicare 'GLP-1 Era' Begins July 1
CMS codified eligibility and Part D participation for the GLP-1 Bridge Program in April, with the demonstration running July 1, 2026โDecember 31, 2027. A temporary Medicare GLP-1 coverage bridge precedes the permanent BALANCE model launch.
FDA Generic Drug Review Times Accelerate; ANDA Approvals Faster
FDA generic drugs program monthly and quarterly activity reports released April 17 showed ANDA average approval time dropping from 35.93 months in Q1 to 32.82 months in Q2; median fell from 25.65 to 20.29 months. April saw 17 first-cycle approvals.
GLP-1 'Ozempic Personality' Side Effect Emerges Clinically; Cycling Safety Unclear
Washington Times (April 30) and NPR (April 15) reported GLP-1 patients experiencing appetite, libido and social engagement declineโtermed 'Ozempic personality'โwith some cycling drug use on and off. Long-term safety and effects of cycling remain understudied.
Lilly Foundayo (GLP-1 Pill) FDA Approval (April 1)โShipped in April
Once-daily GLP-1 pill Foundayo approved. 72-week trial highest-dose group: 12% weight loss. Medicare $50/month; insured $25 coupon; uninsured $149โ349.
Idvynso (HIV Combination) Approved April 21
FDA approved Idvynso for adult HIV-1โcombining doravirine and islatravir as a novel antiretroviral regimen.
OtarmeniโGene Therapy for Hereditary Hearing Loss (Accelerated Approval, April 23)
AAV-based gene therapy Otarmeni received accelerated approval for OTOF-mediated hereditary hearing lossโlandmark for genetic hearing treatments.
Novo's Wegovy Pill Surpasses 600,000 Prescriptions in March
Wegovy oral formulation exceeded 600,000 prescriptions in March alone, outpacing initial forecasts and signaling fierce direct competition with Lilly's Foundayo.
STAT: Beyond GLP-1โNext-Generation Obesity Drug Research Accelerates (April 16)
STAT reports April 16 that developers are actively exploring non-GLP-1 targets to sidestep adverse effects and resistance. New paradigm emerging.
Eli Lilly's Foundayo gains FDA approval and hits market by April 6
Foundayo (orforglipron) received FDA approval on April 1 using the agency's new commissioner voucher program for expedited review. Insurance coverage costs $25/month; self-pay is $149. No meal restrictions required.
Novo's Wegovy pill posts record first-quarter launches; 600,000+ prescriptions
Wegovy's pill formulation set the all-time obesity-treatment launch record. Over 600,000 prescriptions were written in the first quarter. The downside: fasting and a 30-minute wait period are required.
FDA approves Regeneron's Otarmeni (AAV gene therapy for hearing loss)
Regeneron's Otarmeni gained accelerated approval on April 23 for OTOF-related hearing loss. Additional April approvals include Idvynso (HIV-1, 4/21) and Langlara, a Lantus biosimilar (4/29).
Caltech releases CellSAM for automated single-cell identification
Caltech researchers unveiled CellSAM, an AI tool for automatically identifying and segmenting individual cells across optical, fluorescence, and electron microscopy images.
Health insurance burden climbs: family premiums up 23% in five years
Workers' family insurance premiums average $6,900 after a 23% five-year increase. Two-thirds of Americans cite health-cost anxiety. Prior authorization and billing complexity add patient-safety risks.
FDA Approves Eli Lilly's Foundayo as First GLP-1 Obesity Pill
The FDA approved Eli Lilly's orforglipron (Foundayo) on April 1 as the first GLP-1 oral obesity treatment requiring no timing restrictions around food or water.
Stanford Researchers Identify 'Natural Ozempic' Molecule
Stanford researchers identified a BRP molecule that acts on appetite centers without nausea or muscle loss, dubbing it a 'natural Ozempic.' Preclinical data showed diet and body fat reductions.
New Study Flags GLP-1 Resistance in Roughly 10% of Patients
Researchers identified a genetic variant causing GLP-1 resistance in approximately 10% of patients, offering insight into disparities in drug response.
GLP-1 Users Increasingly Stop and Restart Medications Despite Medical Caution
NPR documented a rising trend of patients discontinuing and restarting GLP-1 drugs like Wegovy and Zepbound, a practice clinicians discourage but which occurs frequently in practice.
Novo Nordisk's Wegovy Captures 65% Share of New GLP-1 Prescriptions
Novo Nordisk's Wegovy commands 65% of new GLP-1 obesity drug prescriptions in the United States, extending market dominance.
Foundayo Opens GLP-1 Oral Obesity Treatment Market
Eli Lilly's Foundayo received FDA approval April 1, with cash pricing set at $149 monthly (matching oral Wegovy) and Medicare coverage starting summer at $50 monthly. Projected 2030 sales of $14.8 billion.
Utah Measles Climb to 602 Cases; U.S. Reaches 1,487
Utah has accumulated 602 measles cases with 1,487 nationally confirmed. Twenty-four new cases emerged in 2026, with 93% tied to cluster transmission. The outbreak threatens the U.S. measles elimination status.
Colorado and Pennsylvania Accelerate Avian Flu Culling
Weld County, Colorado culled 1.3 million layers; Lancaster County, Pennsylvania eliminated 720,000 layers. Over 30 days, 59 farms were affected, with 4.9 million birds culled.
FDA Proposes Excluding GLP-1 from Compounding List
The FDA proposed April 30 to exclude Novo Nordisk and Eli Lilly obesity and diabetes active pharmaceutical ingredients from the compounding allowance list, citing lack of clinical need for compounded GLP-1 products.
Late-April FDA Approvals Include HIV and Genetic Therapies
April 21: Idvynso (doravirine/islatravir) HIV-1 approval. April 23: Otarmeni accelerated approval for hereditary OTOF deafness gene therapy. April 29: Langlara (insulin glargine biosimilar) approval.
AstraZeneca Expands Tezspire Asthma Label
On April 13, the FDA granted AstraZeneca's asthma drug Tezspire (tezepelumab-ekko) expanded approval, broadening its indicated uses.
FDA Orders Eli Lilly to Submit Additional Safety Data for Foundayo
Released April 14, FDA approval documents require Eli Lilly to submit further cardiovascular and hepatic safety data on Foundayo (orforglipron). The rapid approval carried the Commissioner's National Priority Voucher.
Medicare GLP-1 Copay Cap at $50 Expands Senior Access
Medicare's GLP-1 benefits program capped out-of-pocket costs at $50 monthly, accelerating both price compression and senior adoption.
Trump Signs Psychedelic Mental Health Executive Order
The Trump administration signed an executive order in April to expedite psychedelic drug research and access for mental health, with veterans prioritized.
Neomorph's $100M Series B Funds NEO-811 Clinical Advancement
The $100 million Series B accelerates NEO-811's Phase 1/2 trials in renal cell carcinoma, setting the stage for near-term readouts.
Stanford "Natural Ozempic": AI peptide BRP
No nausea, no muscle wasting. Appetite suppression in preclinical models. Science Daily, 4/12.
GLP-1 resistance found in 10% of patients
Genome Medicine, 3/29: certain mutations blunt drug response. Precision dosing essential.
Renaissance Pharma daretabart FDA Fast Track for high-risk neuroblastoma
Anti-GD2 antibody. 4/14 announcement. Oncology momentum 4/13โ15 window.
AstraZeneca Tezspire monograph updated 4/13
Tezepelumab-ekko expanded guidance. Eosinophilic asthma and general asthma standard-of-care signals shift.
Celltrion ADC CT-P71 Fast Track (4/9)
Nectin-4-targeting antibody-drug conjugate for advanced metastatic urothelial cancer. Korean ADC export accelerates.
Foundayo Oral GLP-1 FDA Approval (April 1)
FDA approved Foundayo for obese and overweight adultsโthe first oral GLP-1 receptor agonist requiring no food/water constraints before dosing.
Retatrutide -28.7% Weight Loss, -75.8% Pain
In obese adults with knee osteoarthritis, Retatrutide delivered mean -28.7% weight loss and WOMAC pain reduction of -75.8%. Regulatory submission expected in 2026.
AI Mental-Health Apps Clinically Validated
Flourish demonstrated efficacy in two large RCTs. Headspace's Ebb, Woebot, Wysa, and Ash entering mainstream clinical adoption.
AI Integration in Mental-Health Workforce: Mixed Sentiment
NPR April 7 report: mental-health professionals simultaneously embrace and fear AI adoption. Clinical safety and validation gaps persist.
Claude's Internal Emotion Vectors Identified
Mechanistic interpretability research publicly identified internal emotion vectors activating across human emotional contexts in Claude models.
AbbVie ELAHERE Plus Carboplatin: 62.7% Phase 2 ORR
At SGO 2026 (April 10โ13, San Juan), AbbVie presented Phase 2 data (IMGN853-0420) showing mirvetuximab plus carboplatin achieved a 62.7% objective response rate in platinum-sensitive ovarian cancer.
Lilly's Foundayo (Oral GLP-1) Earns FDA Approval April 1
Foundayo, an oral GLP-1, received FDA approval on April 1 based on ATTAIN-1 (non-diabetic obesity/overweight) and ATTAIN-2 (diabetes plus obesity) data. Maximum-dose mean weight loss was 27.3 lbs (12.4%).
Daraxonrasib Doubles One-Year Pancreatic Cancer Survival
The RAS(ON) inhibitor daraxonrasib achieved roughly double the one-year survival rate in advanced pancreatic cancer Phase 1/2 dataโmajor oncology news dominating mid-April coverage (Northwestern, NatGeo, Dana-Farber).
FDA Grants Fast Track to Multiple Oncology Candidates in April
The FDA designated fast-track status to multiple oncology programs in April, spanning ovarian, bladder, and pancreatic indications, including PAS-004 (NF1 pathway).
FDA Launches 'Real-Time' Clinical Trials Pilot
STAT reports the FDA is piloting 'real-time clinical trials' with AstraZeneca, Amgen, and others to accelerate drug development, with oncology as the priority domain.
Foundayo oral GLP-1 starts free shipping via LillyDirect (April 6)
FDA-approved April 1; first GLP-1 pill with no meal or water restrictions. Telehealth and pharmacy rollout follows.
Boehringer Survodutide: 16.6% weight loss at 76 weeks
SYNCHRONIZE-1 Phase 3 GLP-1 plus glucagon dual agonist with waist-circumference reduction. Adverse events mild.
Celltrion CT-P71 FDA Fast Track (April 9)
Nectin-4-targeted ADC for advanced, metastatic urothelial cancer. Korean ADC global entry signal.
NextCure SIM0505 Fast Track (April 7)
Platinum-resistant ovarian cancer ADC. April early-month U.S. oncology ADC Fast Track trend firms.
Stanford: 1 in 10 carry GLP-1 genetic resistance
Specific genetic variants blunt Ozempic and Wegovy response. Precision-medicine matching becomes critical.
FDA approves Eli Lilly Foundayo (oral GLP-1)
Average 27-pound weight loss at 72 weeks, no food or water restriction needed. Approved April 1 as the first oral GLP-1 pill.
Foundayo $25 copay for insured patients
Uninsured pricing $149โ$349 per dose via LillyDirect and telehealth channels.
Novo's Wegovy pill hits 600K prescriptions in March
Novo gets a three-month market head start ahead of Foundayo, cementing early share advantage.
FDA recalls Tridergel and Revitaderm antimicrobial gels April 8
Lysinibacillus fusiformis contamination prompted voluntary lot withdrawal.
Eli Lilly acquires CrossBridge Bio for $300M on April 14
Houston-based ADC oncology startup accelerates Lilly's antibody-drug conjugate portfolio expansion.
FDA Approves Lilly's Oral GLP-1 'Foundayo' April 1 Via Fast-Track
The FDA cleared Lilly's orforglipron (brand name Foundayo) through a newly established CNP voucher fast-track pathway on April 1.
Foundayo's Out-of-Pocket Low Dose Set at $149/Month
Lilly priced Foundayo's lowest dose at $149 monthly out-of-pocket, matching Novo's Wegovy tablet pricing, BioPharma Dive reported.
Wegovy Pill Crosses 600K Prescriptions Post-Launch
Novo's Wegovy tablet tallied over 600,000 prescriptions since launch, a 10-fold faster adoption rate than the legacy Wegovy injection.
Foundayo Differentiated by Meal-Time Flexibility
Lilly's Foundayo, as a small-molecule oral drug, works regardless of meal timing, unlike Wegovy's 30-minute fasting requirement.
FDA Signals End to GLP-1 Compounding Pharmacies
STAT reported April 30 that the FDA declared GLP-1 compounding 'not clinically necessary,' signaling a market shutdown.
FDA approves Lilly 'Foundayo' (orforglipron) April 1
Once-daily oral GLP-1 for obesity in adults. No meal or time restrictions. Peak dose: 12% weight loss.
Foundayo ships; insured patients $25/month
LillyDirect dispatch starts Monday; pharmacies and telehealth follow. Uninsured: $149โ349 depending on dose.
Novo Wegovy pill hits 600K March prescriptions
Novo's pill shows early momentum: 600K+ Rx in March alone. Lilly enters ~three months late.
FDA approves 42 new drugs in Q1
April 7 release of 1Q26 tally: 42 approvals. Precision oncology, metabolic disease, HIV all active.
Idvynso (doravirine-islatravir) HIV therapy expected April 21
BioPharma Dive and FDA tracker peg late-April approval for doravirine combo. Chronic infection line expands.
FDA grants priority review to Orca-T BLA for cell immunotherapy
FDA designated Orca-T, an allogeneic stem cell and T-cell immunotherapy for acute myeloid leukemia, lymphoblastic leukemia, and MDS, for priority review.
FDA approves Dapagliflozin generics and Saxagliptin-Metformin combo April 6
Drugs.com tracker: April 6 FDA approvals included Dapagliflozin 5mg and 10mg tablets plus the Saxagliptin-Metformin combination generic.
GLP-1 one-year retention falls below 25 percent; 74 percent cite restart interest
April research shows GLP-1 one-year retention below 25 percent. Separately, 74 percent of discontinuers reported willingness to restart.
Pfizer-Valneva Lyme vaccine shows 70-plus percent efficacy in Phase 3
Pfizer and Valneva reported Phase 3 VALOR study efficacy exceeding 70 percent for their Lyme vaccine candidate in ages five and up.
Ozempic may preserve lean mass better than Mounjaro
Healthline reported semaglutide (Ozempic) shows potential advantage over tirzepatide (Mounjaro) in lean mass preservation, though part of the difference stems from tirzepatide's larger weight loss magnitude.
FDA clears Foundayo (orforglipron), April 1
FDA approved Eli Lilly's once-daily oral GLP-1 Foundayo for obesity and overweight. The ATTAIN-1 trial showed 12.4% average weight loss (27.3 pounds) at the high dose. LillyDirect began shipping April 6 at $149/month out-of-pocket.
FDA converts brexu-cel (Tecartus) to standard approval
FDA converted the CAR-T cell therapy brexu-cel (Tecartus) from accelerated to standard approval for relapsed and refractory mantle-cell lymphoma, backed by ZUMA-2 long-term follow-up.
Denali's tividenofusp alfa decision due April 5
FDA was scheduled to decide on Denali Therapeutics' tividenofusp alfa for Hunter syndrome on April 5, marking a watershed moment for rare lysosomal-storage disease.
FDA Fast Track: NextCure's SIM0505 for platinum-resistant ovarian cancer
NextCure announced FDA Fast Track designation for its ADC SIM0505 in platinum-resistant ovarian cancer on April 7. Dose optimization begins Q2 2026.
AJMC: FDA speeds approvals with single-trial pathway
AJMC reported FDA now permits one clinical trial for some new-drug approvals, speeding time-to-market but raising safety-validation concerns.
FDA clears orforglipron on April 1โfirst oral small-molecule GLP-1
Eli Lilly's orforglipron earned FDA approval April 1. Once-daily oral dosing, 0.8mg starting, with a contraindication against combining with other GLP-1s. First small-molecule GLP-1 agonist for chronic weight management.
Phase 3 ATTAIN-MAINTAIN shows sustained weight loss vs. placebo
The phase 3 ATTAIN-MAINTAIN trial demonstrated orforglipron's superiority over placebo in maintaining weight loss after semaglutide or tirzepatide injection plateaus. Most common side effects: nausea, vomiting, diarrhea, constipation, indigestion.
April PDUFA calendar flags rheumatology, neurology candidates
Rheumatology Advisor and Neurology Advisor tracked April PDUFA decisions including rheumatology and neurology novel candidates. Ongoing monitoring warranted.
Iran-conflict casualties: Bandar Mahshahr toll mounting
April 4 missile strike on Bandar Mahshahr petrochemical complex killed five and wounded 170. April 3 Karaj bridge bombing wounded 100+, straining medical systems.
Bangladesh factory fire, India road crash claim six
A gas-lighter factory fire in Dakahnya, Bangladesh on April 4 killed five. A vehicle plunge near Soza, Himachal Pradesh, India same day killed four (two children) and wounded 18.
FDA greenlights Foundayo oral GLP-1 obesity pill
April 1: FDA clears Eli Lilly's orforglipron (Foundayo) for overweight and obese adults with comorbidities. No food or water restrictions, anytime dosing. ATTAIN-1 top-dose average 12.4% weight loss (~27.3 lb).
Foundayo ships via LillyDirect April 6; rapid pharmacy rollout
Foundayo accepts prescriptions April 1, ships April 6 via LillyDirect, spreading to US retail and telehealth. Cash $149/month, commercial $25/month.
Trump's 100% drug tariff carves MFN, domestic-production escape hatch
Section 232 patent drug tariffs can hit 0% through Jan 20, 2029 under MFN pricing deals or domestic production commitments; domestic entrants get 20% (100% after four years).
Lilly buys Centessa, plants neuroscience flag with OX2R agonist
Eli Lilly scoops Centessa for $6.3B upfront plus $1.5B CVR, gaining cleminorexton OX2R agonist for narcolepsy and idiopathic hypersomnia.
Project Prometheus targets drug discovery alongside robotics, aerospace
Bezos's Physical AI lab explicitly flags drug discovery alongside aerospace and robotics. Signals industrial AI's pharma R&D crossing.
FDA clears Eli Lilly's oral GLP-1 Foundayo (orforglipron) for obesity
FDA approved Eli Lilly's oral GLP-1 drug orforglipron (Foundayo) April 1 for obesity. It's the first oral GLP-1 obesity medicine with no food or water requirements and free dosingโhead-to-head to injectables Wegovy and Zepbound. Q1's most operationally impactful approval.
Pasithea PAS-004 earns Fast Track status for NF1-associated plexiform neurofibromatosis
Pasithea Therapeutics said April 1 its next-gen macrocyclic MEK inhibitor PAS-004 earned FDA Fast Track designation for NF1-associated plexiform neurofibromatosis.
A2 Bio's A2B543 autologous CAR-T earns Fast Track for MSLN-positive solid tumors
A2 Biotherapeutics announced April 1 that A2B543, an autologous CAR-T candidate, gained FDA Fast Track for relapsed/locally advanced/metastatic MSLN-expressing solid tumors in HLA-A*02-compatible adults.
Revolution Medicines' daraxonrasib doubles survival in Phase 3 pancreatic cancer trial
Revolution Medicines reported Phase 3 data: daraxonrasib plus chemotherapy extended survival to 13.2 months versus 6.7 months for chemo aloneโa 6.5-month gain.
Foundayo positioned as Q1's most operationally significant approvalโpatient demand, payer, pharmacy impact
Lumistry flagged Foundayo as Q1's most operationally impactful approval, citing patient demand, payer coverage shifts, and pharmacy dispensing potential.
FDA approves Eli Lilly oral GLP-1 'Foundayo' for obesity April 1
FDA cleared orforglipron (Foundayo) on April 1, shipping via LillyDirect starting April 6. Lowest-dose patient cash price: $149 monthly, matching Novo Nordisk's Wegovy.
FDA approves Awiqli, first once-weekly basal insulin
Drugs.com records FDA clearance of insulin icodec (Awiqli) on March 26 as the first once-weekly basal insulin for type 2 diabetes in adults.
FDA accelerates Kresladi for pediatric LAD-I
FDA granted accelerated approval to Kresladi on March 27 for pediatric severe leukocyte adhesion deficiency (LAD-I).
Eli Lilly acquires Centessa for roughly $6.3 billion
Dealroom reports Eli Lilly announced March 31 acquisition of Centessa Pharmaceuticals for approximately $6.3 billion, bolstering post-GLP-1 pipeline.
FDA accelerates Avlayah for Hunter Syndrome
Drugs.com notes FDA accelerated approval of tividenofusp alfa-eknm (Avlayah) on March 25 for Hunter Syndrome (MPS II).